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Abstract 
Cheminformatics facilitates the analysis, storage, and collection of large quantities of chemical 
data, such as molecular structures and molecules' properties and biological activity, and it has 
revolutionized medicinal chemistry for small molecules. However, its application to larger 
molecules is still underrepresented. This thesis work attempts to fill this gap and extend the 
cheminformatics approach towards large molecules and peptides.  
This thesis is divided into two parts. The first part presents the implementation and 
application of two new molecular descriptors: macromolecule extended atom pair fingerprint 
(MXFP) and MinHashed atom pair fingerprint of radius 2 (MAP4). MXFP is an atom pair 
fingerprint suitable for large molecules, and here, it is used to explore the chemical space of 
non-Lipinski molecules within the widely used PubChem and ChEMBL databases. MAP4 is a 
MinHashed hybrid of substructure and atom pair fingerprints suitable for encoding small and 
large molecules. MAP4 is first benchmarked against commonly used atom pairs and 
substructure fingerprints, and then it is used to investigate the chemical space of microbial and 
plants natural products with the aid of machine learning and chemical space mapping.  
The second part of the thesis focuses on peptides, and it is introduced by a review 
chapter on approaches to discover novel peptide structures and describing the known peptide 
chemical space. Then, a genetic algorithm that uses MXFP in its fitness function is described 
and challenged to generate peptide analogs of peptidic or non-peptidic queries. Finally, 
supervised and unsupervised machine learning is used to generate novel antimicrobial and non-
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Thesis Scope & Outline 
While cheminformatics has revolutionized medicinal chemistry for small molecules, its 
application to larger molecules still lacks representation. For instance, macromolecules can be 
the object of rigorous molecular dynamics and conformational studies, but an orthogonal two-
dimensional approach that allows a fast analysis and visualization of their space is still missing. 
In fact, in the context of their two-dimensional structural representation, 
macromolecules such as peptides and glycans are almost exclusively handled by bioinformatics 
using sequences formed by specified building blocks.1 This encoding is well established and 
successful; however, it has limitations. In fact, assessing similarity works only within a specific 
macromolecule class and within the established building blocks and topology frame. For 
instance, a classical sequence-based bioinformatics approach would not allow encoding 
modified peptides such as vancomycin,2 or peptides with unusual topologies, such as the 
antimicrobial peptide dendrimer G3KL.3 These molecules can instead be described with a 
cheminformatics approach, for instance, by using molecular fingerprints. However, 
cheminformatics has primarily focused on small molecules and presents its limitation in larger 
molecules encoding.   
Prior to the work reported in this thesis, studies on using a two-dimensional molecular 
fingerprint for peptides4–6 have been carried out in the Reymond group. This thesis’ scope is to 
expand these initial results by building a solid cheminformatic toolbox for large molecules, 
including molecular fingerprints, chemical space visualization, and generation of novel peptide 
sequences. The contributions made towards this objective have been published as scientific 
articles. In this thesis, they are collected and divided into two main sections: (i) encoding of 
large molecules and visualization of their chemical space and (ii) peptide chemical space and 
2 | P a g e  
  
generation of novel peptide sequences. Each section has an introductory chapter, namely 
chapter one and chapter six.  
Part one – Encoding of large molecules and visualization of their chemical space 
• Chapter One. This chapter consists of a general introduction to cheminformatics, 
molecular fingerprints, and chemical space visualization. Since they are important for the 
understanding of the following chapters, the extended connectivity fingerprints (ECFPs),7 
MinHashed fingerprints (MHFPs),8 extended atom pair fingerprint (Xfp),9 RDKit atom pair 
fingerprint (RDKit AP),10 similarity maps,11 and Tree Maps (TMAP)12 are treated in greater 
detail. Then, the state of the art and limitations of molecular fingerprints and chemical space 
visualization for larger molecules and peptides are summarized.  
• Chapter Two. An adaptation of Xfp for large molecules is introduced: the macromolecule 
extended atom pair fingerprint (MXFP). Then, the molecules within PubChem and 
ChEMBL databases breaking more than one of Lipinski's rules of five13 are encoded with 
MXFP, and their similarity maps are visualized. The resulting interactive maps allow for 
exploring a subset of widely used databases that contains often neglected larger structures 
and macromolecules. This chapter is based on the peer-reviewed publication “PubChem 
and CHEMBL beyond Lipinski”.14 
• Chapter Three. A novel descriptor for both small and large molecules is described: the 
MinHashed atom pair fingerprint of radius 2 (MAP4). MAP4 is a MinHashed fingerprint 
that bridges between substructure fingerprints such as ECFPs and MHFPs and atom pair 
fingerprints such as the RDKit atom pair fingerprint. Then, MAP4 is benchmarked against 
MHFP6, ECFP4, the topological torsion fingerprint (TT),15 and RDKit AP using a peptide 
extended version of the Riniker and Landrum small molecules fingerprint benchmark.16 
Contrarily to the other tested fingerprint, MAP4 scores excellent performances with both 
small molecules and peptides. Furthermore, MAP4 is shown to encode the human 
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metabolome database correctly.17 This chapter is based on the peer-reviewed publication 
“One molecular fingerprint to rule them all: drugs, biomolecules, and the metabolome”.18 
• Chapters Four and Five. Due to its capabilities in encoding molecules covering a vast 
size range, MAP4 is suitable to represent and visualize natural products. In chapter four, 
the analysis of the microbial natural products using the Natural product Atlas19 is carried 
over, and the observation that both a MAP4 TMAP of this space and a MAP4 SVM 
classifier can distinguish the natural products based on their fungal or bacterial origin is 
made. In chapter five, the analysis is extended to natural products from plants using the 
recently published Collection of open natural products (COCONUT)20 and obtaining 
similar results. In an unprecedented way, this analysis allows for an interactive 
visualization of the natural products' chemical space and the origin assignment of a natural 
product using a fingerprint-based classifier. Chapter four is based on the peer-reviewed 
publication “Assigning the origin of microbial natural products by chemical space map and 
machine learning”.21 Chapter five is based on the ChemRxiv preprint “Classifying Natural 
Products from Plants, Fungi or Bacteria in the COCONUT Database”.22 
Part two – Peptide chemical space and generation of novel peptide sequences 
• Review Chapter Six. The main computational approaches to the generation of novel 
peptides are listed and the state of the art summarized. Then, the known chemical space of 
linear peptides up to 50 residues collected from the available databases is encoded using 
MAP4 and visualized with TMAP. Review chapter six is based on the peer-reviewed 
publication “Peptides in Chemical Space”.23  
• Chapter Seven. A random subset of the virtual chemical space of linear, cyclic, and 
dendritic peptides is sampled. Then, a novel methodology to translate the dendritic and 
cyclic peptide sequences into SMILES is described and used. The resulting SMILES are 
encoded with MXFP, a PCA is applied, and the first three principal components are 
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visualized using the interactive visualization tool Faerun24. The implementation of the 
peptide design genetic algorithm (PDGA), a genetic algorithm that generates peptides 
sequences and uses MXFP in its fitness function, is described. Next, PDGA is successfully 
challenged to produce peptide analogs of peptidic and non-peptidic queries. PDGA allows 
for the exploration of specific areas of the peptide chemical space through analogs 
generation. Although its first implementation uses MXFP, PDGA has been adapted to use 
the RDKit AP fingerprint and MAP4. This adaptation source code is publicly available at 
https://github.com/reymond-group/PDGA-MAP4_AP. Chapter seven is based on the peer-
reviewed publication “Populating chemical space with peptides using a genetic 
algorithm”.25 
• Chapter Eight. Machine learning is challenged with the design of novel non-hemolytic 
antimicrobial peptides (AMPs) against three problematic and often drug-resistant 
pathogens: P. aeruginosa, A. baumannii, and S. aureus. Highly curated hemolysis and 
antimicrobial activity data on linear peptides are used to train a generative model, fine-tune 
it to generate non-hemolytic peptides against specific bacterial strains, and train an 
antimicrobial activity and a hemolysis classifier. Out of 28 synthesized peptides, eight are 
non-hemolytic and active against the bacterial strains used in the sequence design. The 
presented work permits the exploration of peptide subspaces characterized by a determined 
activity. The used workflow can be adapted to different antimicrobial activities using 
different subsets during the fine-tuning of the generative model. Furthermore, the different 
recurrent neural networks models can be used separately. Chapter eight is based on the 
peer-reviewed publication “Machine Learning Designs Non-Hemolytic Antimicrobial 
Peptides”.26  
Chapter nine. Conclusive thoughts on the impact of this thesis in the field are followed by a 
brief introduction to possible future work within the framework of the presented projects.   
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Chapter One – General 
Introduction 
Cheminformatics facilitates the analysis, storage, and collection of large quantities of chemical 
data, such as molecular structures and molecules' properties and biological activity. While 
several concepts behind the discipline are much older,27,28 the term cheminformatics was first 
defined by Frank Brown in 199829 as an abbreviation of "chemical informatics". The need for 
this definition was probably a consequence of the dramatic importance that cheminformatics 
acquired within the drug discovery process after the advent of high throughput drug screening 
and parallel synthesis between the 1980s and 1990s.30 In fact, this increased capabilities of the 
chemical field produced an unprecedented growth of the synthesized compounds creating the 
need for tools to handle them.1 Need that cheminformatics and, more recently, machine 
learning have transformed into an opportunity to exploit the information within the 
exponentially growing chemical data.31 Nowadays, cheminformatics is deeply interconnected 
with the drug discovery process: from screening protein databases for possible targets during 
the target identification phase, to virtual screening, database generations, property predictions 
in the lead discovery and optimization process, and ADMET profiling prediction prior to 
preclinical studies.32–35 Two typical cheminformatics approaches are molecular fingerprints 
encoding and chemical space exploration. The following sections summarize their state of the 
art and the limitations of their application to large molecules and peptides.   
1.1 Molecular Descriptors 
A frequent task in a cheminformatics project is the comparison between two molecules and 
their similarity assessment. This task is typically tackled using molecular descriptors. 
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Molecular descriptors can be roughly classified as 1, 2, or 3 dimensional (D). 1D descriptors 
take into account the physicochemical properties of a molecule and the presence of specific 
substructures. 2D and 3D descriptors consider the whole molecule. 3D descriptors bring the 
highest level of information. However, they require 3-dimensional information of a molecule, 
which is rarely experimentally available, and its calculation with molecular docking and 
dynamics is often slow to compute. 2D descriptors contain information on the complete 2-D 
structure of molecules, and even without the complexity of 3D representation, their 
performance is generally comparable to the one of 3D descriptors for most typical drug 
discovery tasks.36,37 The following sections will focus on two types of 2D descriptors that are 
important to understand the following chapters of this thesis: circular substructure fingerprints 
and atom pair fingerprints.  
1.1.1 Circular Substructure Fingerprints 
Circular substructure fingerprints encode each atom in a molecule with its circular substructure 
up to a defined radius. A notorious example of this class of fingerprints are the extended-
connectivity fingerprints (ECFPs).7 Recently, Daniel Probst and Jean-Louis Reymond 
published the MinHashed fingerprints (MHFPs), a variation of ECFPs which uses methods 
from natural language processing and data mining.8 While circular substructure fingerprints 
are well-performing with small molecules,16,18,38 they are less suitable for large and repetitive 
structures. In fact, to avoid an overly specific encoding, generally, the radius of the considered 
substructure is relatively small, and when a molecule is large, substructure fingerprints can lose 
the perception of the whole structure.18 Since they are important for the understanding of the 
MinHashed atom pair fingerprint (MAP4),18 which is introduced in the second chapter of this 
thesis, the RDKit implementation of ECFPs7 (Figure 1.2a) and the implementation of MHFPs 
(Figure 1.2b) are described in detail in the following sections. 
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ECFPs. ECFPs (Figure 1a) are among the most widely used and best-performing fingerprints 
available in cheminformatics. In the RDKit implementation of the ECFP fingerprints, all atoms 
are assigned hashed numerical identifiers that encode the properties of the atom itself and the 
properties of their neighboring atoms within their circular environment of the given radius. The 
considered atom properties are the atom's element, the number of heavy neighbors, number of 
hydrogens, charge, isotope, and if the atom belongs to a ring. The unique numerical identifiers 
representing the molecule are then brought to a fixed-length binary array using the modulo 
operation. Following this logic, ECFP0 will encode each atom in a molecule using solely the 
information related to the atom itself, ECFP2 will encode each atom with its properties and the 
properties of the atoms in its circular environment of diameter 2, and so on. The resulting 
fingerprint is binary, and its default version has 1024 bits. The most used ECFPs are the ones 
of diameter 4 (ECFP4) and diameter 6 (ECFP6).  
 
Figure 1. Substructure fingerprints encoding schematic. (a) ECFP4 encoding of atom k. (b) MHFP4 
encoding of atom k. 
 
MHFPs. MHFPs (Figure 1b) is a family of very recently published fingerprints that, as ECFPs, 
encode each atom in a molecule with its circular environment up to a given diameter. However, 
MHFPs represent atom's properties and environment using their Simplified molecular-input 
line-entry systems (SMILES). David Weininger first introduced SMILES in 1988.39 They 
exemplify a molecular graph as a string, where atoms are represented with their standard 
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abbreviation (e.g., C for carbon atoms) and ramifications with brackets. In addition, bonds, 
stereochemistry, charges, and aromaticity are represented with different characters. In MHFPs, 
the substructures SMILES up to the defined diameter are extracted for each atom in a molecule, 
and then they are made unique and mapped to numbers using the SHA-1 hashing function.40 
Finally, the set of unique numbers is MinHashed41 to a fixed length. MinHashing is a relatively 
slow procedure compared to the application of the modulo operation. However, the Jaccard 
similarity (Equation 1) of two MinHashed fingerprints a and b can be estimated (1) counting 
of elements with the same value and the same index across a and b, and (2) dividing the 
obtained value by the fingerprint length.  
 Equation 1 
Therefore, using a MinHashed fingerprint has the advantage of allowing for fast similarity 
calculations. Furthermore, the fingerprint values derived from the MinHashing procedure can 
be directly stored within LSH forest trees,8,42 making the methodology particularly compatible 
with the TMAP visualization described later in this introduction. The default MHFP has radius 
3 and 1024 dimensions. 
1.1.2 Atom Pair Fingerprints 
Atom pair fingerprints represent molecular structures through atom pairs instead of single 
atoms. They encode atom pairs as the properties of both atoms and the distance that separates 
them. Depending on the maximum encoded distance between atoms, atom pair fingerprints can 
be used for small molecules or large molecules. For instance, the chemically advanced template 
search (CATS)43 and Xfp9 consider atom distances only up to 10 bonds, while the RDKit Atom 
pair fingerprint (RDKit AP)10 encodes unlimited atom distances. Another 2D atom pair 
fingerprint suitable for large molecules is the 2D-Protein fingerprint (2DP).6 2DP considers 
long atom distances and has been proven capable of comparing non-linear peptides;4–6 
13 | P a g e  
  
however, 2DP assigns all atoms to the α-carbon atom of their parent amino acid residue, and 
then it counts the distances between the pairs of α-carbon atoms. Therefore, its use is limited 
to peptides. Atom pair fingerprints have been shown to represent molecular shape and 
pharmacophore, and they have been used for scaffold hopping.9,43 However, they can represent 
fewer details than substructure fingerprints, which remain the fingerprints of choice for most 
cheminformatics projects involving small molecules. In the next section, we will focus on the 
implementation of the RDKit AP (Figure 2a) and Xfp (Figure 2b) since they are important to 
understand the macromolecule extended atom pair fingerprint (MXFP)14 and the MAP4 
fingerprint discussed in the first two chapters of this thesis. 
RDKit AP. In the RDKit Atom pair fingerprint, all atom pairs are encoded with a numerical 
identifier that collects the atom type of the two atoms that form them and the distance in bonds 
that separates them. The considered properties to determine the atom type are the atom's 
element, number of heavy neighbors, and number of pi electrons. Since it encodes substructural 
paths (i.e., the atom pair and the bond path between them), this fingerprint can be further 
labeled as path-based atom pair or substructural atom pair. The RDKit AP can be brought to 
fixed-length using the modulo operation, resulting in a binary array that by default has 2048 
bits.  
Xfp. Xfp is an atom pair fingerprint developed to encode small molecules and optimized using 
the DUD44 dataset. Xfp classifies each atom as belonging to one or more of the following 
categories: hydrophobic (Hyb), H-bond acceptor (HBA), H-bond donor (HBD), and planar 
atoms (sp2). Atom pairs from bond distance one up to bond distance ten are counted within all 
categories and across the HBA and HBD categories. To avoid an overrepresentation of 
molecular size, the values are then normalized by the number of atoms in each specific 
category, and for the HBA-HBD cross pair, the HBA atom number is used. Finally, the bit 
values in HBA same-property pairs are doubled to increase their weight, resulting in a 55 
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dimensions array. Since Xfp, as well as CATS and 2DP, counts the number of atom pairs at 
defined bond distances, it can be further labeled as counted atom pair fingerprint.  
 
Figure 2. Atom pair fingerprints encoding schematic. (a) RDKit AP encoding of atom pair jk. (b) Xfp 
encoding of atom pair xk.  
1.2 Chemical Space 
The chemical space describes all possible molecules, including the available ones and those 
yet to be discovered.45–47 This space can be considered limitless. However, Cheminformatics 
has been historically focused on the space of small drug-like molecules. This space has been 
estimated to be 1060 molecules by Bohacek,48 1033 molecules by Polishchuk,49 and 
1024 molecules by Peter Ertl.50 Independently from the different size estimations, the complete 
enumeration of this space is not feasible, and the current most significant attempt is represented 
by the generated databases (GDBs).51–53 However, generating, encoding, and visualizing the 
known chemical space, virtual subsets of the chemical space, or the chemical space of a specific 
set of molecules, has been successfully attempted, and it has contributed to drug 
discovery.47,54,55  
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1.2.1 Visualization of Chemical Spaces 
As discussed in the previous section, the enumeration of the entire chemical space is not 
feasible. However, it is instead possible to focus on the characterization and visualization of 
the chemical space of a specific set of molecules. A chemical space is not only characterized 
by its molecules but also by the descriptor chosen to encode them. However, to effectively 
characterize molecules, molecular descriptors have more than three elements, while three are 
the maximum number of dimensionalities that are non-trivial to visualize. To overcome this 
impasse and visualize a chemical space, a dimensionality reduction methodology needs to be 
applied. Different methods are available, including t-distributed stochastic neighbor 
embedding (tSNE),56 uniform manifold approximation and projection for dimension reduction 
(UMAP),57 principal components analysis (PCA),58 similarity maps,11 and TMAPs.12 Here, we 
will discuss the three approaches that will be found later in the chapters of this thesis.   
PCA. A common approach to reducing the dimensionality of a dataset encoded with a multi-
dimensional fingerprint is to do PCA and then visualize the first two or three principal 
components in a scatter plot.59 PCA dates back to the beginning of the 19th century,58 and it 
consists in reducing the dimensionality of a dataset while preserving as much information as 
possible. Preserving as much information as possible translates into finding new variables that 
are linear functions of those in the original dataset, maximize variance, and that are 
uncorrelated with each other.  
Similarity maps. The visualization of the first two or three principal components of a PCA 
directly applied to a fingerprint encoding of a dataset does not always work well with molecular 
fingerprints that store a large amount of information, such as ECFPs or atom pair fingerprints. 
In fact, the two first principal components' explained variance can remain below 50% in these 
cases, making the visualization not informative. Similarity maps were developed in the 
Reymond group as an attempt to solve this problem.11 In a similarity map, the PCA is computed 
16 | P a g e  
  
on the similarity matrix formed by the normalized similarity of each molecule in the database 
to a set of molecules (so-called satellites) randomly picked from the database. Similarity maps 
in the feature space of atom pairs and substructure fingerprints typically show a variance of the 
two first principal components above 50% and allow for a meaningful visualization.  
Tree Map (TMAP). TMAP12 layout can be calculated from a locality-sensitive hashing (LSH) 
forest42 or a similarity matrix. K nearest neighbors (NNs) in the chosen feature space are 
extracted from the LSH forest or the similarity matrix to form a graph in which nodes are the 
structures and edges are the NN relationships weighted by the fingerprint distance. Kruskal's 
algorithm60 is then applied to remove cycles and find the path with the lowest total distance 
between all the molecules in the graph. Finally, Fearun24 can be used to display the obtained 
minimum spanning tree interactively. MHFPs are particularly suitable for this methodology 
since the indices generated by the MinHash procedure can be readily used to create an LSH 
forest.  
1.2.2 Chemical Space of Large Molecules 
More recently, drug discovery has extended its interest to the chemical space of larger 
molecules. For instance, the chemical space of the currently available natural products (NPs) 
contains molecules having a wide size range (Table 9 and Figure 46a), and it has been explored 
using physicochemical properties, the presence of specific substructures, hierarchical scaffold 
classification, and circular substructure fingerprints.61–67 However, when looking at a more 
uniform and repetitive space such as the human metabolome17 chemical space, substructure 
fingerprints become almost entirely incapable of distinguishing different entries (Figure 16 
panels a, c, d, and e and Figure 15 panels b and c).18 In fact, when talking about chemical space, 
one should not forget that this concept is deeply interconnected with a specific descriptor space 
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and that the organization of a chemical space can dramatically change when changing the 
descriptor used to encode the molecular structures.  
For instance, since the MHFP6 fails to distinguish between related metabolites 
properly, the TMAP of the human metabolome database in this feature space is not very 
informative (Figure 15b). Furthermore, an analysis of the occupancy of fingerprint value bins 
illustrates how for MHFP6, ECFP4, and TT, the ten most populated fingerprint value bins 
contain many molecules, thousands for ECFP4 and MHFP6, and hundreds for TT (Figure 15c). 
On the contrary, the RDKit AP seems better equipped to distinguish between human 
metabolites, with only two or three molecules per fingerprint bin. However, as previously 
discussed, the RDKit AP, due to the lack of detailed substructural information, cannot 
distinguish between structurally correlated small molecules such as the metabolites 
HMDB0059800 and HMDB0059800 (Figure 16b). This analysis is found in its extended 
version in the second chapter of this thesis. 
Due to their generally larger and repetitive structures, the same limitations can be 
extended to peptides and their chemical space, which can be explored using substructure 
fingerprints only when considering very short sequences.68 In fact, TT, ECFP4, and MHFP6 
are incapable of distinguishing scrambled peptide structures (Figure 16d). The known and the 
virtual chemical space of peptides, together with a summary of the methods applied to explore 
it, is thoroughly discussed in review chapter six. Review chapter six also contains general 
explanations of genetic algorithms and machine learning, which are introductory topics for the 
last two chapters of this thesis. 
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Chapter Two – PubChem and 
ChEMBL beyond Lipinski 
This work is based on the peer-reviewed publication:  
Capecchi, A.; Awale, M.; Probst, D.; Reymond, J.-L. PubChem and ChEMBL beyond 
Lipinski. Mol. Inform. 2019, 38 (5). https://doi.org/10.1002/minf.201900016. 
This work is republished in this dissertation with the authorization of Wiley-VCH Verlag with 
Order License ID 1157319-1. 
Abstract  
Seven million of the currently 94 million entries in the PubChem database break at least one 
of the four Lipinski constraints for oral bioavailability, 183,185 of which are also found in the 
ChEMBL database. These non-Lipinski PubChem (NLP) and ChEMBL (NLC) subsets are 
interesting because they contain new modalities that can display biological properties not 
accessible to small molecule drugs. Unfortunately, the current search tools in PubChem and 
ChEMBL are designed for small molecules and are not well suited to explore these subsets, 
which therefore remain poorly appreciated. Herein we report MXFP (macromolecule extended 
atom-pair fingerprint), a 217-D fingerprint tailored to analyze large molecules in terms of 
molecular shape and pharmacophores. We implement MXFP in two web-based applications, 
the first one to visualize NLP and NLC interactively using Faerun (http://faerun.gdb.tools/), 
the second one to perform MXFP nearest neighbor searches in NLP. We show that these tools 
provide a meaningful insight into the diversity of large molecules in NLP and NLC.  
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2.1 Introduction 
PubChem and ChEMBL are public repositories of molecules and their biological activity.69,70 
While both databases contain a vast majority of small molecules, they also contain a small 
percentage of larger biomolecules such as peptides, oligonucleotides, oligosaccharides, and 
large natural products, as well as synthetic macromolecules such as peptide nucleic acids, 
fullerene derivatives, modified porphyrins and dendrimers. Such large molecules are 
interesting because they might serve as new modalities to address drug design problems which 
cannot be solved by small molecule drugs, for example blocking protein-protein interaction 
sites or delivering siRNA cargos into cells.71 Unfortunately, PubChem and ChEMBL do not 
offer many options to explore these larger molecules. For instance, no overview of the database 
contents is provided, and the similarity search tools currently available on the respective 
websites focus on substructures, which is not well suited when relatively large molecules such 
as peptides are used as queries. An overview and searching across the entire content of this 
diverse family of large molecules is also not possible through specialized databases of 
biomolecules,72 such as those for peptides,73,74 oligonucleotides,75 lipids,76,77 or glycans.78–80 
Furthermore, the descriptions of chemical spaces for large molecules to date have remained 
focused on specific classes such as peptides and peptide macrocycles.81,68  
 Here we address this problem by designing web-based interactive tools to explore large 
molecules in PubChem and ChEMBL. We focus on molecules breaking at least one of the four 
Lipinski constraints for oral bioavailability (rule of 5: Molecular weight MW ≤ 500, number 
of hydrogen bond donor atoms HBD ≤ 5, number of hydrogen bond acceptor atoms HBA ≤ 10, 
calculated octanol/water partition coefficient clogP ≤ 5). 13 Although many orally available 
drugs, including peptides in particular, largely exceed Lipinski’s rule of 5 limits,82–85 Lipinski’s 
criteria represent a useful definition to identify molecules that are clearly different from 
classical small molecule drugs. This concerns seven million of the 94 million entries in 
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PubChem and 180,185 of the nearly 2 million  entries in ChEMBL 24.1, which are described 
herein as the non-Lipinski PubChem (NLP) and non-Lipinski ChEMBL (NLC).83,86   
 To describe NLP and NLC, we aimed to create an interactive map of the databases and 
a similarity search tool to identify analogs of user-defined query molecules. We have 
previously reported interactive 2D- and 3D-maps and similarity search tools for a variety of 
small molecule databases.24,46,87–91 In these applications, composition fingerprints such as 
MQN (Molecular Quantum Numbers)92 and SMIfp (SMILES fingerprint)93 provided readily 
interpretable maps when projected by principal component analysis (PCA).94 Composition 
fingerprints also provide interesting associations between molecules in similarity search 
tools.95 However, maps and similarity searches based on these composition fingerprints are not 
well suited for larger molecules. For example, they do not distinguish between peptides of 
different sequences if they have the same amino acid composition.   
 To obtain a meaningful classification of NLP and NLC, we use the principle of atom-
pair fingerprints, which consider pairs of atoms and the distance separating them as structural 
features, and assign these features to bit values either by hashing or by counting.10,43,88,96. Atom 
pair fingerprints tailored for small molecules such as CATS,43 Xfp,9  and 3DXfp97 have been 
shown to represent molecular shape and pharmacophores. Furthermore, we have already used 
atom pair fingerprints successfully to describe large molecules, in one case for detailed 
comparisons of 3D-models of biomacromolecules such as proteins and nucleic acids in the 
Protein DataBank (PDB),98 and in the second case to perform virtual screening in libraries of 
peptide dendrimers and bicyclic peptides.4–6 In the latter case our atom-pair fingerprint analysis 
perceives meaningful differences between peptides of identical composition but different 
sequences.  
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Here we introduce a new fingerprint denoted MXFP (macromolecule extended atom-pair 
fingerprint), which counts atom pairs in seven different categories up to topological distances 
exceeding 300 bonds. We show that MXFP is well suited to describe NLP and NLC in the form 
of two web-based applications. First, we present interactive chemical space maps based on 
MXFP featuring an easily interpretable classification of NLP and NLC. Second, we report a 
similarity search tool identifying analogs of any query molecules based on MXFP similarity. 
These tools offer an unprecedented insight into the contents of NLP and NLC and reveal 
associations between large molecules which are otherwise difficult to identify. 
2.2 Methods 
2.2.1 Non-Lipinski subsets  
Compound ID (CID) and SMILES were extracted for each entry in the PubChem Compound 
Database (downloaded April 5, 2018). For each entry, if more than one molecule was present, 
only the biggest fragment SMILES (based on its length) was considered for property and 
fingerprint calculations, however the entire SMILES was preserved. The SMILES were 
protonated (pH 7.4) using ChemAxon MajorMicrospecesPlugin (https://chemaxon.com). 
Hydrogen bond donor and acceptor count, cLogP and MW were computed for the largest 
fragment in each entry using RDKit, with Lipinski, Descriptors and Crippen modules 
respectively. All molecules violating more than one Lipinski rule were then classified as non-
Lipinski. This led to 7,132,623 entries forming NLP and 183,185 entries forming NLC. 
2.2.2 Property calculation 
For each NLP and NLC entry atoms were classified into the following categories: heavy atom (HA), 
hydrophobic (HY), aromatic (AR), hydrogen bond acceptor and donor (HBA, HBD), positively and 
negatively charged (POS, NEG). AR, and HBA/HBD were assigned with, respectively, the 
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ChemAxon TopologyAnalyzerPlugin, and the ChemAxon HBDAPlugin. HY was assigned to 
aromatic carbons, halogens, sulfur atoms without heteroatom neighbors, and to carbon atoms with 
at least one hydrogen atom neighbor. POS and NEG were assigned based on the atom formal charge.  
2.2.3 Fingerprint calculation 
MXFP is a 217D atom pair topological distance fingerprint calculated using an in-house Java 
program in a similar manner to our previously reported atom pair fingerprints 3DP and 2DP tailored 
for peptides and proteins.4–6,98 Topological distances are measured using the 
TopologyAnalyzerPlugin provided as part of the JChem library by ChemAxon. There are seven 
atom categories: heavy atom (HA), hydrophobic (HY), aromatic atoms (AR), hydrogen bond 
acceptor and donor (HBA, HBD), positively charged (POS) and negatively charged (NEG), and 
only same-category atom pairs are considered. Each of the 217 values is the sum of contributions of 
atom pairs at a given distance for a given atom category. For each category C, all possible atom pairs 




Atom pair distances djk are topological distances counted in bonds through the shortest path between 
two atoms. For each atom pair jk, gjk(di) is the value at distance di of a Gaussian of 18 % width 
centered on djk (Figure 4a). Gaussian values gjk(di) are sampled at the following 31 distance values 
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84.8, 100.0, 118.0, 139.3, 164.4, 193.9, 228.9, 270.0, 318.7. Each of these 31 gaussian values is 
normalized to the sum of all 31 values, sjk, so that each atom pair contributes equally to the 
fingerprint. The sum of normalized gaussian contributions from all atom pairs of a certain atom 
category at distance di, is normalized by the number of category atoms to the power 1.5 to reduce 
the sensitivity of the fingerprint to molecule size, multiplied by 100 and rounded to unity to give the 
final fingerprint bit value vci. The 31 fingerprint bit values from each of the 7 atom categories are 
finally corrected by a category specific factor and joined, yielding the 217D fingerprint vector. In 
this work, we corrected the fingerprint bit values for the heavy atoms (HA) and aromatic atom (AR) 
categories by a factor 0.5 because the bit values were too high relative to the other atom categories. 
We calculated MXFP for the largest fragment in each NLP entry, but retained the complete SMILES 
in each entry.  
2.2.4 Linearity calculation 
The linearity of molecule m, L(m), is a descriptor derived from MXFP. L(m) is defined as the 
ratio of w(m) and w(a), where a is the linear alkane with the same number of heavy atoms as 
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compound was selected at random in each of the 1,000 resulting value triplets, which provided 
324 reference molecules (676 of the value triplets did not contain any entry). For each database 
entry, the city-block distance in the MXFP chemical space, CBDMXFP, to each of these 324 
reference molecules was then calculated, giving a 324D NLP similarity space. The same 
approach was used to select reference molecules for NLC. Of the 1,000 triplets, 800 were 
discarded as they were not occupied by any entry, leading to a 200D NLC similarity space. The 
324 NLP and 200 NLC references have very diverse structures (SMILES are provided in the 
SI).    
2.2.6 Visualization in Faerun 
The first three PCA components of the NLP and NLC similarity spaces were visualized in 
Faerun (variance covered, respectively: PC1 49%, PC2 28%, PC3 8%, and PC1 70%, PC2 
15%, PC3 6%). A plain text file containing CID, SMILES, fingerprint, and properties of each 
NLP entry was processed using the Faerun preprocessing chain, which also includes a PCA 
service. Then Faerun was run using a docker container (https://github.com/reymond-
group/faerun). Color coding of the Fearun map was enabled for HAC, HY/HAC (hydrophobic 
atoms fraction), AR/HAC (aromatic atom fraction), HBA/HAC (H-bond acceptor fraction), 
HBD/HAC (H-bond donor fraction), POS/HAC (positive charged atoms fraction), NEG/HAC 
(negative charged atoms), C/HAC (carbon fraction), RBC (rotatable bond count), CY/HAC 
(cyclic atom fraction), MW, HBA, HBD and clogP. Fraction values of atom categories are 
calculated from MXFP values, carbon fraction, rotatable bonds, cyclic fraction, MW, HBA, 
HBD and clogP are calculated with RDKit.  
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2.2.7 NLP-NLC comparison 
20,000 entries were randomly picked from NLP or NLC and cut in two subsets of 10,000 entries 
each, A and B. Five series of 10,000 CBDMXFP distances were then calculated as follows: a) 
ANLP to the entire NLC, keeping the smallest non-zero value in each case; b) ANLC to the entire 
NLC, keeping the smallest non-zero value in each case; c) ANLP to BNLP; d) ANLC to BNLC; e) 
ANLP to ANLC. 
2.2.8 Similarity Search 
The similarity search tool is a Python Flask (http://flask.pocoo.org/) app which uses 
Annoy(https://github.com/spotify/annoy) to search the MXFP NLP and NLC chemical spaces. 
Annoy is a C++ library with Python bindings developed by Erik Bernhardsson. Given its high 
speed and low memory requirements, Annoy was used to create two separate Annoy search 
files of NLP and NLC (for both, using n_trees = 50, matrix = Manhattan). In each similarity 
search instance, the user chooses to search NLP or NLC, and the correspondent Annoy file is 
selected. The Annoy file is used by the web app (with search_k = default) to retrieve the 
compound IDs of a pool of nearest neighbors (the no. of molecules to retrieve is a user choice). 
Then the compound IDs are associated back to the correspondent PubChem or ChEMBL 
SMILES. The results are displayed using SmilesDrawer.99 The Similarity Search code is 
available open source at https://github.com/reymond-group/SimilaritySearch. 
2.3 Results and Discussion 
2.3.1 Non-Lipinski subsets 
We define non-Lipinski molecules as those breaking at least one of the four Lipinski criteria 
(MW ≤ 500, HBD ≤ 5, HBA ≤ 10, clogP ≤ 5). For each PubChem and ChEMBL entry we 
applied the analysis to the largest molecular fragment, ignoring counter ions in the case of salts. 
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When applied to the currently 94 million PubChem entries, these criteria selected 7,132,623 
entries, which are defined here as NLP. NLP is a diverse set, with MW spanning from 181.15 
Da to 19511.8 Da, clogP from -219.4 to +132.4, HBA from 0 to 442, and HBD from 0 to 235 
(Figure 3, in green). The same analysis applied to ChEMBL led to 183,185 molecules, defined 
here as NLC, with MW spanning from 298.1 to 10173.49 Da, clogP from -67.9 to +101.8, HBA 
from 0 to 286, and HBD from 0 to 124 (Figure 3, in magenta). 
 
Figure 3. 1D-Histrograms of NLP (green) and NLC (magenta). a) MW, b) clogP, c) HBA, d) HBD. the 
vertical red dashed line indicates Lipinski’s rule thresholds (MW = 500 Da, clogP = 5, HBA = 10, 
HBD = 5). 
 
2.3.2 Macromolecule extended atom-pair fingerprint MXFP 
MXFP is a 217D fingerprint counting atom-pairs using a fuzzy approach to assign atom-pairs 
to distance bins as done previously in our analysis of proteins and peptides.4–6,98 In the case of 
proteins, we used an atom-pair fingerprint called 3DP which considers through-space distances 
between atoms in experimental 3D-structures from the Protein Databank.98 To analyze peptides, we 
adapted our approach to use topological distances between residues in a related fingerprint called 
MW clogP
HBA count HBD count
a) b) 
c) d) 
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2DP, with all atoms in a residue positioned at the α-carbon atom.6 For both fingerprints we consider 
four categories of atom pairs deemed essential for peptides, namely all heavy atoms (HA), 
hydrophobic (HY), positively charged (POS), and negatively charged atoms (NEG). For the 
MXFP presented here, we compute exact topological distances between atoms, which is suitable for 
any molecule. Furthermore, we use seven atom categories by additionally computing aromatic 
(AR), H-bond donor (HBD), and H-bond acceptor atoms (HBA), which are important to 
differentiate molecules such as polycyclic aromatic hydrocarbons, oligosaccharides, and 
oligonucleotides. As for 3DP and 2DP, we do not consider cross-category atom pairs in MXFP.   
The 7,132,623 molecules in NLP correspond to 4,753,197 unique MXFP value bins. 
The occupancy of the MXFP bins follows a power law distribution with 75% of the bins 
containing only a single NLP entry (blue line, Figure 4b). A similar molecules/MXFP-bins 
distribution is found for NLC, where the 183,185 molecules correspond to 153,616 unique 
MXFP values bins (green line, Figure 4b).  
 
Figure 4. (a) In red Gaussian gjk for an atom pair at topological distance djk = 220. In blue the 31 
distances d0 to d30 at which gjk is sampled for calculating the contributions to MXFP. (b) Distribution 
of database entries in the unique MXFP-value bins (NLP in blue, NLC in green) and in the Faerun bins 
(NLP in orange, NLC in magenta). (c) Values of the first 31 MXFP bits for C70 Fullerene (magenta) 
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The multiply occupied MXFP bins mostly contain entries sharing the same largest molecular 
fragment, or molecules with different structures but identical MXFP values such as 
diastereomeric carbohydrates (MXFP does not consider stereochemistry), or molecules with 
identical frameworks but different degrees of unsaturation such as lipids with fatty acids of 
equal length but different numbers of double bonds (MXFP does not distinguish non-aromatic 
carbon atoms with different degree of unsaturation). Note that grouping salts of the same 
compound with different counter ions, diastereoisomers of the same molecule or molecules 
only differing in the number of non-aromatic double bonds, makes perfect sense in the 
perspective of an analysis aiming at providing an overview of the database rather than a unique 
identifier for each entry. MXFP values are calculated using the same approach and the same 
parameters as used previously for 3DP and 2DP. In detail, each atom pair is converted to a 
Gaussian of 18 % width centered at the atom pair topological distance, which is the shortest 
path between the two atoms counted in bonds. This Gaussian is then sampled at 31 distances 
di spanning from d0 = 0 to d30 = 317.8 bonds at exponentially increasing intervals (Figure 4a). 
The sampled Gaussian values are normalized and added to the MXFP distance bins for the 
corresponding atom-pair category, and distance bins of each category are normalized to size 
(Equation 2). Sampling atom-pair Gaussians at exponentially increasing distances allows to 
describe molecules up to a very large size using only a limited number of dimensions in the 
atom pair fingerprint. The approach furthermore partly erases differences between atom pairs 
separated by a similar number of bonds at large distances, which favors the perception of global 
molecular shape over structural detail. 
 Atom-pair fingerprints such as MXFP perceive molecular shape because spherical or 
cyclic molecules have a larger number of atom-pairs separated by short distances compared to 
linear molecules of the same size. Here we define a linearity descriptor L as a measure of 
topological molecular shape derived from the MXFP fingerprint. The linearity L(m) of 
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molecule m is defined as the ratio of the weighted mean of the heavy atom pair bin index in the 
MXFP of molecule m, w(m), to the same value for a linear alkane a with the same number of 
heavy atoms, w(a) (Equation 3). The linearity value is 1 for the linear alkane, and lower for 
more globular molecules, e.g. L(fullerene) = 0.4 (Figure 4c). The linearity does not depend on 
building a 3D-model of the molecule as for the principal moments of inertia,100 and is 
applicable to any molecule independent of its conformational flexibility.  
2.3.3 MXFP chemical space visualization in Faerun 
To lower the dimensionality of MXFP for visualizing NLP and NLC, we first attempted a direct 
principal component analysis (PCA) of the two datasets, however the first three PCs only gave 
partial coverage of data variance (48 % and 49%, respectively). We therefore constructed a 
representation based on the principle of similarity mapping.11,101,102 Similarity mapping 
involves calculating similarities to a series of reference molecules in order to create a high-
dimensional similarity fingerprint, which is then projected to lower dimensions by principal 
component analysis (PCA). The approach is interesting because the calculation of similarity 
maps is much faster than other dimensionality reduction methods for visualizing chemical 
space,103,104 and is therefore applicable to very large datasets. Furthermore, many high-
dimensional fingerprints, including MXFP, do not project well into lower dimensions if PCA 
is applied directly to the fingerprint values, even when adding molecules with extreme 
properties, called satellites, as introduced by Oprea and coworkers.65,105 However the 
projection of the corresponding similarity space often produces good results. 
 Similarity maps calculated by randomly choosing a few hundred reference molecules 
usually provide an approximately constant representation which is independent of the choice 
of references. However, the representation can be optimized for specific purposes by selecting 
the reference molecules, for example series of active compounds to visualize a structure-
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activity relationship study,106 or references obtained by sampling regularly across important 
molecular properties to produce an ordered overview of a dataset.107 Here we constructed 
similarity maps by calculating MXFP similarities to reference molecules selected across the 
range of MW, aromaticity and linearity covered by the NLP and NLC datasets, and then 
performing PCA (see methods). The procedure gave 3D-similarity maps covering 85% (NLP) 
and 91% (NLC) of the data variance, which was judged as sufficient to provide a good 
overview of the databases.   
 The 3D-similarity maps were then imported into Faerun, an open-source application 
recently reported by our group for rendering 3D-data interactively on the web.[12g] In this 
application each molecule is represented as a sphere, color-coded by a selected property, while 
its molecular structure is displayed on hover using SmilesDrawer, a compact molecular 
drawing program. These interactive 3D-maps enable rapid browsing through NLP and NLC to 
gain an overview of their contents. As for the MXFP space itself, the distribution of NLP and 
NLC entries into Faerun bins follows a power law (Figure 3b, NLP orange line, NLC magenta 
line). The high-resolution NLP map contains a total of 1,413,817 bins, corresponding to an 
average of five molecules per bin. Multiple occupancies per bin in the NLP similarity map 
occur in part for the same reasons as for the MXFP bins, but also due to rounding of coordinates 
in the similarity map since bins (spheres) are placed on a 500 × 500 × 500 grid. The similarity 
map of NLC contains 123,878 bins, with an average of 1 molecule per bin. Note that each bin 
(sphere) in the Faerun map can be opened in a separate tab showing the distribution of 
molecules in the similarity space at higher resolution. 
 The MXFP-similarity 3D-maps of NLP and NLC are best inspected by using the web-
based view (http://faerun.gdb.tools/). We have color-coded these maps according to different 
descriptors from lowest (blue) to highest (magenta) value (see methods for details). A selection 
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of images of these color-coded representations illustrate the organization of NLP (Figure 5) 
and NLC (Figure 6) in the MXFP similarity space.  
 NLP forms a curved 3D-shape resembling a wave in which the smallest molecules are 
grouped on one side of the wave’s head, intermediate sized molecules occupy the rest of the 
wave’s head and the wave’s body, and the largest molecules form the wave’s tail, as illustrated 
by color-coding according to molecule size (Figure 5a). Color-coding by aromatic atom 
fraction shows that the outer shell of the wave’s head contains molecules with the highest 
fraction of aromatic atoms (magenta), which are mostly polycyclic hydrocarbons (Figure 5b). 
The same view shows that the inner shell along the entire wave contains molecules with very 
few aromatic carbon atoms (blue), which comprise many linear alkanes, polyethyleneglycols, 
polyamines, as well as peptides. The intermediate layer contains molecules with intermediate 
aromatic atom fraction values (green), which are linker-extended drug-type molecules in the 
wave’s head containing the lower size range, and oligonucleotides at the edge of the wave’s 
tail containing the largest molecules. Oligonucleotides at the wave’s tail are well visible in the 
map, color-coded by the fraction of negatively charged atoms (Figure 5c). This map also shows 
a group of smaller and more compact anionic molecules within the wave’s head, which 
correspond to a variety of aliphatic polyphosphates and polycarboxylates.  
 The NLP similarity map also separates molecules according to their shape as measured 
by the MXFP derived linearity descriptor L discussed above (Figure 5d). The narrow blue 
region at the wave’s head corresponds to globular molecules with a high percentage of aromatic 
carbons such as fullerenes. A second narrowly defined region at the center of the inner shell is 
colored in magenta and features strictly linear molecules containing long alkyl or polyethylene-
glycol chains without any branching points. Peptides and oligonucleotides appear at 
intermediate values of linearity (yellow), which reflects the fact that these molecules are 
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multiply branched by the attachment of amino acid side-chains (peptides) and nucleosides 
(oligonucleotides) along the main peptide respectively phosphodiester chain. 
 The different compound families are nicely separated by color-coding by the fraction 
of carbon atoms (Figure 5e). The figure shows examples of polycyclic hydrocarbons 
(exabenzocoronene, carbon fraction = 1.0, magenta), carbohydrates (difucosyllacto-N-
hexaose, carbon fraction = 0.56, blue), peptides (exenatide, carbon fraction = 0.62, green) and 
oligonucleotides (mipomersen sodium, carbon fraction = 0.50, blue). Note that a close 
inspection of the MXFP similarity map of NLP using Fearun reveals many entries that are 
obvious mistakes in the PubChem database. For example, most mipomersen structures in 
PubChem are not drawn as the correct phosphorothioates but as the incorrect phosphate 
thioesters. Further structures of doubtful identity are also visible that contain linear chains of 
nitrogen and oxygen atoms. 
 NLC forms a similar but more sparsely populated wave-shaped 3D-similarity map. As 
with NLP, molecular size increases when navigating the map from the wave’s head to its tail 
(Figure 6a, HAC color code). Aromaticity is higher in the outer shell of the wave head and 
diminishes upon traversing the map towards its inner shell (Figure 6b, AR/AHC color code). 
Compared to NLP (Figure 5b) the highly aromatic outer shell is less populated. Browsing this 
area in Fearun reveals an almost total absence of polycyclic hydrocarbons. As for NLP, the 
inner shell of the wave-shaped map contains mostly polyethylene-glycols, polyamines, and 
peptides, however the linear alkanes seen in NLP are mostly missing. As in NLP, the 
intermediate shell at the edge of the wave’s tail with intermediate aromatic fraction (in green) 
contains oligonucleotides. Oligonucleotides are also well visible in blue using the NEG/HAC 
color code (Figure 6c). In terms of molecular shape, color coding by linearity L shows a similar 
distribution as for NLP (Figure 6d).  
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Figure 5. Similarity map of the NLP chemical Space colored using HAC (a), AR/HAC (b), 
NCHRG/HAC (c), linearity (d), and carbon fraction (e). In d are shown different rotation of the map. 
In e is shown the placement and the structure of hexabenzocoronene, difucosyllacto-N-hexaose, 
exenatide, and mipomersen sodium, as representative compounds of, respectively, polycyclic 
hydrocarbons, carbohydrates, peptides, and oligonucleotides. 
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Figure 6. Similarity map on the MXFP NLC chemical Space colored using HAC (a), AR/HAC (b), 
NCHRG/HAC (c), linearity (d), and carbon fraction (e). In d are shown different rotation of the map. 
In e is shown the placement and the structure of hopenyl Palmitate, acemannan, pramlintide, 
andagatolimod, as representative compounds of, respectively, high carbon fraction molecules, 















Agatolimod (0.49 C fraction)Hopenyl Palmitate (0.96 C fraction)
Acemannan (0.57 C fraction)
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As with NLP, coloring the NLC similarity map by carbon fraction separates different 
compound families (Figure 6e). The figure shows examples of steroids (hopenyl palmitate, 
carbon fraction = 0.96, magenta), carbohydrates (acemannan, carbon fraction = 0.57, blue), 
peptides (pramlintide, carbon fraction = 0.62, green) and oligonucleotides (agatolimod, carbon 
fraction = 0.49, blue). 
2.3.4 Comparing NLC with NLP 
Because ChEMBL is one of the sources that feeds into PubChem, NLC represents a small 
(2.7%) subset of NLP.108,109 To investigate if the remaining 97,8% of NLP cover a broader or 
different chemical space compared to this small NLC subset, we analyzed the CBDMXFP 
distance distribution between 10,000 randomly picked NLP molecules and their NLC nearest 
neighbors, between NLC nearest neighbors, and between random pairs in NLP, NLC, and 
between NLP-NLC cross-pairs (Figure 7).  
 
 
Figure 7. Distribution of CBDMXFP distances between NLC and NLP molecules for nearest neighbors 
(NNs) and random pairs (RPs). See text and methods for details.   
 
The analysis shows that 50% of NLP molecules have a nearest neighbor in NLC within 
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a slightly larger distance distribution compared to the distance separating NLC nearest 
neighbors (Figure 7, magenta line). These nearest neighbor distances are much shorter than 
distances between random pairs of molecules within NLP (Figure 7, cyan line), within NLC 
(Figure 7, orange line), or between NLP and NLC molecules (Figure 7, blue line). We conclude 
that NLC and NLP cover a similarly broad chemical space, that NLC represents an almost 
random subset of NLP, and that NLP, although being 37-fold larger than NLC, does not cover 
a significantly different chemical space.  
2.3.5 MXFP similarity search 
PubChem currently offers a similarity search window in its beta version, which provides 
meaningful analogs of most query molecules. Unfortunately, this search option is designed for 
small molecules and fails to return any analog or does not return meaningful analogs when 
challenged with large molecules, most often when the query molecule is not itself present in 
PubChem. The same issue is experienced using the search function in ChEMBL. Examples of 
failed searches are shown in Table 21.  
 Here we designed an MXFP-similarity search tool for NLP and NLC as a web-portal 
using the approximate nearest neighbor search Annoy (Approximate Nearest Neighbors Oh 
Yeah, https://github.com/spotify/annoy) (Figure 8). This search option allows the user to 
browse NLP or its subset NLC and returns hundreds of MXFP-analogs of a query molecule in 
approximately 30 second per query.  
 The MXFP similarity search often returns results comparable to those provided by the 
PubChem and ChEMBL webpages whenever matched molecules have comparable 
substructures. However, compared to the PubChem and ChEMBL websites, which often fail 
to return results for unusual queries, MXFP similarity search provides a list of analogs in all 
cases. Analogs identified by MXFP similarity often comprise molecules with an overall 
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molecular shape comparable to the query molecules, but with different structural composition. 
A good example is provided by searching NLP and NLC for analogs of T7, an antimicrobial 
peptide dendrimer with an unusual multi-branched peptide architecture which is active against 
multidrug resistant Gram-negative bacteria.4 While the PubChem and ChEMBL webpages do 
not find any meaningful analogs for this query, returning smaller and linear peptides, our 
MXFP similarity search points to related polycationic dendritic molecules of very different 
detailed structure. Besides many structures coming from patents, one example of interest at 
rank 4 in the search is CID 49775868, which is a peptide derivatized dendrimer of overall 
similar size, charge and shape as T7, but with very different detailed structure, reported to be 
active against HIV (Figure 8).110  
2.4 Conclusion  
Here we focused on developing interactive tools to visualize and search large molecules in 
PubChem and ChEMBL breaking at least one of Lipinski’s constraints for bioavailbility, 
defined here as NLP (7 million molecules) and NLC (180 185 molecules). We defined a 217D 
atom-pair fingerprint, MXFP, to describe these molecules in terms of molecular shape and 
pharmacophores. While MXFP is in principle suitable to describe molecules across the entire 
size range, here we focused on using this fingerprint to represent NLP and NLC in an 
interactive 3D-map and to enable a similarity search tool. These tools allow to rapidly browse 
through these diverse collections of macromolecules with unprecedented efficiency and 
identify interesting compound families and similarities between molecules which are otherwise 
difficult to perceive. 
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Figure 8. MXFP web interface. MXFP similarity search results for peptide dendrimer T7. 
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Chapter Three – One Molecular 
Fingerprint to Rule them All: 
Drugs, Biomolecules, and the 
Metabolome 
This work is based on the peer-reviewed publication: 
Capecchi, A.; Probst, D.; Reymond, J.-L. One Molecular Fingerprint to Rule Them All: Drugs, 
Biomolecules, and the Metabolome. J. Cheminformatics 2020, 12 (1), 43. 
https://doi.org/10.1186/s13321-020-00445-4. 
This article is licensed under a Creative Commons Attribution International License (CC BY 
4.0).  
Abstract 
Background: Molecular fingerprints are essential cheminformatics tools for virtual screening 
and mapping chemical space. Among the different types of fingerprints, substructure 
fingerprints perform best for small molecules such as drugs, while atom-pair fingerprints are 
preferable for large molecules such as peptides. However, no available fingerprint achieves 
good performance on both classes of molecules. 
Results: Here we set out to design a new fingerprint suitable for both small and large molecules 
by combining substructure and atom-pair concepts. Our quest resulted in a new fingerprint 
called MinHashed atom-pair fingerprint up to a diameter of four bonds (MAP4). In this 
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fingerprint the circular substructures with radii of r = 1 and r = 2 bonds around each atom in 
an atom-pair are written as two pairs of SMILES, each pair being combined with the 
topological distance separating the two central atoms. These so-called atom-pair molecular 
shingles are hashed, and the resulting set of hashes is MinHashed to form the MAP4 fingerprint. 
MAP4 significantly outperforms all other fingerprints on an extended benchmark that 
combines the Riniker and Landrum small molecule benchmark with a peptide benchmark 
recovering BLAST analogs from either scrambled or point mutation analogs. MAP4 
furthermore produces well-organized chemical space tree-maps (TMAPs) for databases as 
diverse as DrugBank, ChEMBL, SwissProt and the Human Metabolome Database (HMBD), 
and differentiates between all metabolites in HMBD, over 70 % of which are indistinguishable 
from their nearest neighbor using substructure fingerprints.   
Conclusion: MAP4 is a new molecular fingerprint suitable for drugs, biomolecules, and the 
metabolome and can be adopted as a universal fingerprint to describe and search chemical 
space. The source code is available at https://github.com/reymond-group/map4 and interactive 
MAP4 similarity search tools and TMAPs for various databases are accessible at http://map-
search.gdb.tools/ and http://tm.gdb.tools/map4/.  
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3.1 Introduction  
The diversity and size of the organic molecules of possible interest as drugs steadily increases 
as medicinal chemistry addresses ever more complex biological processes while also exploiting 
the expanding scope of synthetic organic chemistry.111–113 Cheminformatics enables the 
exploitation and understanding of this diversity by describing molecules as molecular 
fingerprints, encoding their structural characteristics as a vector.114,115 These fingerprints can 
be used for fast similarity comparisons forming the basis for structure-activity relationship 
studies, virtual screening, and the construction of chemical space maps.45,116–118   
 Most molecular fingerprints have been conceived, validated, and used in the context of 
small molecule drugs within the classical Lipinski limits, 13 and are not well suited to describe 
larger molecules. For instance, the most popular molecular fingerprint is the Morgan 
fingerprint, also known as extended-connectivity fingerprint ECFP4.7 ECFP4 belongs to the 
best performing fingerprints in small molecule virtual screening16 and target prediction 
benchmarks,119,120 together with the related MinHashed fingerprint MHFP6.8 Both fingerprints 
perceive the presence of specific circular substructures around each atom in a molecule, which 
are predictive of the biological activities of small organic molecules. However, both have a 
poor perception of the global features of molecules such as size and shape. They also fail at 
perceiving structural differences that may be important in larger molecules, such as 
distinguishing between regioisomers in extended ring systems (e.g. 2,7- versus 2,8-
dichlorodioxin), between linkers of different lengths, or between scrambled peptide sequences 
of identical composition and length.  
 The above limitations can be addressed by using atom-pair fingerprints, 10 which 
encode molecular shape and are often used for scaffold-hopping.121,97,9 We have shown that 
atom-pair fingerprints are suitable to describe large molecules by mapping the Protein 
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DataBank.98 We also used atom-pair fingerprints to discover and optimize novel antimicrobial 
peptides in virtual libraries of bicyclic peptides5,6 and peptide dendrimers,4,122 to create 
chemical space maps24 of molecules beyond the Lipinski limit found in the PubChem and 
ChEMBL databases,14 and to drive a genetic algorithm to produce analogs of peptides with 
diverse chain topologies.25 Overall, atom-pair fingerprints have an excellent perception of 
molecular shape for both large and small molecules and overcome the above-mentioned 
limitations. However, they do not encode molecular structure in detail and perform poorly in 
small molecule benchmarking studies compared to substructure fingerprints such as ECFP4 
and MHFP6.  
 Here we set out to investigate if the atom-pair approach could be combined with circular 
substructures as implemented in the above mentioned MinHashed fingerprint MHFP6 to create 
a new fingerprint suitable for small molecule virtual screening but also capable of describing 
large molecules including biopolymers such as peptides. Such a fingerprint would provide an 
elegant unified description of molecules across very different sizes and might also be useful to 
describe molecules of intermediate size such as large natural products and metabolites. Our 
quest uncovered a new fingerprint which we call MAP4 (MinHashed Atom-Pair fingerprint up 
to four bonds). MAP4 encodes atom pairs and their bond distance similarly to the AP 
fingerprint implemented by RDKit,123 however in MAP4 atom characteristics are replaced by 
the circular substructure around each atom of the pair, written in SMILES format. MAP4 uses 
the same MinHashing technique as MHFP6, a principle borrowed from natural language 
processing which enables fast similarity searches in very large databases by locality sensitive 
hashing (LSH). LSH is a technique that allows the creation of self-tuning indexes, which are 
then used to generate a forest of trees that can be traversed for an approximate but fast similarity 
search.124,125,42,126  
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We show that MAP4 outperforms substructure fingerprints in small molecule benchmarking 
studies16 and at the same time outperforms other atom-pair fingerprints in a peptide benchmark 
designed to evaluate performance on large molecules. Furthermore, we show with the example 
of various interactive tree-maps (TMAPs) 12 that MAP4 has excellent properties to map the 
chemical space of databases of molecules of interest across the life sciences such as bioactive 
molecules of various sizes (DrugBank,127 ChEMBL,128 non-Lipinski ChEMBL),14 peptides 
(peptides up to 50 residues from SwissProt),129,130 and metabolites (Human Metabolome 
database).17  
3.2 Methods 
3.2.1 Fingerprint calculation 
The MinHashed Atom Pair (MAP) fingerprint calculation requires a canonical and anisomeric 
SMILES representation of the input molecule, as well as the parameter r, which signifies the 
maximal radius of the circular substructures to be considered (default radius value r = 2 
corresponding to a diameter d = 4 for MAP4). The fingerprint is calculated as follows: First, 
the circular substructures surrounding each non-hydrogen atom   in the molecule at radii 1 to 
r are written as canonical, non-isomeric, and rooted SMILES string   𝑟    using RDKit.
131 
Second, the minimum topological distance 𝑇     separating each atom pair       in the input 
molecule is calculated. Third, all atom-pair shingles   𝑟   |𝑇    |  𝑟    are written for each 
atom pair       and each value of  , placing the two SMILES strings   𝑟    and   𝑟    in 
lexicographical order (Figure 9). Fourth, the resulting set of atom-pair shingles is hashed to a 
set of integers    using the unique mapping SHA-1,
40 and its corresponding transposed vector 
  
𝑇 is finally MinHashed to form the MAP4 vector Equation 4). A detailed description of the 
MinHash method used here can be found in our recent publication on MHFP6.8  





In this work, we investigate twelve different variations of the atom pair MinHashed fingerprint  
considering different shingle radii r as MAP2 (r = 1), MAP4 (r = 2), MAP6 (r = 3), and MAP8 
(r = 4), each of them in a 1024-dimensions and 2048-dimensions versions, as well as 2048-
dimensions folded (instead of MinHashed) variants using the modulo operation in form of 
foldedAP2 (r = 1), foldedAP4 (r = 2), foldedAP6 (r = 3), and foldedAP8 (r = 4).  
3.2.2 Peptide benchmark datasets 
Thirty random linear sequences (ten 10-mers, ten 20-mers, and ten 30-mers) were generated 
with each of all 20 proteogenic amino acids picked with the same probability (Table 22). For 
each sequence, we produced 10,000 scrambled unique versions using all amino acids of the 
parent sequence in random different combination. We also produced 10,000 mutated unique 
versions by considering the sequence length as the maximum number of possible mutated 
residues, and for each possible number of point mutations, we generated n mutated sequences, 
where n=ceiling(10,000/maximum number of possible mutations); if more than 10,000 
sequences were produced, only the first 10,000 were selected. The scrambled and the mutated 
sets were searched with BLAST124 using the original sequence as a query. The search was 
performed with blastp using default settings (Gap opening penalty = 11, Gap extension penalty 
= 1, Expectation value = 10.0, Word size = 3, Max scores = 25, Max alignments = 15, Query 
filter = SEG, Matrix = blosum62). The resulting BLAST analogs (Expectation value < 10.0) 
were labelled as active, while the remaining sequences were labelled as decoys. The protonated 
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SMILES of all peptide sequences were generated using a method of the recently published 
Peptide Design Genetic Algorithm (PDGA). 25 To generate the extended fingerprint benchmark 
training lists for each peptide dataset, 50 different sets of 5 actives and 10% of decoys were 
randomly picked and stored using the Python package pickle. The peptide active and inactive 
datasets and the training lists can be found at https://github.com/reymond-group/map4.  
3.2.3 Benchmark metrics and parameters  
To evaluate the fingerprints in the extended benchmark, we used the following metrics: AUC, 
EF1, EF5, BEDROC20, BEDROC100, RIE100, and RIE20. The virtual screening was 
repeated five times with five different queries. To assess similarity (or dissimilarity) among 
molecules in the benchmark virtual screenings, we used the Jaccard similarity for MinHash-
based fingerprints, Manhattan distance for the 217-dimensions atom-pair fingerprint MXFP 
(macromolecule extended atom-pair fingerprint), and Dice similarity in all other cases. Details 
regarding the benchmark implementation can be found in the 2013 Riniker et. al. publication.16 
3.2.4 Similarity Search databases preprocessing  
ChEMBL 25.0 and Metabolome 4.0 were extracted and manipulated as follows: (1) All 
structures were canonicalized and chirality information was removed using RDKit; (2) 
fragments were removed; (3) Heavy atoms were counted using RDKit and compounds with 
less than 2 heavy atoms were discarded. The filtering resulted in 1,699,888 and 96,456 unique 
SMILES for the ChEMBL and Metabolome datasets respectively. For ChEMBL molecules, 
activity information was extracted if present but only when the confidence score was above 5 
for a standardized value ≤ 10,000 nM. In the Human Metabolome database preprocessing, the 
metabolite source was always annotated if available. Natural peptide sequences with 50 of 
fewer residues were extracted from the SwissProt dataset and translated into non-chiral 
SMILES using PDGA, 25 resulting in 9,054 unique structures. 
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The three datasets were encoded with MAP4 and MHFP6 in 512-dimensions. For each 
database and fingerprint variant, an LSH forest of 32 trees was generated using the TMAP 
class. These LSH forests were used as an index for the similarity search. For details on MHFP6, 
and LSH forest implementation please refer to the recent Probst and Reymond publications.8,12  
3.2.5 Similarity Search Implementation 
A fast similarity search tool was implemented for ChEMBL, SwissProt, and the Metabolome 
databases. The given query is canonicalized and chirality information is removed with RDKit. 
Then, the nearest neighbors of the processed query are retrieved using the LSH forest 
corresponding to the chosen database to search in. The query molecule can be provided as a 
SMILES (drawn structure or pasted SMILES in the JSME editor)132 or as a linear sequence of 
a natural peptide. In the latter case, the sequence is transformed into its corresponding SMILES 
using PDGA as for the SwissProt database and the benchmark compounds. The code of the 
similarity search is available at https://github.com/reymond-group/map4. 
3.2.6 Databases preprocessing for TMAP 
For SwissProt, the previously mentioned similarity search LSH forest was used. ChEMBL 
25.0, Metabolome 4.0, and Drugbank 5.4 were extracted and compounds with less than 2 atoms 
were discarded, resulting in 1,870,343, 114,016, and 10,607 SMILES for the ChEMBL, 
Metabolome, and Drugbank datasets respectively. A subset of the ChEMBL database was 
generated by random sampling of 187,034 compounds (10%). Activity information of 
ChEMBL molecules and sources of metabolome molecules were extracted as previously 
described for the Similarity Search databases. To provide a TMAP focused on the larger 
structures in the database, ChEMBL molecules that broke more than one Lipinski’s rules of 
five 13 were collected to form an additional dataset containing 229,067 entries (Lipinski 
descriptors were calculated using RDKit).  
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For the SwissProt database, positive and negative charges were calculated directly from the 
peptide sequences: R and K counted as a positive charge each, D and E counted as a negative 
charge each, all other residues were considered neutral. The number of aromatic atoms (AR) 
was calculated counting all lowercase “c”, “n”, “s”, and “o” not belonging to a two-letter 
element in the canonical SMILES. All other properties were calculated using RDKit. 
The five datasets were encoded with MAP4 in 512-dimensions. For each database and 
fingerprint version, an LSH forest of 32 trees was generated using the TMAP class. The 
obtained LSH forests were used to layout the corresponding TMAPs. The color-codes of 
property values on each TMAP (accessible via the TMAP menu) were obtained by first ranking 
molecules using SciPy,133 and then assigning the rank to a color linearly along the color scale. 
For the property “Phosphorus count” we used a dense ranking, in which molecules with the 
same number of P atoms receive the same rank. For all other properties a standard (or average) 
ranking was used: the average of the ranks that would have been assigned to all the tied values 
was assigned to each value. For details on TMAP please refer to the related publication. 12 
3.2.7 Nearest neighbor analysis 
The Human Metabolome data set was sorted unique after removing stereochemistry 
information and for each molecule, the distance from its nearest neighbor was calculated in the 
MAP4-1024, MHFP6-1024, TT (not hashed), AP (not hashed), and ECFP4-1024 chemical 
spaces. AP, TT, and ECFP4 were calculated with RDKit. In each fingerprint space, for each 
structure, a similarity search against the entire dataset was performed and the NN retrieved. 
The similarity was assessed as Tanimoto Distance calculated with RDKit. 
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3.3 Results and Discussion 
3.3.1 Fingerprint Design 
Our atom-pair fingerprint is designed similarly to the AP fingerprint implemented by RDkit. 
AP encodes atom pairs using atomic invariants combined with their bond distances. Instead of 
using atomic invariants, we use the circular environment of each atom in the pair up to a preset 
radius, written as canonical SMILES, similar to the method used for MHFP6. Recording 
circular substructures is expected to lead to a more detailed perception of substructures in the 
fingerprint enabling better performance in small molecule benchmarks, while the bond distance 
information should translate into a perception of molecular size and shape. For each radius 
value r (typically r = 1 and 2), we encode each atom pair as a character string consisting of the 
two canonical SMILES of the circular substructure around each atom up to the set radius and 
the bond distance information. We then hash these atom-pair strings and use MinHash to 
produce the actual fingerprint to capitalize on the advantages of this approach over binary 
encoding as previously demonstrated with MHFP6 (see methods, Equation 4).8 For example, 
our MinHashed Atom Pair fingerprint with r = 2 (MAP4) encodes pairs of circular 
substructures with radius r = 1 and 2 (Figure 9).  
 
Figure 9. MAP4 atom pair encoding. The circular substructures around atoms j and k at radius r = 1 
and r = 2 are written as SMILES placed in lexicographical order separated by the bond distance between 
the two atoms along the shortest path (blue). These character strings are the atom-pair molecular 
shingles for this atom-pair for r = 1 and r = 2.  
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3.3.2 Benchmarking study design 
To evaluate the performance of MAP4 we use a modified version of the fingerprint benchmark 
developed by Riniker and Landrum. 16 The benchmark provides a detailed insight about the 
performance of an evaluated fingerprint in the recovery of actives in a virtual screening of a 
database of known actives and decoys, where the actives/decoys sets are taken from the DUD,44 
the MUV,134 and the ChEMBL128 datasets. However, since most molecules are within the rules 
of five limits (Figure 38), the benchmark gives no explicit information on the performance of 
an evaluated fingerprint in encoding larger molecules. We have therefore extended the 
benchmark with a series of peptides as exemplary large biomolecules not only because they 
are an important class of drugs, but also because their similarity can be assessed with BLAST, 
a reliable and widely used tool. Our peptide benchmark consists of 60 scrambled and mutated 
peptide datasets generated from 30 randomly generated sequences. In each set the actives and 
decoys are defined through their sequence similarity to the corresponded query: the BLAST 
analogs are labelled as active, while the remaining sequences are labelled as inactive (see 
methods and Table 1). 
  
Table 1. Average number and percentage of actives in all datasets used for the benchmark. 







30.0±0.0 91.3±80.5 100.0±0.0 500.2±0.7 56.0±27.4 
Average % 
actives 
0.2±0.0% 2.2±0.4% 1.0±0.0% 5.3±0.0% 0.6±0.2% 
a) Known actives used in the Riniker and Landrum 16 benchmark. b) BLAST analogs of a defined query 
generated for this study.  
 
We include twenty-one different fingerprints in the comparison, comprising the twelve 
variations of our MAP4 fingerprint as described in the methods, and nine reference fingerprints 
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performing particularly well for small or large molecules. This reference set includes ECFP4 
and MHFP6 in their 1024-dimensions and 2048-dimensions versions as best performing 
fingerprints for small molecules, MXFP (macromolecule extended atom-pair fingerprint, 217-
dimensions atom-pair fingerprint) as a good performing fingerprint for large molecules and 
peptides,25 and the Atom Pair (AP) and Topological Torsion (TT) fingerprints from RDKit. In 
the AP and TT fingerprints atoms are represented using their atom type, their number of heavy 
neighbors, and their number of pi electrons. AP encodes all atom pairs and their distance as a 
number, while TT encodes all atoms along the path between two atoms up to topological 
distance of four bonds. Note that AP and TT are not hashed as in the original benchmark. 
Finally, our reference set includes MACCS and ECFP0 as baseline fingerprints following the 
Riniker benchmark. 16 
We use five different metrics in the benchmark, namely AUC (Figure 10a), RIE100 
(Figure 39a) and RIE20 (Figure 39b), BEDROC100 (Figure 10b) and BEDROC20 (Figure 
39c), and EF1 (Figure 39d) and EF5 (Figure 10c). The relative performance of the different 
fingerprints is then assessed by computing their average rank in each of the metrics following 
the Riniker approach (Figure 11a-c). The statistical relevance of the ranks is assessed with the 
Friedman Test provided in the Riniker benchmark, where the post hoc analysis is performed 
using Wilcoxon-Nemenyi-McDonald-Thompson test (Figure 40 to B.5).135,136 
3.3.3 Benchmarking results 
We first compare MAP4 with the nine reference fingerprints presented above. In the small 
molecule benchmark MAP4 is slightly better than substructure fingerprints (ECFP4, MHFP6, 
and TT), yet the difference is not statistically significant. However, MAP4 outperforms atom-
pair fingerprints such as AP and MXFP, which perform significantly worse in this benchmark 
(Figure 11a and Figure 40). The situation is reversed in the peptide benchmark, where atom-
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pair fingerprints significantly outperform substructure fingerprints (Figure 11b). MAP4 
performs best among these atom-pair fingerprints, however, the difference is not statistically 
significant (Figure 41). Remarkably, MAP4 is the only fingerprint maintaining good 
performances in both benchmarks.  
 Having established that MAP4 outperforms other known fingerprints in the combined 
small molecules and peptides tasks, we next investigate if further improvements might be 
possible in 12 variations of the MAP4 fingerprint considering different shingle radii (r = 1, 2, 
3, 4), compression methods (MinHash versus folding), and the number of dimensions (1024 or 
2048). We include MHFP6-2048 and the RDKit AP as reference fingerprints in this 
comparison. Comparing the average fingerprint rank for small molecules (Figure 12a) and 
peptides (Figure 12b), as well as the performance metrics on each dataset (Figure 42) shows 
that the MinHashed fingerprints (MAPs) rank better than their folded versions (foldedAPs) in 
a statistically significant manner, except for foldedAP2 when using only the small molecule 
datasets (Figure 40 and B.4). The better performance of MinHashed over folded versions of 
the same fingerprint was already observed in our study of MHFP6,8 and probably results from 
the fact that MinHashing creates fewer unintended bit collisions as compared to modulo-based 
hashing (folding) as an information compression method. Bit collision is most likely also the 
reason for the decreasing performance of foldedAPs when the radius, and therefore the encoded 
information, increases. 
Among the different MAPs, those with larger radii perform better, however, the 
difference is not statistically significant. At the same time increasing the radius from r = 1 
(MAP2) to r = 2 (MAP4), r = 3 (MAP6) and r = 4 (MAP8) defines an exponentially increasing 
number of unique atom-paired molecular shingles, as exemplified for the case of the ChEMBL 
database (Table 2). The selected MAP4 (r = 2) represents a compromise to represent 
substructures in reasonable but not exaggerated detail. In the MAP4 ChEMBL space, there are 
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46,430,912 atom-pair molecular shingles. While half of them are seen only once, the most 
common Shingle is present in 85% of ChEMBL structures (Figure 12d). Note that the radius 
can be selected by the user in the current implementation.  
 
 
Figure 10. AUC (a), BEDROC100 (b), and EF5 (c) of MAP4 (magenta), ECFP4 (orange), MHFP6 
(blue), MXFP (solid green line), TT (dashed green line), AP (dotted green line), MACCS (solid gray 
line), and ECFP0 (dashed gray line) across all small molecules and peptide targets (17 MUV targets, 
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Figure 11. Average ranking of MAP4 (magenta), ECFP4 (orange), MHFP6 (blue), MXFP (solid green 
line), TT (dashed green line), AP (dotted green line), MACCS (solid gray line), and ECFP0 (dashed 
gray line) in in the fingerprint benchmark when using only small molecules datasets (17 MUV targets, 
21 DUD targets, and 50 ChEMBL targets, a) and only peptide datasets (30 mutated peptide targets and 
30 scrambled peptide targets, b). Note that 11 out of 21 fingerprints are shown. 
 
Table 2. Analysis of ChEMBL using MinHashed atom-pair fingerprint variants.  
Fingerprinta) Unique Shinglesb) 
MAP2 (r = 1) 1,913,607 
MAP4 (r = 2) 46,430,912 
MAP6 (r = 3) 205,576,613 
MAP8 (r = 4) 465,393,948 
a) MinHashed atom-pair fingerprint version with different shingle radii. b) Number of different atom-
paired molecular shingles in the entire ChEMBL database. 
 
a) DUD, MUV, ChEMBL b) Mutated and scrambled peptides
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Figure 12. (panels a and b) Average rank of AP2 (orange), AP4 (magenta), AP6 (blue), AP8 (green), 
in their 1024-dimensions (solid) and 2048-dimensions (dashed) MinHashed implementation (MAPs), 
and in their 2048-dimensions folded (dotted) implementation (foldedAPs) in the fingerprint benchmark 
when using only small molecules datasets (17 MUV targets, 21 DUD targets, and 50 ChEMBL targets, 
a) and only peptide datasets (30 mutated peptide targets and 30 scrambled peptide targets, b). In both 
panels a and b, MHFP6 (solid) and AP (dashed) are reported in grey. Note that 14 out of 21 fingerprints 
are shown. (c) ChEMBL MAP4 shingles frequency analysis, examples of shingles with different 
frequencies are reported.   
 
The above benchmarking study shows that our MinHashed Atom-Pair fingerprint MAP4 
performs among the best fingerprints for small molecules and the best fingerprints for peptides, 
but is the only fingerprint performing best on both benchmarks. We attribute this combined 
performance to the fact that MAP4 combines circular substructures, which are optimal to 
describe small molecules, with atom pairs as a method particularly well suited for large 
molecules. The benchmark among the different MAP versions furthermore shows that the level 
of detail perceived by the 1024-dimensions MAP4 version is optimal for good performance.   




c) ChEMBL MAP4 Shingles frequency
b) Mutated and scrambled peptides
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3.3.4 Chemical space maps 
To further illustrate the suitability of MAP4 as a molecular fingerprint across various molecule 
families, we consider different databases covering various molecular size ranges and types 
(Table 3), and visualize them in form of chemical space tree-maps (TMAPs). 12 These 
interactive tools can be readily computed exploiting the fact that similarly to MHFP6, MAP4 
is a MinHashed fingerprint, for which one can use locality sensitive hashing (LSH) for 
computing the k-NN tree that is represented in the TMAP even for databases of millions of 
molecules. The TMAPs discussed below are freely accessible at http://tm.gdb.tools/map4/.  
Table 3. Databases illustrated as MAP4 tree-maps.  
Database Sizea) HACb) 
ChEMBLc) 1,870,343 30.0 ± 17.5 
Non-Lipinski ChEMBL 203,850 55.7 ± 38.7 
Human Metabolome 114,016 61.7 ± 28.1 
SwissProt 9,054 237.4 ± 104.7 
DrugBank 229,067 26.2 ± 20.7 
a) number of molecules in the database after pre-processing (see methods). b) HAC = heavy atom count 
given with standard deviation. All non-hydrogen atoms in the molecule. c) The TMAP for ChEMBL is 
limited to a random 10% subset (187,034 compounds) to reduce server load. 
 
Comparing MHFP6 and MAP4-based TMAPs for the ChEMBL database,128 its non-Lipinski 
subset, 14 and DrugBank127 shows that both fingerprints perform comparably well in organizing 
these databases. Although one would expect that MAP4 would perform better than MHFP6 in 
separating molecules by size, this is not the case (Figure 13a/b). The ability of MHFP6 to 
separate molecules by size reflects the fact that in these databases, large molecules contain 
either a larger diversity of substructures or simply different substructures compared to small 
molecules, which results in an implicit size perception in the substructure encoding even if 
these substructures are small. The ability of both MAP4 and MHFP6 to classify molecules 
across different size ranges is well illustrated by visualizing phosphorous-containing 
molecules, which span from inorganic phosphates through cofactors (CoA, NADH) to large 
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therapeutic oligonucleotides (AGRO100, Figure 13c/d). On the other hand, in TMAPs of the 
SwissProt dataset MAP4 separates molecules by size much better than MHFP6 (Figure 14a/b). 
In this case BLAST analogs are also better grouped in the MAP4-based maps than in the 
MHFP6-based maps, in line with the peptide benchmark study (Figure 14c/d).  
 MAP4 also performs much better than MHFP6 for mapping the Human Metabolome 
Database (HMDB). This database contains diverse lipids, phospholipids, carbohydrates, 
glycosides, amino acid derivatives and more.17 In this case, MAP4 produces a very well defined 
TMAP because encoding atom-pairs up to any distance ensures a differentiation between 
molecules containing different numbers of repetitive substructures such as lipids and 
glycosides (Figure 15a). By contrast, MHFP6 fails to properly distinguish between related 
metabolites and the map consists of very large groups of molecules appearing as “grapes” 
(Figure 15b). Analyzing the occupancy of fingerprint value bins shows that for the three 
substructure fingerprints, the ten most populated fingerprint value bins contain a large number 
of molecules, thousands for ECFP4 and MHFP6 and hundreds for TT (Figure 15c). These 
molecules are lipids and phospholipids, and in the case of ECFP4 and MHFP6, these are the 
same molecules (Figure 43, Figure 44, Figure 45). By contrast, atom-pair fingerprints contain 
either a single molecule per bin (MAP4) or at most two or three molecules per bin (AP).  
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Figure 13. TMAPs of Drugbank using MAP4 and MHFP6. (a) MAP4 TMAP color-coded by molecule 
size (HAC). (b) MHFP6 TMAP color-coded by molecule size. (c) Close-up view of (a) color-coded by 
the number of phosphorous atoms per molecule (P count). (d) Close-up view of (b) color-coded by P 
count. Interactive TMAPs of Drugbank, ChEMBL, and non-Lipinski ChEMBL, color-coded with 
additional properties, are accessible at http://tm.gdb.tools/map4/.  
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Figure 14. TMAPs of the SwissProt dataset. (a) MAP4 TMAP and (b) MHFP6 TMAP color-coded 
by HAC. (c) MAP4 TMAP and (d) MHFP6 TMAP color-coded by BLAST analogs of 
MTQRTLRGTNRRRIRVSGFRARMRTASGRQVLRRRRAKGRYRLAVS (P1), 
MELFAALNLEPIFQLTFVALIMLAGPFVIFLLAFRGGDL (P2), TNRNFLRF (P3), and 
MRVNITLECTSCKERNYLTNKNKRNNPDRLEKQKYCPRERKVTLHRETK (P4), 
INLKALAALAKKIL (P5) in the MAP4 (c) and MHFP6 (d) chemical spaces. The interactive maps are 
accessible at http://tm.gdb.tools/map4/.  
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Figure 15. TMAPs of the Human Metabolome Database. (a) MAP4 TMAP and (b) MHFP6 TMAP 
color-coded by OH count. The interactive maps with additional properties are accessible at 
http://tm.gdb.tools/map4/. (c) Human Metabolome compounds per fingerprint bins in the MAP4-1024 
(magenta line, solid), AP (green line, dashed), TT (green line, dotted), MHFP6-1024 (blue line, solid), 
and ECFP4-1024 (orange line, dash-dotted) chemical spaces. 
 
3.3.5 Nearest neighbor searches 
The difference in the MAP4- and MHFP6-based TMAPs of HMDB reflects the ability of 
MAP4 to distinguish between closely related metabolites perceived as identical by MHFP6. 
HMDB contains 96,456 structurally different metabolites not considering stereochemistry. 
Performing an exhaustive nearest-neighbor (NN) search on these metabolites shows that MAP4 
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distinguishes all metabolites from one another without exception (Table 4). By contrast 
MHFP6 finds an indistinguishable NN (JD = 0) in 72.5 % of HMDB molecules. The situation 
is even slightly worse with ECFP4 (72.9 %) and slightly better with TT (71.1 %). On the other 
hand, AP sees an indistinguishable NN in only 1,677 molecules (1.7 %) and is therefore almost 
as good as MAP4. 
Table 4. Nearest neighbor analysis of the Human Metabolome database.a) 
HMBD Subset All  OH = 0 OH = 1 1 < OH ≤ 4  OH > 4 
All 96,456 33,721 10,663 41,493 10,579 
JD(MAP4-1024) = 0 0 0 0 0 0 
JD(AP) = 0 1,677 13 35 1,611 18 
JD(TT) = 0 68,623 27,897 5,782 32,909 2,035 
JD(MHFP6-1024) = 0 69,972 28,502 6,215 33,359 1,996 
JD(ECFP4-1024) = 0  70,329 28,561 6,243 33,294 2,231 
a) Subsets of the Human Metabolome 4.0 Database according to the number of hydroxyl groups per 
molecule separating lipids (OH = 0, 1) from carbohydrate derivatives (OH > 4). For each subset 
(column), the number of molecules is indicated in total (All, line 2) and counting those with an 
indistinguishable nearest neighbor (Jaccard Distance JD = 0) according to the indicated fingerprint (line 
3-7). Molecules were considered after removing stereochemical information.  
 
HMDB can be sorted by OH-count, which approximately separates triglycerides and related 
apolar lipids (OH = 0), diglycerides, alcohols and acids (OH = 1), phospholipids (1 < OH ≤ 4) 
and carbohydrates (OH > 4). Analyzing the number of indistinguishable NN as a function of 
OH count shows that AP mostly fails with phospholipid-type molecules (1 < OH ≤ 4), where 
96.1 % of the 1,677 AP-indistinguishable NN are found. A remarkable example is provided by 
the complex phospholipids HMDB0072949 and HMDB0076236, which are distinguished from 
one another only by MAP4 (Figure 16a). AP also fails to distinguish between 4-phenanthrol 
(HMDB0059800) and 9-phenanthrol (HMDB0059801), the latter being an inhibitor of the ion 
channel TRPM4 (Figure 16b).137 This lack of differentiation by AP is somewhat surprising 
since all other fingerprints easily distinguish between these two isomers, and reflects the fact 
that AP is the only fingerprint in the series which does not perceive atom environments but 
only atomic properties.  
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MAP4 and AP perceive differences between many closely related metabolites that are 
indistinguishable for substructure fingerprints. An interesting example among carbohydrates is 
provided by the branched hexasaccharides HMDB0006605 and HMDB0006614, which only 
differ from one another by the permutation of the fucoside and 4-sialyl-galactoside at the C(3)-
OH and C(4)-OH groups of the central N-acetylglucosamine (Figure 16c). This differentiation 
is enabled by the encoding of atom-pairs at distances longer than the maximum length spanned 
by the substructure fingerprints MHFP6 (six bonds), ECFP4 and TT (four bonds).  
 Encoding atom-pairs at long distances is also what enables atom-pair fingerprints to 
perform well in the peptide benchmark discussed above where BLAST-analogs must be 
recovered from scrambled or mutated sequences. This is well illustrated for NN searches in the 
case of heptapeptides KLLKKLL and KLKKLLL, which are only distinguished from one 
another by MAP4 and AP (Figure 16d). A similar situation arises when considering 
oligonucleotides such as the pair ACTG and ATCG which only differ by the permutation of 
the two central pyrimidine bases (Figure 16e).  
 Inspecting nearest neighbors of any molecule of interest provides an additional 
opportunity to explore the content of large databases, often as a means to perform virtual 
screening to identify analogs. The MinHashed nature of MAP4 enables us to perform extremely 
rapid approximate nearest neighbor (k-NN) searching using locality sensitive hashing (LSH). 
We have therefore prepared MAP4 similarity search portals for the ChEMBL, the Human 
Metabolome, and the SwissProt subset described above, which are freely accessible at 
http://map-search.gdb.tools/. Note that NN-searches using LSH forests are approximate and 
not identical with the exact NN-searches using in the benchmarking study, however, it is well-
known that the results of approximate k-NN searches based on LSH forests are not significantly 
different from exact k-NN searches.138 
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Figure 16. Pairs of molecules better differentiated with MAP4 than with MHFP6, MAP4, TT, AP, and 
ECFP4 and their JD values. (a) Lipids from HMDB, the different position of the lipidic chains is 
highlighted using blue and magenta. (b) Phenanthrol isomers from HMDB. (c) Hexasaccharides from 
HMDB, the α-L-fucosyl and β(3-sialyl)-galactosyl groups exchanged at positions 3 and 4 of the central 
N-acetylglucosamine are highlighted using blue and magenta (structures as given in HMDB with open-
chain form of the first carbohydrate and missing stereochemistry at one center each). (d) Scrambled 
heptapeptides. (e) Scrambled tetranucleotides. 
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3.4 Conclusion 
In summary, combining the principles of circular substructures, atom-pairs, and MinHashing 
produces the MinHashed atom-pair fingerprint MAP4. MAP4 is a new molecular fingerprint 
performing as good as extended connectivity fingerprints such as ECFP4 and MHFP6 on the 
Riniker and Landrum small molecule benchmark, and as good as the RDkit AP fingerprint on 
a new peptide sequence similarity benchmarking set for recovering BLAST analogs among 
scrambled and mutated peptide sequences, designed to evaluate performance on large 
molecules. The high performance of MAP4 in the small molecule benchmark is made possible 
by the substructure encoding which is absent in previous atom-pair fingerprints, while high 
performance in the peptide benchmark reflects the perception of atom-pairs at unrestricted 
topological distances which is missing in substructure fingerprints. While the current version 
of the MAP fingerprint is implemented in Python and therefore it is relatively slow, the 
performance might increase by rewriting the fingerprint in C or C++. 
 The MinHashing used for MAP4 allows the construction of k-NN trees and the creation 
of high-resolution chemical space tree-maps (TMAPs) for databases as diverse as DrugBank, 
ChEMBL, Swissprot, and the Human Metabolome. The MAP4 based TMAPs are much better 
defined than those obtained using the substructure MinHashed fingerprint MHFP6, in 
particular for the case of the Human Metabolome. This is because MAP4 perceives differences 
among highly similar molecules such as lipids with related fatty acid chains which are not seen 
by MHFP6. MAP4 also distinguishes between high-similarity pairs of peptides and 
oligonucleotides perceived as identical by substructure fingerprints such as MHFP6. MAP4 
represents a universal fingerprint to search and map the chemical space across molecules of all 
types and sizes and should be generally useful in the field of cheminformatics.  
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Chapter Four – Assigning the 
Origin of Microbial Natural 
Products by Chemical Space Map 
and Machine Learning 
This work is based on the peer-reviewed publication: 
Capecchi, A.; Reymond, J.-L. Assigning the Origin of Microbial Natural Products by Chemical 
Space Map and Machine Learning. Biomolecules 2020, 10 (10), 1385. 
https://doi.org/10.3390/biom10101385. 
This article is licensed under a Creative Commons Attribution International License (CC BY 
4.0).  
Abstract 
Microbial natural products (NPs) are an important source of drugs. However, their structural 
diversity remains poorly understood. Here we used our recently reported MinHashed Atom 
Pair fingerprint with diameter of four bonds (MAP4), a fingerprint suitable for molecules 
across very different sizes, to analyze the Natural Products Atlas (NPAtlas), a database of 
25,523 NPs of bacterial or fungal origin downloaded from https://www.npatlas.org/joomla/. 
To visualize NPAtlas by MAP4 similarity, we used the dimensionality reduction method tree 
map (TMAP) (http://tmap.gdb.tools). The resulting interactive map 
(https://tm.gdb.tools/map4/npatlas_map_tmap/) organizes molecules by physico-chemical 
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properties and compound families such as peptides and glycosides. Remarkably, the map 
separates bacterial and fungal NPs from one another, revealing that these two compound 
families are intrinsically different despite of their related biosynthetic pathways. We used these 
differences to train a machine learning model capable of distinguishing between NPs of 
bacterial or fungal origin.   
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4.1 Introduction 
Natural products (NPs) of microbial origin are an important source of drugs. Numerous 
examples of antibiotic, antifungal, immunosuppressive, anti-inflammatory, and anti-cancer 
agents on the market originate from fungi or bacteria 139. A notable effort has been done to 
explore the known and virtual chemical space of microbial NPs and NPs in general 140–143. 
Furthermore, machine learning (ML) has been extensively applied to natural product structures, 
for example to classify limonoids and protolimonoids 144, to establish the structural class of a 
natural product with its NMR data 145, to learn estimates of natural product conformational 
energies 146, to generate derivates of NPs or compounds with natural product characteristics 
147–149, to predict Meridian in Chinese traditional medicine 150, and to elucidate the biological 
effects of natural products 151. The recently published Natural Products Atlas (NPAtlas) is a 
collection of 25,523 NPs of fungal and bacterial origin 19. Among other tools, the NPAtlas 
website (https://www.npatlas.org/joomla/) provides a global view of the database in a spherical 
representation. To generate this view, The NPAtlas entries are clustered by Dice similarity 152 
using the substructure fingerprint ECFP4 (extended connectivity fingerprint with a diameter of 
four bonds) 7. The resulting clusters are grouped in nodes, which are arranged in a spherical 
plot where the position of each node is determined by molecular formulas. While this 
representation provides interesting insights on the composition of the NPAtlas, individual 
compounds cannot be visualized in the global overview but only within clusters. Therefore, 
comparing compounds across two different clusters is not possible.  
A defining feature of NPAtlas is that NPs featured in this database span across a broad 
range of sizes, with the largest NPs reaching up to almost 3 kDa (Figure 46). We showed 
recently that the ECFP4 fingerprint, although well suited for small molecule drugs, perform 
poorly with larger molecules typically found in NP collections such as lipids, oligosaccharides, 
and peptides 18. To address this limitation, we recently investigated molecular fingerprints 
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combining the concept of atom pairs 10, which is well suited to analyze large molecules such 
as proteins and peptides 6,14,25,98, with extended connectivity substructures and bit compression 
using MinHash as used in the substructure fingerprint MHFP6 8, and proposed the MinHashed 
atom pair fingerprint with a diameter of four bonds (MAP4) as an optimal molecular fingerprint 
to analyze molecules of very different sizes 18.  
Here we asked the question whether analyzing NPAtlas using MAP4 might provide 
new insights into the composition of this collection. To organize molecules according to their 
MAP4 similarity, we used TMAP, a recently reported dimensionality reduction method 
suitable to analyze very large high-dimensional datasets 12. TMAP performs better for the 
visualization of large high-dimensional data sets than other dimensionality reduction methods 
such as t-SNE 153 or UMAP 57. Furthermore, TMAP is particularly well suited to analyze 
databases of molecules associated with MinHashed fingerprints.  
4.2 Methods 
4.2.1 NPAtlas Dataset 
The December 2019 version of the NPAtlas was used. This version of the database contains 
25,523 entries, 15,759 of fungal origin and 9,764 entries of bacterial origin, with no entry 
sharing bacterial and fungal origin. For each compound, simplified molecular-input line-entry 
system (SMILES), molecular weight (MW), origin (fungal or bacterial), and the DOI of the 
associated publication were downloaded. For the MAP4 fingerprint calculation the SMILES 
were canonicalized 131 and the stereochemistry was removed using the RDKit toolkit 123. After 
removing stereochemistry, the NPAtlas counts 23,928 unique SMILES and 76 entries common 
among both origins. 
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4.2.2 MAP4 Fingerprint 
The MAP4 fingerprint combines the circular substructure and atom pair fingerprints concepts. 
MAP4 encodes each atom pair in a molecule as the SMILES of the circular substructure of 
radii 1 and 2 around both atoms and the distance in bonds that separates them. The resulting 
set of strings is hashed to integers using the SHA-1 algorithm 40 and MinHash scheme 154. The 
obtained MAP4 fingerprint is an array of unsorted numbers, where each feature is characterized 
by its value and its position in the array (index). MAP4 perceives substructure details while 
maintaining a global overview; therefore, it is suitable to describe molecular structures across 
different sizes. The similarity between two MAP4 fingerprints a and b is calculated (1) 
counting of elements with the same value and the same index across a and b, and (2) dividing 
the obtained value by the number of elements of fingerprint a. The similarity between two 
MinHashed MAP4 fingerprints calculated as described above is an estimation of the Jaccard 
Similarity between the two non-MinHashed objects 154. For a detailed explanation if the MAP4 
implementation and benchmark please refer to our recent publication 18. The 1024-dimensions 
MAP4 fingerprint of all NPAtlas entries was calculated using canonical SMILES without 
stereochemistry information.  
4.2.3 TMAP Layout 
The TMAP layout was calculated from the MAP4 fingerprint dataset using the open source 
implementation of TMAP12. In short, the indices generated by the MinHash procedure of the 
MAP4 calculation are used to create a locality-sensitive hashing (LSH) forest 42 of n trees. For 
each NPAtlas entry, the k approximate nearest neighbors (NNs) in the MAP4 feature space are 
then extracted from the LSH forest to form a graph in which nodes are the structures and edges 
are the NN relationships weighted by the fingerprint distance. The Kruskal’s algorithm is then 
applied to remove cycles and to find the path with the lowest total distance between all 
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molecules in the graph 60. Finally, Fearun 24 is used to interactively display the obtained 
minimum spanning tree. In this this study we set n = 32 and k = 20.  
4.2.4 Properties Calculation 
For all NPAtlas entries, the number of hydrogen bond acceptors (HBA) and hydrogen bond 
donors (HBD), logP following Crippens approach (AlogP) 155, topological polar surface area 
(TPSA), and fraction of sp3 carbon (fsp3C) were calculated with RDKit. The boiling point was 
calculated using the open source code of the JRgui 156 as the Joback boiling temperature (TJob, 






where and    is the occurrence of a functional group in the molecule and 𝑡𝑏  is its empirically 
obtained contribution value. Molecules that violated more than one Lipinski rules 13 were 
labelled as non-Lipinski. To identify glycosylated and/or peptidic structures, Daylight 158 
SMARTS language was used. SMILES arbitrary target specification (SMARTS) were used 
with RDKit to identify NPAtlas entries containing a dipeptide substructure, defined as 
“[NX3,NX4+][CH1,CH2][CX3](=[OX1])[NX3,NX4+][CH1,CH2][CX3](=[OX1])[O,N]”, or 
a glycoside substructure, defined as “[CR][OR][CHR]([OR0,NR0])[CR]”. 
4.2.5 TMAP color gradients 
The calculated properties were used to color the generated TMAP. For a clearer color gradient, 
some of the highest and lowest displayed values of the non-ranked properties have been 
adjusted. All MW values ≥ 1,000 Da are displayed as 1,000 Da, all boiling point values ≥ 2,000 
K are displayed as 2,000 K, all HBD count values ≥ 10 are displayed as 10, all AlogP values ≥ 
8 are displayed as 8, all AlogP values ≤ -2 are displayed as -2, and all TPSA values ≥ 500 are 
displayed as 500. The color-codes of the ranked property values were obtained by average 
𝑇𝐽𝑜𝑏 = 198.2 +    𝑡𝑏 
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ranking them using SciPy 133. In average ranking if two or more values have the same rank the 
average rank of the tied values is assigned to each of them. For details on TMAP please refer 
to the related publication 12.  
4.2.6 Support vector machine (SVM) and k-nearest neighbor (k-NN) 
classifiers 
The k-nearest neighbor (k-NN) algorithm is a simple ML method that predicts the query to 
belong to the class most found amongst its k nearest neighbors. A support vector machine 
(SVM) represents a more complex ML approach; an SVM maps its input into a high-
dimensional feature space and tries to find the best separation between two classes, such as 
they entirely lay on the opposite side a hyperplane. To do so, the SVM maximizes the margin 
between the closest points, known as support vectors, and the hyperplane. Mapping features 
explicitly into a higher dimensional space is computationally expensive and not feasible even 
for small datasets. To avoid it the SVM uses the so-called “kernel trick”, which essentially uses 
a similarity matrix of the input data instead of the input itself; this allows the SVM to define 
the hyperplane and the support vectors in a less expensive manner 159. In cheminformatics, both 
k-NN and SVM inputs can range from SMILES to various molecular descriptors. For this work 
three classifiers were implemented: a MAP4 based k-NN (MAP4 k-NN), a MAP4 based SVM 
(MAP4 SVM), and an SVM based on physico-chemical properties (physchem SVM).  
The MAP4 SVM and MAP4 k-NN classifiers were implemented as follows. The 
canonicalized SMILES without stereochemistry information used to generate the TMAP were 
made unique, and they were assigned to training or test set with a 50% random split. The 35 
unique SMILES of the 76 entries common between both origins were randomly assigned to 
one origin. Both classifiers were trained using MAP4 fingerprints. In both cases the class 
weights were inversely proportional to the class frequency, and their hyperparameter were 
optimized using a 5-fold cross validation. During the 5-fold cross validation, 20% of the 
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training set was left out as validation set, and the final set of parameters maximized the ROC 
AUC on the validation set. For the SVM classifier the hyperparameter C was optimized among 
the values 0.1,1, 10, 100, and 1000, resulting in C = 10. The SVM utilized a custom kernel that 
calculates the similarity matrix between two MAP4 fingerprints. Platt scaling 160 was used to 
obtain probabilistic prediction values. For the k-NN model the number of nearest neighbors k 
was optimized among the values 5, 7, 9, and 11, resulting in k = 7. As a distance metric between 
two MAP4 fingerprints the k-NN classifier uses one minus the similarity between the two 
fingerprints.  
The physchem SVM model was trained with the same training/test split, but using the 
MW, fsp3C, HBA, HBD, AlogP, TPSA, and calculated boiling point as input. The properties 
were scaled to zero mean and unit variance. A radial basis function (RBF) kernel 161 was used, 
and the hyperparameters C and γ were optimized with a grid search among. C was optimized 
considering the values 0.1,1, 10, 100, and 1000, resulting in C= 10, and γ was optimized 
considering the values 0.01, 0.1, 1, 10, and 100, resulting in γ = 1. 
For the evaluation of the classifiers we considered the class “bacterium” to be the 
positive class and the class “fungus” to be the negative one. All SVM and the k-NN classifiers 
were implemented using scikit-learn 162, and all not mentioned hyperparameters were used in 
their default values. The source code for all classifiers can be found at 
https://github.com/reymond-group/MAP4-Chemical-Space-of-NPAtlas. 
4.2.7 Classifiers evaluation metrics 
ROC AUC is the area under the ROC curve, and the ROC curve is obtained by plotting the true 
positive rate (TPR) against the false positive rate (FPR): 
𝑇   
𝑇 
𝑇    
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where TP stands for true positives, TN for true negatives, FP for false positives, and FN for 
false negatives predicted by the classifier.  
The F1 score is defined as the harmonic mean of precision and recall: 
   𝑐 𝑠 𝑜  𝑇    
  𝑐    
𝑇 
𝑇    
 
   𝑠𝑐𝑜   2 ×
    𝑐 𝑠 𝑜 ×   𝑐    
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The balanced accuracy is defined as: 
     𝑐    𝑐𝑐   𝑐𝑦  
𝑇   
𝑇 
𝑇    
2
 
The Matthews correlation coefficient (MCC) is a correlation between the observed and the 
predicted class and it is defined as: 
    
𝑇 × 𝑇 −   ×   
√ 𝑇      𝑇      𝑇      𝑇     
 
In all metrics, the probabilistic prediction values were converted into binary classification 
values using a threshold of 0.5. 
4.3 Results and discussion 
4.3.1 The TMAP of NPAtlas 
The 25,523 structures in NPAtlas were downloaded and encoded using the MAP4 fingerprint, 
which is well suited to analyze molecules across different sizes such as those in NPAtlas 
ranging between 70 and 2,900 Da in MW (Table 5, Figure 46, method sections 4.2.1 and 4.2.2). 
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The generated dataset was then visualized using TMAP which represents the minimum 
spanning tree connecting nearest neighbors, here according to the MAP4 similarity measured 
as Jaccard distance (Figure 47, see method section 4.2.3 for details). To understand how the 
NPs in NPAtlas are organized on the MAP4 TMAP, we generated color codes based on various 
physico-chemical descriptors, as well as on categorical classification by compound type and 
observed or predicted origin (Table 5, method section 4.2.4 and 4.2.5, Figure 48, Figure 49, 
Figure 50, https://tm.gdb.tools/map4/).  
 Inspecting the colored TMAPs reveals that molecules are organized by structural 
features.  For example, inspecting the TMAP colored by MW shows that most of the high MW 
compounds (MW ≥ 1,000 Da, 6.8% of NPAtlas) belong to three structural families, namely 
peptides type compounds (minimal substructure: dipeptide), glycosides (minimal substructure: 
cyclic N- or O-acetal) and glycopeptides (both substructures present) (Table 6, Figure 17a, 
Figure 46). Typical examples of such large NPs are shown in Figure 18, featuring the cyclic 
peptides jizanpeptin A (NPA022688, bacterial) 163 and arbumelin (NPA020152, fungal) 164, the 
glycosides butirosin A (NPA009292, bacterial) 165 and quinofuracin A (NPA005440, fungal) 
166, and the glycopeptides cycloaspeptide F (NPA000712, the only fungal glycopeptide in 
NPAtlas) 167 and orienticin D (NPA021348, bacterial) 168.  
 Another striking insight is provided by inspecting the TMAP colored by the fraction of 
sp3 carbons (fsp3C, Figure 17b), which allows the identification of areas rich in aromatic 
polyphenols with very low fsp3C such as nocatrione A (NPA014210, bacterial)169 and 
sydowiol E (NPA001030, fungal) 170, as well as areas populated by terpenoids with very high 
fsp3C such as neoverrucosane diterpenoids (e.g. neoverrucosan-5β,9β,18β-triol, NPA001820, 
bacterial) 171 and the anti-influenza virus diterpene wickerol B (NPA008911, fungal) 172. The 
structures of these compounds are shown in Figure 18. 
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The TMAP not only organizes molecules by structural features, but also separates molecules 
according to their origin, with fungal and bacterial NPs forming well-defined groups across the 
TMAP (Figure 17c). This separation is striking because biosynthetic pathways in bacteria and 
fungi are generally similar, and because the different compound families contain NPs of both 
bacterial and fungal origin (Table 6).  
Table 5. Calculated properties of NPAtlas molecules available as TMAP color-codes. 







Molecular weight a) 70.1 2,901.3 (1,000 f)) 292 408.9   562.6 
Sp3 C fraction a) 0.0 1.0 0.4 0.6 0.7 
HBA count a,b) 0 68 (20 f)) 4 6 9 
HBD count a,c) 0 47 (10 f)) 3 2 4 
AlogP a,d) -28.9 (-2 g)) 33.8 (8 f)) 1.2 2.5 4.1 
TPSA a,e) 0.0 1,135.81 (500 f)) 69.64 99.66 152.8 
Boiling point a, h) 311.5  7,806.5 (2,000 f)) 890.8 1,141.6 1,518.5 
Is Lipinski Categorical: yes/no 
Substructures i) 
Categorical: contains dipeptide moiety/contains glycoside 
moiety/contains dipeptide and glycoside moieties 
Origin Categorical: Bacterial/Fungal 
MAP4 SVMj) prediction Categorical: Bacterial/Fungal 
MAP4 SVMj) performances Categorical: correct/wrong 
a) Continuous properties; shown also as rank in the map. b) Hydrogen bond acceptors (HBA). c) 
Hydrogen bond donors (HBD). d) LogP Calculated following Crippens approach (AlogP). e) 
topological polar surface area (TPSA). f) Maximum value shown in the map, all values above are 
represented to with the same color code. g) Minimum value shown in the map, all values below are 
represented to with the same color code. h) Joback calculated boiling point. i) SMARTS matched 
substructures. j) Support vector machine (SVM). 
 
 
Table 6. NPAtlas entries and unique publications number according to origin and molecular weight.  
 Fungala) Bacteriala) 
NPAtlas entries (≥ 1,000 Da) 15,759 (347) 9,764 (1,392) 
Unique publicationsb) 6,110 (145) 4,653 (711) 
Peptides (≥ 1,000 Da)c) 722 (311) 2,144 (901) 
Glycosides (≥ 1,000 Da)d) 814 (12) 1,616 (421) 
Glycopeptides (≥ 1,000 Da)e) 1 (0) 112 (89) 
Aromatic NPs (≥ 1,000 Da)f) 1,322 (0) 800 (31) 
Aliphatic NPs (≥ 1,000 Da)g) 2,184 (59) 1,366 (220) 
a) Natural product origin. b) Number of unique publications used for the extraction of all NPAtlas 
entries c) Containing a dipeptide moiety. d) Containing a glycoside moiety. e) both glycoside and 
dipeptide moiety. f) fsp3C < 0.2. g) fsp3C > 0.8.  
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Figure 17. (a) NPAtlas MAP4 TMAP colored by MW, with a rainbow scale where the lowest values 
are purple, and the highest values are red. Two areas of the map are zoomed and colored by SMARTS 
substructure match: compounds containing a dipeptide moiety are highlighted in green, compounds 
containing a glycoside moiety are highlighted in magenta, compounds containing both moieties are 
highlighted in yellow; six examples of NPAtlas entries are reported with the same color code. (b) The 
NPAtlas MAP4 TMAP colored by fsp3C with a rainbow scale where the lowest values are purple, and 
the highest values are red. A low and a high fsp3C area of the map are zoomed, and two examples of 
polyphenols and of terpenoids are reported. (c) The NPAtlas MAP4 TMAP colored by a microbial 
origin classification, the compounds originated from fungi are colored in magenta, the compounds 
produced by bacteria are colored in green. 
 
 




Figure 18. Structural formula of natural products examples selected from the TMAPs in Figure 17.  
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4.3.2 Distinguishing between bacterial and fungal NPs 
The separation between bacterial and fungal NPs on the MAP4 TMAP and the fact that the 
map also separates NPs by physico-chemical descriptor values suggested to us that ML models 
trained either with the MAP4 fingerprint or simply with physico-chemical descriptors might 
be able to distinguish between NPs of bacterial or fungal origin. We investigated SVM and k-
NN models since this type of ML models are generally well suited for classifying bioactive 
molecules 173. We considered both an SVM and a k-NN model with MAP4, and only an SVM 
model with physico-chemical descriptors and we evaluated their performance on the test set 
(see section 4.2.6).  
The MAP4 SVM was the best performing model with an area under the receiver 
operating characteristic curve (ROC AUC) of 0.97, an F1 score of 0.91, a balanced accuracy 
of 0.93, and a Matthews correlation coefficient (MCC) of 0.86 (Table 7). The MAP4 k-NN 
classifier also had excellent evaluation metrics with an accuracy of 0.90 and an MCC of 0.8, 
suggesting the high performance of the MAP4 SVM classifier might depend on a nearest 
neighbor effect. On the other hand, the physchem SVM performed significantly worse than the 
MAP4 based classifiers and was only partially capable of distinguishing between bacterial and 
fungal NPs (F1 score and a balanced accuracy above 0.7). This suggests that successful 
classification requires a model distinguishing between specific substructures and not only 
overall molecular properties. For closer inspection, the prediction (fungal or bacterial origin) 
and the performance (correct or wrong) of the best performing classifier (MAP4 SVM) are 
color-coded on the MAP4 TMAP of NPAtlas (Figure 50).  
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Table 7. SVM and k-NN classifiers performance on the test set. 
Classifier ROC AUCa) F1 scorea) Balanced accuracya) MCCa) 
MAP4 SVMb) 0.97 0.91 0.93 0.86 
MAP4 k-NNc) 0.96 0.88 0.90 0.81 
Physchem SVMd) 0.86 0.73 0.78 0.56 
a) Area under the receiver operating characteristic curve (ROC AUC), F1 score, balanced accuracy, and 
MCC are metrices used to evaluate a machine learning model. MCC can assume values from -1 to 1, 
all other parameters can assume values from 0 to 1, and in all cases 1 is a perfect classification. b) SVM 
classifier trained with the MAP4 fingerprint. c) k-NN classifier trained with the MAP4 fingerprint. d) 
SVM trained with physiochemical properties. 
 
4.3.3 Predicting the origin of newly discovered NPs 
Discussion with natural product chemists informed us that assigning NPs to their origin only 
from its chemical structure is not trivial, and can be problematic when isolating a new NP due 
to the occurrence of endosymbiosis, i.e. the fact that bacteria often live as symbionts within 
larger organisms 170,174. We therefore asked the question whether our MAP4 SVM classifier 
would correctly predict the origin of NPs newly reported in 2020 and which are not part of 
NPAtlas (Table 8). To our delight, the classifier correctly predicted the fungal origin for the 
newly reported epicospirocins 1 175, penicimeroterpenoid A 176, and rhizolutin 177, as well as 
the bacterial origin of the recently reported bosamycin A 178. The correct origin assignment is 
probably related to the presence of structurally similar NPs within the NPAtlas training set, 
illustrated here by the MAP4 nearest-neighbor NPs aspermicrone A 179, isocitreohybridone H 
180, Monacolin K 181, and AIP I 182 (Figure 19).  
 When challenged with the recently reported NP phakefustatin A isolated from the 
marine sponge Phakellia fusca 183 (Figure 19), the MAP4 SVM classifier predicted a bacterial 
origin (Table 8). Indeed, the NPAtlas training set contained closely related NPs of bacterial 
origin such as the MAP4 NN Samoamide A 184 (Figure 19). Although phakefustatin A was 
isolated from a marine sponge, our prediction is probably correct because many marine sponges 
contain endosymbiotic bacteria, which can make up to 60% of the sponge biomass and are 
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often responsible for the production of metabolites 185. More specifically, it is known that 
Phakellia fusca coexists with diverse actinobacteria which have been held responsible for the 
production of many bioactive NPs found in the sponge 186.  





nearest neighbor (NN) 
JD from 
NNb) 
Epicospirocin 1 0.99, 0.01 Aspermicrone A (NPA024935) 0.66 
Penicimeroterpenoid A 1.0, 0.0 Isocitreohybridone H (NPA016454) 0.63 
Rhizolutin 0.83, 0.17 Monacolin K (NPA009354) 0.80 
Bosamycin A 0.04, 0.96 AIP I (NPA010987) 0.77 
Phakefustatin A 0.12, 0.88 Samoamide A (NPA022212) 0.68 
a) Predicted origin: fungal or bacterial. b) Approximated Jaccard Distance (JD, see methods for details) 
from the training set NN.  
 
While the example above might be a case of endosymbiosis and potential origin 
misclassification, it must be noted that our MAP4 SVM classifier can only label NPs as of 
bacterial or fungal origin. In fact, our classifier mistakenly assigns such classification to well-
known non-microbial NPs (Table 23, Figure 51). An extension of our analysis to non-microbial 
natural products could be of interest, however the task cannot be completed due to a lack of 
annotated public datasets for NPs of diverse origins 187,188. 
4.4 Conclusion 
In summary, we showed that mapping the 25,523 NPs reported in NPAtlas as a MAP4 TMAP 
organizes molecules by physico-chemical properties and by substructures and thereby provides 
an unprecedented insight into the composition of this collection. Most strikingly, the map 
separates the different NPs according to their bacterial or fungal origin. Furthermore, a SVM 
model trained with the MAP4 fingerprint dataset performs remarkably well in distinguishing 
between fungal and bacterial NPs. The classifier can be of aid where the origin of a natural 
product is unknown, especially when the molecule is isolated from a symbiotic complex. The 
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MAP4 TMAP of NPAtlas is accessible at https://tm.gdb.tools/map4/ and the source code is 




Figure 19. Examples of natural products reported in 2020, absent from NPAtlas, annotated with their 
predicted origin, and connected to its MAP4 NN in the training set. 
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Bacteria in the COCONUT 
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This work is based on the ChemRxiv preprint: 
Capecchi, A.; Reymond, J.-L. Classifying Natural Products from Plants, Fungi or Bacteria in 
the COCONUT Database. 2021. https://doi.org/10.33774/chemrxiv-2021-gxjgc  
This article is licensed under a Creative Commons Attribution International License (CC BY-
NC-ND 4.0).  
Abstract 
Natural products (NPs) represent one of the most important resources for discovering new 
drugs. Here we asked whether NP origin can be assigned from their molecular structure in a 
subset of 60,171 NPs in the recently reported Collection of Open Natural Products 
(COCONUT) database assigned to plants, fungi, or bacteria. Visualizing this subset in an 
interactive tree-map (TMAP) calculated using MAP4 (MinHashed atom pair fingerprint) 
clustered NPs according to their assigned origin (https://tm.gdb.tools/map4/coconut_tmap/), 
and a support vector machine (SVM) trained with MAP4 correctly assigned the origin for 94% 
of plant, 89% of fungal, and 89% of bacterial NPs in this subset. An online tool based on an 
SVM trained with the entire subset correctly assigned the origin of further NPs with similar 
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performance (https://np-svm-map4.gdb.tools/). Origin information might be useful when 
searching for biosynthetic genes of NPs isolated from plants but produced by endophytic 
microorganisms.     
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5.1 Introduction  
Due to the importance of natural products (NPs) in drug discovery,189,190  there is a considerable 
interest in describing and understanding their structural diversity, particularly by exploiting NP 
databases140 using in silico methods such as machine learning (ML).188 Computational 
approaches have been reported to distinguish between NPs and non-Nps,191–194,147 between 
terrestrial and marine NPs,195 and to classify NP structural types196,197 and visualize their 
chemical space.67  
 In our own approach to this problem,21 we recently analyzed NPAtlas, an open-access 
database listing 25,523 NPs from bacterial or fungal origin,19  by computing the MAP4 
fingerprint (MinHashed Atom-Pair fingerprint up to four bonds)18 of each NP and creating a 
TMAP (tree-map) 12 of the resulting high-dimensional dataset. In this analysis, NPs from 
bacterial or fungal origin formed separated clusters. This separation effect was confirmed by 
showing that a support vector machine (SVM) trained with the MAP4 of NPAtlas was able to 
distinguish bacterial or fungal origin, including a recently reported NP isolated from the marine 
sponge Phakellia fusca assigned by our classifier to be of bacterial origin, in line with the fact 
that many NPs from this sponge originate from endosymbiotic actinobacteria.183,186  
 The possibility to assign the origin of NPs from their structure was intriguing because 
most NPs are secondary metabolites produced by biosynthetic gene clusters198 which are 
sometimes transferred between different organisms.199 Such horizontal gene transfer may 
reflect adaptative relationships between host organisms such as plants and sponges and 
endosymbiotic bacteria or fungi.200 Among the many endophytic NPs,201,202 striking examples 
include the cancer drug paclitaxel, a plant NP also produced by endophytic fungi of the yew 
tree,203,204 and maytansine, used in antibody-drug conjugates for cancer therapy and produced 
by endophytic bacteria in plants.205 Due to the very widespread occurrence of endophytic 
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bacteria and fungi in plants, we asked whether our MAP4 analysis might be able to distinguish 
plant NPs from bacterial and fungal NPs. To test this hypothesis, we considered the recently 
reported COCONUT database, a recently reported open-access database currently offering the 
most extensive coverage and including plant NPs.20  
5.2 Results and discussion 
5.2.1 Chemical space analysis of plant and microbial NPs from the 
COCONUT database 
COCONUT collects over 400 thousand NPs from 52 different databases, 135 thousand of 
which are annotated with a taxonomical origin. For our analysis, we considered the 68 thousand 
entries annotated with a source organism that were also associated with a publication. We 
focused on those annotated as originating from plants (50 %), fungi (23 %), or bacteria (16 %), 
leaving out a smaller subset of NPs originating from animals (2 %), homo sapiens (2.5 %), of 
marine origin (1.5 %), or lacking a superclass annotation (5 %). The selected subset of 60,171 
NPs contained 33,772 plant NPs, 15,648 fungal NPs and 10,751 bacterial NPs.  
 The subset spanned from molecular weight MW = 81 Da for 1,2-dihydropyridine, a 
plant NP,206 to MW = 2,901 Da for lacticin 481, a bacterial peptide.207 Plant NPs dominated 
the intermediate molecular weight range (200 < MW < 800), while fungal NPs were most 
abundant in the low molecular weight range (MW ≤ 200) and bacterial NPs in the high MW 
range (MW ≥ 800). The three series had rather similar distributions of the fraction of sp3 carbon 
atoms (Fsp3), which measures the degree of saturation. However, the estimated octanol:water 
partition coefficient AlogP indicated that highly polar NPs were almost absent from fungal 
NPs. Furthermore, plant NPs had overall higher percentages of glycosides, while peptides were 
almost absent from plant NPs and most abundant in bacterial NPs (Table 9). 
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Table 9. Property distribution and origin of the 60,171 COCONUT entries with a DOI and annotated 
as plants, fungal, or bacterial. 
 Plants NPsa) Fungal NPsa) Bacterial NPsa) 
MW ≤ 200b) 7,072 (21%) 4,919 (31%) 2,237 (21%) 
200 ≤ MW < 80 b) 24,078 (71%) 10,111 (65%) 6,066 (56%) 
MW ≥ 800b) 2,622 (8%) 618 (4%) 2,448 (23%) 
Fsp3 ≤ 0.2c) 4,213 (13%) 1,580 (10%) 1,073 (10%) 
0.2 ≤ Fsp3 < 0.8c) 22,032 (65%) 11,334 (72%) 7,986 (74%) 
Fsp3 ≥ 0.8c) 7,527 (22%) 2,734 (18%) 1,692 (16%) 
AlogP ≤ -2 d)  4,855 (14%) 373 (2%) 1,446 (13%) 
-2 ≤ AlogP < 8 d) 28,315 (84%) 15,000 (96%) 8,906 (83%) 
AlogP ≥ 8 d) 602 (2%) 275 (2%) 399 (4%) 
Glycosides e) 8,260 (24%) 797 (5%) 1,793 (17%) 
Peptides f) 194 (<1%) 676 (4%) 2,053 (19%) 
a) COCONUT entries with a DOI and the specified taxonomical origin annotated; percentages refer to 
the total number of the selected entries within the specified class: 33,772 plants NPs, 15,648 fungal 
NPs, and 10,751 bacterial NPs. b) Molecular weight (MW) calculated with RDKit. c) Fraction of sp3 
(Fsp3) calculated with RDKit. d) Octanol: water partition coefficient calculated with RDKit following 
the Crippen method (AlogP). e) Containing a cyclic N- or O-acetal substructure defined through 
SMARTS language. f) Containing a dipeptide substructure defined through SMARTS language. 
 
To get a closer insight into structural features, we calculated the MAP4 fingerprint for each of 
the 60,171 selected NPs. MAP4 encoding combines the characteristics of substructure 
fingerprints, which are well suitable for small molecules, and of atom pair fingerprints, which 
are instead preferable for larger structures, and it has been proven suitable for both.18 It consists 
of listing all pairs of circular substructures of radius 1 and 2 as SMILES, separated by their 
topological distance in bonds, and MinHashing the resulting set of SMILES pairs to a defined 
dimensionality (1024 in the present analysis). We then represented the MAP4 annotated NP 
dataset using the dimensionality reduction method TMAP. This method is suitable for very 
large high-dimensional datasets and performs better than t-SNE or UMAP in preserving local 
and global relationships in the data. 12 To create a TMAP, the algorithm computes an 
approximate nearest neighbor graph by locality sensitive hashing (LSH), cuts edges to obtain 
the minimum spanning tree of this graph, and creates an optimized 2D representation of the 
minimum spanning tree, in which each node represent a molecule connected to its approximate 
nearest neighbors. This tree is then displayed with interactive visualization tool Faerun. 24 
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Faerun shows each node as a sphere that can be color-coded according to various properties 
and uses Smilesdrawer99 to depict molecular structures. The TMAP of our NP subset is 
available interactively at https://tm.gdb.tools/map4/coconut_tmap/. 
 The TMAP of our NP subset color-coded by MW showed that most high MW 
compounds appeared in two groups, the first one (at right on the TMAP), contained peptides 
and related macrocycles, and the second one (at middle/lower left on the TMAP) corresponded 
to glycosylated triterpenoids (Figure 20a). Color-coding by Fsp3 showed that the TMAP 
separated high Fsp3 molecules (left half of the TMAP), comprising many terpenes, steroids, 
and glycosides, from low Fsp3 molecules (right half of the TMAP) featuring many polyphenols 
and related polyaromatic molecules (Figure 20b). Furthermore, the color-code by the calculated 
octanol:water partition coefficient AlogP, estimating polarity, showed several islands of highly 
polar NPs (low AlogP, magenta) corresponding mostly to nucleosides and glycosylated 
polyphenols (upper part of the TMAP), glycosylated triterpenoids (lower left on the TMAP) 
and peptides (middle right on the TMAP), as well as a few groups of apolar NPs (high AlogP, 
red), corresponding primarily to lipids, terpenes, and steroids (Figure 20c). 
 Color-coding by the annotated origin showed that NPs from plants, fungi, or bacteria 
formed many well-defined clusters spread across the entire TMAP (Figure 20d). On the one 
hand, this separation illustrated how NP origin corresponded to differences in molecular 
structure that were well perceived by the MAP4 fingerprint used to generate the map. On the 
other hand, the taxonomical origin color code also showed that each subset contained diverse 
structural types. While there was no correlation of origin with properties such as MW, Fsp3, 
or AlogP, most glycosides were associated with plants, and most peptides were of bacterial or 
fungal origin, in line with Table 9 (Figure 20e). These relationships were also well visible by 
color-coding the TMAP by prioritized categories (Figure 20f).  
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Figure 20. MAP4 TMAP of the 60 thousand selected COCONUT entries. The maps are colored 
according to (a) molecular weight MW in Da, (b) fraction of sp3 carbon atoms Fsp3, (c) calculated 
octanol:water partition coefficient AlogP, (d) COCONUT annotated origin, (e) presence of a glycoside 
(blue) or peptide (green) substructure, or both (magenta), (f) prioritized categories:  glycosides (blue) > 
peptides (cyan) > high MW (green) > high Fsp3 (yellow) > low Fsp3 (orange) > low MW (red). Entries 
not belonging to any category are reported in gray. All maps are accessible in an interactive format at 
https://tm.gdb.tools/map4/coconut_tmap/. 
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5.2.2 Statistical modeling of NP origin using support vector machines 
(SVM) 
The clear separation of NPs from plants, fungi, or bacteria in the TMAP above clearly showed 
that our MAP4 fingerprint distinguished between NPs of plant, bacterial or fungal origin. To 
further investigate this separation, we trained an SVM classifier using the MAP4 similarity 
matrix of half of the COCONUT subset and used the other half to evaluate it. Indeed, the 
obtained MAP4 SVM correctly predicted the origin of 94% of plant NPs, 89% of fungal NPs, 
and 89% of the bacterial NPs (MAP4 SVM), resulting in a balanced accuracy of 0.897, an 
MCC (Matthews correlation coefficient) of 0.890, and an F1 score of 0.920 (for a detailed 
explanation of the used metrics, please refer to the section 5.4.5).  
To better identify the role of the MAP4 molecular encoding in the reported successful 
prediction, we compared the performances of a MAP4 SVM with the performances of an SVM 
trained using ECFP4 (Extended Connectivity Fingerprint ECFP of radius 2, ECFP4 SVM) and 
the RDKit atom pair fingerprint (AP SVM). We chose ECFP4 and the RDKit AP as widely 
used and available examples of substructures fingerprints and atom pair fingerprints. As a 
baseline model, we also included an SVM trained with a set of 11 calculated physico-chemical 
properties, namely MW, Fsp3, HBD (hydrogen bond donor) count, HBA (hydrogen bond 
acceptor) count, AlogP, the number of carbons, oxygens, and nitrogens, the total number of 
atoms, number of bonds, and TPSA (topological polar surface area) (properties SVM). The 
selected 60 thousand COCONUT entries were divided into five subsets, and each model was 
trained and evaluated five times using the five different 80-20 training test splits combinations 
of one subset as test set and the other four as training set. Then the mean balanced accuracy, 
MCC, and F1 score of the five evaluations were calculated.  
The results of this evaluation are presented in Table 10 and Figure 21. Remarkably, all 
four SVM performed reasonably well. The good performance of the property based SVM 
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reflected the fact that relatively large NP families with characteristic properties are essentially 
all from the same origin. For example, almost all large peptides or cyclic peptides are assigned 
to bacteria, while most glycosylated triterpenoids and polyphenols are assigned to plants. 
Nevertheless, there was a significant performance increase with the ECFP4 SVM and MAP4 
SVM, which performed best, showing that correct origin assignment works better if specific 
substructures are considered. Among the four SVM evaluated, our MAP4 SVM performed best 
with significantly higher values compared to the ECFP4 SVM, probably because the MAP4 
fingerprint encodes a more precise representation of the molecular structures than ECFP4. 
Indeed, MAP4 considers pairs of local substructures and the topological distance between 
them, while ECFP4 only encodes the presence of local substructures. 
Table 10. SVM evaluation with balanced accuracy, MCC, and F1 score.  
 Balanced acc. MCC F1 
MAP4 SVM a,b) 0.919±0.005 0.879±0.005 0.929±0.003 
ECFP4 SVM a,b) 0.890±0.005 0.827±0.006 0.897±0.003 
RDKit AP SVM a,b) 0.735±0.005 0.592±0.006 0.752±0.004 
Properties SVM a,c) 0.758±0.005 0.613±0.007 0.761±0.004 
a) Mean value and standard deviation (σ) of the five different test/training sets split of the 5-fold cross-validation. 
b) 1024 dimensions. c) 11 properties: MW, Fsp3, HBD) and HBA, calculated logP with the Crippen method 
(AlogP), number of carbons, oxygen, and nitrogen, the total number of atoms, number of bonds, and topological 
polar surface area (TPSA).   
 
Figure 21. 5-fold cross-validation mean values and 3σ confidence intervals of the (a) balanced 
accuracy, (b) MCC, and (c) F1 score for the four SVM classifiers. In all panels, the MAP4 SVM is 
reported in blue, the ECFP4 SVM in orange, the RDKit AP (AP) SVM in green, and the properties 
(Prop.) SVM in red. 
 
(a) (b) (c)
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5.2.3 Using the MAP4 SVM to assign the origin of NPs  
The SVM evaluation above showed that the MAP4 analysis of NP molecular structure 
identified features distinguishing between NPs assigned to plants, fungi, and bacteria. 
Assuming that most of the assigned origins were correct among the 60,171 NPs used for 
training, one may use an SVM to tentatively assign the origin of further NPs as originating 
from plants, fungi, or bacteria. To best exploit the information in the COCONUT database, we 
trained a MAP4 SVM using the entire set of 60 thousand COCONUT NPs assigned to plants, 
fungi, or bacteria. We used the resulting classifier to build an online tool that takes any 
molecular structure as input (drawn or pasted as SMILES) and returns the assigned origin and 
the corresponding percentages from the SVM classifier. This tool is freely accessible online at 
https://np-svm-map4.gdb.tools/.  
 The online tool performed quite well in assigning the origin of newly published NPs 
which were not present in COCONUT. Among thirteen recently reported NPs from plants, 
fungi, or bacteria, eleven were correctly assigned to their origin, while only two were 
misassigned (Table 11, Figure 22). In details, the fungal epicospirocin 1,175 
penicimeroterpenoid A,176 and beetleane A,208 the bacterial bosamycin A,178 and the plant 
hunzeylanine A,209 hyperfol B,210 pegaharmol A,211 mucroniferal A,212 meloyunnanine A,213 
perovsfolin A,214, and horienoid A215 were correctly classified. On the other hand, the fungal 
rhizolutin177 and the bacterial marinoterpin A216 were misclassified as plant NP. Note that in 
these cases, the percentage values to the assigned class were lower than for the correct 
predictions.  
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Table 11. MAP4 SVM origin prediction for thirteen recently published microbial and plants NPs that 
are not present in COCONUT.  
Natural Product Origin MAP SVM predictiona) 
epicospirocin 1 fungal fungal (97%) 
penicimeroterpenoid A fungal fungal (82%) 
beetleane A fungal fungal (97%) 
rhizolutin fungal plant (55%, fungal: 29%) 
bosamycin A bacterial bacterial (94%) 
marinoterpin A bacterial plant (44%, bacterial: 37%) 
meloyunnanine A plant plant (99%) 
hyperfol B plant plant (93%) 
pegaharmol A plant plant (77%) 
mucroniferal A plant plant (73%) 
hunzeylanine A plant plant (95%) 
perovsfolin A plant plant (92%) 
horienoid A plant plant (95%) 
a) Predicted using the MAP4 SVM available online at https://np-svm-map4.gdb.tools/. 
 




Figure 22. Chemical structure of thirteen recently published microbial and plants NPs which are not 
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In several cases, the SVM prediction conflicted with the superclass of the reported source 
organism. For example,  the indole alkaloids cephalinones A-D and cephalandoles A-C isolated 
from the orchid Cephalanceropsis gracilis217 and whose structures were partly revised by total 
synthesis,218 were all assigned to bacteria by our SVM. In fact, These NPs might stem from an 
endophytic bacterium considering that endophytic microorganisms produce several related 
indole alkaloids.219 Our SVM also reassigned the cancer drug maytansin from an annotated 
plant origin in the training set to a predicted bacterial origin, in line with its endophytic 
origin.205 On the other hand, our classifier also assigned a bacterial origin to two cyclic peptides 
(CNP0085258 and CNP0085259)220 and a cyclotide (CNP0085363)221 isolated from plants. 
Although these plants indeed contain endophytic bacteria, the plant origin of such peptides is 
well established,222,223 and the SVM assignment to bacteria reflects the fact that the majority of 
cyclic peptides and cyclotides in the COCONUT set used for training the SVM were assigned 
to bacteria, compared to only a handful of cyclotides of plant origin.   
 While the classifier may point to the possible endophytic origin of NPs isolated from 
plants, its use on NPs from other sources is problematic. For instance, among the 1,035 marine 
NPs from COCONUT with an annotated origin, 639 were assigned to plants by our SVM. This 
prediction must be mostly wrong considering that most marine organisms such as algae, corals, 
and sponges are not plants. For example, the 44 NPs from the soft coral Sinularia, or the 
macrocyclic terpene lactone lobophytolide A (CNP0275045) stemming from the soft corral 
lobophytum cristagalli,224,225 were all incorrectly assigned to plants. However, the remaining 
231 fungal and 165 bacterial predictions might be partly correct considering that many marine 
organisms carry endosymbionts. For example, our classifier assigned a bacterial origin for 
echinosulfonic acid B (CNP0318329), a brominated bis-indole NP isolated from the marine 
sponge Echinodictyum gorgonoides.226 In this case, other authors have reported the isolation 
of a bacterial strain from the same sponge as a probable source of its biological activities.227  
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5.3 Conclusion 
In summary, we visualized the chemical space covered by a subset of 60 thousand NPs from 
the COCONUT database with an assigned origin and publication using a TMAP calculated on 
the basis of MAP4 as molecular fingerprint, which is available at 
https://tm.gdb.tools/map4/coconut_tmap/. Analyzing this TMAP revealed that NPs from plant, 
fungal or bacterial origin form well separated groups. We then trained an SVM classifier with 
the MAP4 fingerprint to assign the origin of NPs and found that it performed excellently and 
significantly better than classifiers trained with ECFP4, RDkit AP, or physico-chemical 
descriptors.  
 To help assign NP origin, we then trained a MAP4 SVM classifier using the entire set 
of 60 thousand NPs. This tool is available online at https://np-svm-map4.gdb.tools/ and returns 
an origin prediction for any molecular structure drawn or pasted as SMILES. We found that 
this classifier correctly predicts the origin of plant, bacterial or fungal NPs not included in the 
60 thousand COCONUT set used for training, as exemplified with the correct prediction of 
eleven out of thirteen newly published NPs. Broader testing of the classifier with further NPs 
from COCONUT showed limitations for NPs not from plant or microbial origin, such as marine 
NPs, but it also led to interesting use cases suggesting that the tool might serve as a help to 
assign NP origin. This concerns in particular NPs isolated from plant but which might in fact 
be produced by endophytic microorganisms. Such information could be essential when 
searching for the corresponding biosynthetic genes. 
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5.4 Methods 
5.4.1 Database preprocessing 
The coconut database was downloaded. Only the 135,091 (out of 400,837) entries having a 
taxonomical annotation were selected. The selected subset was further filtered down to the 
67,730 entries having an annotation not shorter than ten characters in the DOI field. Then, the 
taxonomy field was split by commas and match towards the words "plant"/"plants", 
"fungi"/"aspergillus", "bacteria"/"bacillus"/"bacta" to select the NPs with an annotated plant, 
fungal, or bacterial origin, respectively. The entries common between multiple origins were 
assigned with the following priority: human > animal > bacteria > fungi > plant > marine.  The 
process led to the selection of 33,772 plant NPs, 15,648 fungi NPs, and 10,751 bacterial NPs 
with annotated DOI, for a total of 60,171 structures. The number of carbons, oxygen, and 
nitrogens, the total number of atoms, number of bonds, and TPSA were extracted from the 
COCONUT annotations. MW, Fsp3, HBD, and HBA count, AlogP, were calculated using 
RDKit. 123 The presence/absence of a peptide or a glycoside moiety was evaluated using 
Daylight158 SMILES arbitrary target specification (SMARTS) language. SMARTS were used 
with RDKit to identify COCONUT entries containing a dipeptide substructure, defined as 
“[NX3,NX4+][CH1,CH2][CX3](=[OX1])[NX3,NX4+][CH1,CH2][CX3](=[OX1])[O,N]”, or 
a containing a glycoside defined as cyclic N- or O-acetal substructure with the SMARTS  
“[CR][OR][CHR]([OR0,NR0])[CR]”. 
5.4.2 Fingerprint calculation 
The 1024 dimensions MinHashed atom pair fingerprint of radius 2 was calculated using the 
open-source code of MAP4. 
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5.4.3 TMAP layout 
The indices generated by the MinHash procedure of the MAP4 calculation were used to create 
a locality-sensitive hashing (LSH) forest42 of 32 trees. Then, for each structure, the 20 
approximate nearest neighbors (NNs) in the MAP4 feature space were extracted from the LSH 
forest, and the tree layout was calculated. The LSH forest and the minimum spanning tree 
layout were calculated using the TMAP open-source code. Finally, Fearun24 was used to 
display the obtained layout interactively.   
5.4.4 MAP4 SVM implementation  
The coconut SUBSET entries used to generate the TMAP were assigned to training or test set 
with a 50% random split. The SVM was trained using the MAP4 fingerprints of the training 
set. It utilized a custom kernel that calculates the similarity matrix between two MAP4 
fingerprints, where the similarity of fingerprint a and fingerprint b is calculated (1) counting of 
elements with the same value and the same index across a and b, and (2) dividing the obtained 
value by the number of elements of fingerprint a. The class weights were inversely proportional 
to the class frequency, and the hyperparameter C was optimized using 5-fold cross-validation. 
During the hyperparameter optimization, 20% of the training set was left out as a validation 
set, and the balanced accuracy of the validation set was maximized. The hyperparameter C was 
optimized among the values 0.1,1, 10, 100, and 1000, resulting in C = 1.  The classifier was 
implemented using scikit-learn162 with the "one versus rest" strategy, and all not mentioned 
hyperparameters were used in their default values. Platt scaling,160 was used to obtain 
probabilistic prediction values. After the evaluation process, a second version of the MAP4 
SVM classifier was trained using both training and test to learn from all curated 60 thousand 
data points.  
101 | P a g e  
  
5.4.5 MAP4, ECFP4, RDKit AP, and properties SVMs comparison  
The MAP4, ECFP4, and the RDKit AP fingerprints and a set of 11 properties (MW, Fsp3, 
HBD and HBA count, AlogP, number of carbons, oxygens, and nitrogens, total number of 
atoms, number of bonds, and TPSA) were used to train four different SVM classifiers in a 5-
fold cross-validation. For all classifiers, the class weights were inversely proportional to the 
class frequency, and the hyperparameters were optimized using 10% of the available data 
(Table 12). For the properties SVM, the 11 values were scaled to zero mean and unit variance. 
Table 12. Non-default and optimized hyperparameters used in the 5-fold cross-validation MAP4, 
ECFP4, RDKit AP, and properties SVMs comparison.  
Classifier Kernel a) C a) γ a) 
MAP4 SVM MAP4 b) 0.01, 0.1, 1, 10, 100 - 
ECFP4 SVM Tanimoto c), Dice c) 0.01, 0.1, 1, 10, 100 - 
RDKit AP SVM Tanimoto c), Dice c) 0.01, 0.1, 1, 10, 100 - 
Properties SVM RBF d) 0.01, 0.1, 1, 10, 100 0.01, 0.1, 1, 10, 100 
a) Used hyperparameters are reported in bold. b) Calculates the similarity matrix between two MAP4 
fingerprints, where the similarity of fingerprint a and fingerprint b is calculated (1) counting of elements 
with the same value and the same index across a and b, and (2) dividing the obtained value by the 
number of elements of fingerprint a. c) Ralaivola et al. 228 d) Radial basis function (RBF) kernel.161 
 
5.4.6 Classifiers evaluation metrics 
The F1 score is defined as the harmonic mean of precision and recall: 
   𝑐 𝑠 𝑜  
𝑇 
𝑇    
 
  𝑐    
𝑇 
𝑇    
 
   𝑠𝑐𝑜   2 ×
    𝑐 𝑠 𝑜 ×   𝑐    
    𝑐 𝑠 𝑜    𝑐    
 
Where TP stands for true positives, TN for true negatives, FP for false positives, and FN for 
false negatives predicted by the classifier. 
The balanced accuracy is defined as: 
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The Matthews correlation coefficient (MCC) is a correlation between the observed and the 
predicted class and it is defined as: 
    
𝑇 × 𝑇 −   ×   
√ 𝑇      𝑇      𝑇      𝑇     
 
5.4.7 Online MAP4 SVM 
The MA4 SVM classifier trained with the whole 60 thousand COCONUT subset is found at 
https://np-svm-map4.gdb.tools/. The query molecule can be provided as a drawn structure or 
pasted SMILES in the JSME editor132. The given query is canonicalized, chirality information 
is removed with RDKit, and the MAP4 fingerprint is calculated. To obtain probabilistic 
prediction values for each class, we use Platt scaling.160  
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Part Two – Peptide Chemical 
Space and Generation of Novel 
Peptide Sequences 
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Review Chapter Six – Peptides in 
Chemical Space 
This work is based on the peer-reviewed publication:  
Capecchi, A.; Reymond, J.-L. Peptides in Chemical Space. Med. Drug Discov. 2021, 9, 
100081. https://doi.org/10.1016/j.medidd.2021.100081 
This article is licensed under a Creative Commons Attribution International License (CC BY-
NC-ND 4.0) 
Abstract 
Peptides and their chemical space are highly relevant in the field of medicine. The recent 
advances in computer hardware and software led to a wide application of computational 
methods for the analysis and the selection of bioactive peptides. In this review, we report 
different in silico strategies for the discovery of new bioactive peptides with a focus on 
structure-based design, genetic algorithms, machine learning, and the use of molecular 
fingerprints to sample virtual libraries. Then, we describe the chemical space of known peptides 
through an analysis of 11 available peptide and peptide-containing databases, and we provide 
an interactive MAP4 (MinHashed Atom Pair fingerprint of diameter 4) TMAP (Tree Map) of 
the over 40 thousand extracted unique sequences available at 
https://tm.gdb.tools/map4/peptide_databases_tmap/.  
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6.1 Introduction 
Peptides, defined as sequences of amino acids up to approximately 50 residues in length, 
represent an extremely large reservoir of potentially bioactive compounds, referred to here as 
the peptide chemical space. The relevance of this chemical space for medicine is evidenced by 
a large number of therapeutic peptides, in particular hormones and analogs such as insulin229 
or the recently FDA-approved bremelanotide 230–232. Despite its size, the peptide chemical 
space can be precisely defined through a list of amino acid building blocks, usually the 
proteinogenic amino acids, and the length and topologies of the peptide chains that are 
considered, which may be linear, cyclic, or branched.  
 Following the invention of solid-phase peptide synthesis (SPPS) and recombinant 
methods in molecular biology, a number of experimental approaches have been developed to 
search the peptide chemical space for compounds binding to a specific molecular target by 
synthesizing and testing large combinatorial libraries 233. More recently, advances in computer 
hardware and software have made it possible to select bioactive peptides by computational 
methods 234–238, thereby focusing experimental evaluation to a selected set of test sequences,  
as well as to develop a global understanding of the peptide chemical space by comparing all 
known bioactive peptides with each other. In this review, we summarize recent advances in 
computational peptide design. We classified computational design approaches as follows: a) 
structure-based design, where 3D-modeling of the site of action guides the selection of test 
peptides; b) GA (genetic algorithms), which select test peptides by iterative cycles of mutations 
and fitness selection; c) ML (machine learning methods), which exploit information on known 
bioactive peptides to propose new ones; and d) molecular fingerprints, which focus on 
calculated molecular similarity between peptide structures to enable a focused sampling 
(Figure 23). Finally, we present an overview of the currently know chemical space of bioactive 
peptides in form of an interactive chemical space map.    
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Figure 23. (a) The SARS-CoV-2 spike protein RBD (Receptor Binding Domain, green) binds ACE2 
(Angiotensin-converting enzyme 2, pink), causing the virus to enter the cell. The miniprotein LCB3 
(blue) was designed to bind the RBD (green) and inhibit the interaction between RBD and ACE2. (b) 
Genetic algorithm workflow schematic and classification based on the fitness function. (c) Example of 
an RNN (Recurrent Neural Network) architecture and sequences of the antimicrobial HHC-10 and 
HHC-36 discovered with this approach. (d) schematic representation of the sampling of a virtual library 
using molecular fingerprints.   
 
6.2 Structure-Based Design  
If the 3D-structure of the targeted site of action of the desired peptide is known in advance, one 
can select potentially bioactive peptides by modeling their interactions with this site using 
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bioactive peptides computationally and has been extensively reviewed 239–243. A recent example 
of this approach is the computational design by Cao et al. of miniprotein inhibitors of the 
SARS-CoV-2 spike protein ACE2 (Angiotensin-converting enzyme 2) interaction stopping the 
viral entry into cells 244. The inhibitors were designed in silico using two different strategies. 
Firstly, a library of peptide sequences was designed using the Rosetta software 245 to 
incorporate the ACE2 helix responsible for the most interaction with the spike protein RDB 
(Receptor Binding Domain). Secondly, a set of sequences was designed from scratch though 
large large-scale de novo design of small helical scaffolds, followed by RIF (Rotamer 
Interaction Field) docking with the spike protein RBD (receptor binding domain), where RIF 
docking has the peculiarity of considering multiple conformations of the binding pocket 
(Figure 23a) 246.  
Other recent examples of structure-based peptide design include the discovery of cyclic 
peptides with high binding affinity to diverse influenza strains through modeling based on 
antibody loops by Sevy et al. 242, and the design of stapled peptides that activate the VapC 
complex of the Mycobacterium Tuberculosi and lead to the arrest of bacterial cell growth by 
Kang et al. 247. Structure-based design sometimes simply aims to identify peptides that mimic 
the structure of a known bioactive peptide. A recent example of this approach is the design of 
peptides that assemble into cross-α amyloid-like structures by Zhang et al. 248. 
6.3 Genetic Algorithms  
A GA is a search algorithm inspired by the evolution theory which optimizes a population of 
solutions towards a given goal through iterative cycles of mutations and selection of the fittest 
solutions using a fitness function 249. If the solutions searched by the algorithm are set to be 
peptide sequences, GAs can be applied to find novel peptides (Figure 23b).  
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The fitness function of a peptide GA can be based on calculated properties. In 2003, Teixido 
et. al. used a GA to identify peptides capable of crossing the BBB (blood-brain barrier) with a 
fitness function based on a set of descriptors comprising molecular weight, length, 
amphiphilicity, isoelectric point, LogP, secondary structure, presence of aromatic and positive 
residues, potential hydrogen bonds, and the nature of C- and N-termini. The ideal set of values 
for these descriptors was derived from a statistical analysis of the experimental data on peptide-
BBB permeability 250. More recently, Beltran and Brizuela used mean hydrophobicity, helical 
hydrophobic moment, net charge, and isoelectric point to design selective cationic antibacterial 
peptides 251. In another recent example of GA guided by properties, Port et al. optimized a 
guava antimicrobial peptide using a fitness function based on the ratio between hydrophobic 
moment and α-helix propensity 252.  
 Predicted protein-peptide interaction can also be used as fitness function of a GA. In 
2011, Knapp et al. optimized peptides for major histocompatibility complex binding using a 
GA and the consensus of five different binding prediction methods in its fitness function 253. 
More recently, King et al. discovered an α-conotoxin analog with optimal binding to the α3β2-
nicotinic acetylcholine receptor using a GA and an AutoDock based fitness function to guide 
their search 254.  
 The fitness function used to guide selection in a GA can also be estimated with ML 
(machine learning) property prediction. For example, Fjell et al. used the prediction of an 
artificial neural network to drive a GA towards active antimicrobial peptides 255. Additional 
ML approaches are discussed in the following sections. A further example of GA for peptide 
design exploiting molecular fingerprint similarity as fitness function is discussed below in 
section 6.5.  
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It is also possible to use the feedback of experimental analysis to guide a GA as exemplified 
by the work of Yoshida et al. that combines supervised ML with in vitro testing as fitness 
function of GA to optimize antimicrobial peptides 256. Another recent example is the work of 
Neuhaus et al. Starting from known ACPs (anticancer peptides), the authors used a GA coupled 
with in vitro testing to generate new ACPs with improved activity, and they showed that both 
the interaction with the membrane and peptide dimerization degree were responsible for the 
anticancer activity 257. 
6.4 Machine learning  
ML approaches are used for two major tasks: property prediction and generation of new 
sequences. For the first case of property prediction, one uses supervised ML techniques, for 
which the task consists of mapping an input to a specific output (Figure 23c) 258–263. The input 
can be the peptide sequence itself, but also descriptors, structure-based features, molecular 
fingerprints, or a combination of the previous. The output of the ML model is usually a label, 
such as active/inactive for a specific application. Property prediction by ML requires a large 
amount of highly curated data, highlighting the importance of manually curated peptide 
databases that collect sequence activity and toxicity.  
 The first example of this approach was reported in 2009  by Cherkasov et al. with the 
discovery of two tryptophan- and arginine-rich antimicrobial peptides, HHC-10 and HHC-36, 
which were more potent and shorter than similar arginine-rich peptides found in Nature such 
as indolicidin (Figure 23c) 264. The authors trained an artificial neural network classifier with 
44 QSAR descriptors to discern between antimicrobial and non-antimicrobial peptides, and 
then they used this trained neural network to classify each peptide in a virtual library of 100,000 
random nonapeptides enriched with tryptophan, arginine, and lysine, as active or inactive. In a 
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recent example of this approach 265, Timmons and Hewage showed that one can use supervised 
ML to train a neural network classifier to distinguish between hemolytic and non-hemolytic 
peptides at the example of peptides from the DAASPDB and the Hemolytic 266 databases.  
 The second application of ML consists of training generative models to output new 
peptide sequences with specific characteristics. For example, Müller et al. recently reported an 
LSTM-RNN (long short-term memory recurrent neural network) capable of generating helical 
peptides with predicted antimicrobial activity 267. In a similar approach, Grisoni et al. trained 
an LSTM-RNN to generate alpha-helical cationic amphipathic sequences, and then they fine-
tuned it using 26 known ACPs. Twelve of the proposed sequences were synthesized and ten 
showed the expected membranolytic activity 143.  
 Classification and generative ML models can also be combined. For example, Tucs et 
al. recently reported a GAN (Generative Adversarial Network) to generate antimicrobial 
peptides 268. A GAN is a ML architecture composed of a ML generative model and a 
discriminator, which is generally a ML classifier, whereby both models are trained as a pair. 
The task of the generator is to generate sequences resembling known antimicrobial peptide 
sequences, while the task of the discriminator is to distinguish between potential antimicrobial 
peptides and random sequences.  
6.5 Molecular fingerprints 
We recently showed that one can discover bioactive peptides computationally in the absence 
of precise structural modeling by using molecular fingerprint comparisons. This approach is 
well-known in small molecule drug discovery 117 but still underexploited with peptides. We 
demonstrated the feasibility of this approach by discovering antimicrobial bicyclic peptides 
against the Gram-negative bacterium Pseudomonas aeruginosa and its biofilms6.  
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To discover active bicyclic peptides, we used a shape and pharmacophore fingerprint called 
2DP describing the relative positions of cationic and hydrophobic groups, an important 
parameter for the targeted membrane disruptive activity. The workflow comprised the 
following steps: 1) establishing a SPPS protocol for bicyclic peptides comprising nine variable 
positions; 2) enumerating a virtual library considering all possible combinations of lysine, 
leucine at the variable positions; 3) computing 2DP-fingerprint similarities between all pairs of 
bicyclic peptides and clustering the virtual library to sample the overall diversity of the virtual 
library; 4) synthesizing and testing a small set of sampled bicyclic peptides. This approach led 
to the identification of a single active bicyclic peptide, which we then optimized by 
synthesizing and testing further analogs identified by 2DP-similarity searching in the virtual 
library (Figure 23d). The virtual library of this proof-of-concept experiment only comprised 
6,230 different bicyclic peptides. In a subsequent project, we applied the same approach to a 
differently designed and much larger virtual library of 4.7 million bicyclic peptides and 
identified the cysteine bridged bicyclic peptide bp50 and its D-enantiomer bp56 as a potent 
antimicrobial peptide against multidrug-resistant strains of A. baumannii and P. aeruginosa 
(Figure 24a) 5. Note that membrane disruptive peptides are generally conformationally flexible 
and that this conformational flexibility is necessary for their activity 269. Indeed, molecular 
dynamics studies and CD-spectra suggest that bp56 exists in a dynamic equilibrium between 
a β-sheet conformation in water and a partially α-helical amphiphilic conformation in a 
membrane environment (Figure 24b). 
 Considering that our 2DP molecular fingerprint could be applied to any type of peptide 
chain topology, we further implemented this fingerprint-based approach to search for analogs 
of AMPD (antimicrobial peptide dendrimer) G3KL, which contains a highly ramified peptide 
chain 270. This AMPD kills a broad range of Gram-negative bacteria including multidrug-
resistant clinical isolates by a membrane disruptive mechanism with almost no resistance 
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3,271,272, and it exhibits angiogenic as well as antibiofilm properties 273,274. By generating a 
virtual library of G3KL analogs and testing 2DP-nearest neighbors of G3KL, we identified 
AMPD T7 exhibiting enhanced serum stability and a broader activity spectrum (Figure 24c)4. 
Interestingly, AMPD T7 corresponds to minor sequence changes at the dendrimer core 
compared to G3KL, which were thought to be negligible by design but turned out to have a 
major impact on antimicrobial activity.  
115 | P a g e  
  
 
Figure 24. Molecular fingerprint guided discovery of antimicrobial peptides. (a) Synthesis and virtual 
library design and selection of bp56. (b) Molecular dynamics studies of bp56 in water with or without 
TFE (trifluoroethanol) to mimic the membrane environment reveals a dynamic conformation. (c) 
Optimization of antimicrobial peptide dendrimer G3KL by virtual library enumeration, nearest 
neighbor selection, synthesis, and testing.  
 
bp56 in water
bp56 in 20% TFE
a) Synthesis design and selection b) Structural model
c) Dendrimer optimization
1) Virtual library enumeration
2) Select 2DP analogs of G3KL
3) Synthesis and testing
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We recently implemented molecular fingerprint similarity as a fitness function in a GA called 
PDGA (peptide design genetic algorithm) capable of generating peptides of diverse topologies 
(linear, cyclic, polycyclic, or dendritic) resembling any target molecule of choice.  In a typical 
PDGA run, all generated sequences above a defined molecular fingerprint similarity threshold 
are identified as analogs. Because the molecular fingerprint can be computed for any molecule 
of interest, PDGA can generate peptide analogs of both peptides and non-peptides25. 
Furthermore, PDGA operates with diverse peptide topologies including linear, cyclic, or 
polycyclic peptides as well as peptide dendrimers. In a proof-of-principle computation, we 
showed that PDGA generates known analogs of the cyclic peptide tyrocidine A and peptide 
dendrimer G3KL.  
6.6 Visualizing the peptide chemical space 
The ability to compute similarities between peptides allows representing the peptide chemical 
space in the form of maps in which distances represent similarities. Such maps provide an 
overview that helps to perceive the structural diversity of peptides. In our first implementation 
of this approach, we created an interactive map of the Protein Data Bank chemical space based 
on computed 3D-shape similarities 98. However, this representation was only applicable to 
macromolecules with known 3D-structures such as those in the Protein Data Bank.  
 To represent peptide structural diversity in a general context, we have used the 
molecular shape similarity fingerprint used above with PDGA to compute similarities between 
molecules featured in non-Lipinski part of the ChEMBL and PubChem databases, which 
comprise 376,504 respectively 15,798,352 entries, 16 % respectively 7 % of which contain a 
dipeptide substructure 14. These similarity comparisons can be represented in interactive 3D-
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maps displayed using Faerun24, in which each molecule appears as a point color-coded by a 
property of choice, and its structure is displayed using Smilesdrawer 99.  
More recently we created a high-resolution molecular fingerprint called MAP4 useful 
to analyze diverse molecular classes spanning from small molecule drugs to metabolites, 
natural products, and macromolecules including peptides, DNA, and oligosaccharides 18. The 
MAP4 fingerprint can be used in combination with the TMAP mapping tool 12 to create 
insightful representations of molecular databases, as recently shown for the case of the Natural 
Product Atlas 21.  
 For the present review, we have collected bioactive peptides from eleven publicly 
accessible databases that cover a wide range of size and scope (Table 13) 275,130,276–284. We 
considered 40,531 database entries corresponding to sequences of between 2 and 50 natural 
amino acids, calculated their SMILES representation using RDKit 123, and used this data to 
compute a TMAP based on the MAP4 fingerprint. This organizes peptides by their size and 
sequence (Figure 25a, https://tm.gdb.tools/map4/peptide_databases_tmap/). The map colored 
by source database shows that several databases tend to cover specific regions of the peptide 
chemical space, which is not surprising for activity-specific databases such as SPdb in which 
sequences have limited diversity, but somewhat surprising for the peptides retrieved from PDB 
(Figure 25b). Color-coding the map by the number of databases in which a peptide is listed 
shows that most peptides (60%) occur only in one database, while 11% are present in two 
databases, 3.4% in three, 1.4% in four, and less than 1% in five databases (Figure 25c). Color-
coding by activity type illustrates that the largest fraction of peptides in these databases (17,260 
sequences, 43 % of the total) are annotated as antimicrobial and anticancer, and stem from the 
DBAASP, DRAMP, AVPdb, and the antimicrobial and anticancer sections of the SATPdb 
(Figure 25d and online map).  
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Table 13. Peptide and peptide-containing databases publicly available and downloadable in bulk. 
 
Name Description Sizea) Web Page Ref. 




https://www.rcsb.org/  275 
SwissProtc)  Sequences and functional 
information of peptides and 
proteins manually annotated 
9,129 
 
https://www.uniprot.org/  130 





DBAASPe) Antimicrobial peptides 10,999
  
https://dbaasp.org/  277 
DRAMPf) Antimicrobial peptides 3,673 cpu-bioinfor.org 278 
AVPdbg) Antiviral peptides 1,801  http://crdd.osdd.net/servers/avpd
b/  
279 
SPdbh) Signal peptides 2,340  http://proline.bic.nus.edu.sg/spd
b/  
280 
NeuroPediai) Neuropeptides 392 http://proteomics.ucsd.edu/Soft
ware/NeuroPedia/  
281 
DADPj) Anuran defense peptides 743  http://split4.pmfst.hr/dadp/  282 
Quorumpepsk) Quorum sensing peptides 243  http://quorumpeps.ugent.be/  283 
AntiAngioPre
dl) 
Angiogenic peptides 197  http://clri.res.in/subramanian/too
ls/antiangiopred/index.html  
284 
Total of peptidic entries constituted by 2 to 50 
natural amino acids 
53,307   
Unique sequences collected across databases 40,531   
a) Number of unique peptidic entries constituted by 2 to 50 natural amino acids. b) PBD = Protein Data 
Bank. c) SwissProt = peptide sequences from the Uni-Prot database. d) SATPdb = Structurally Annotated 
Therapeutic Peptides database. e) DBAASP = Database of Antimicrobial Activity and Structure of 
Peptides. f) DRAMP = Data Repository of Antimicrobial Peptides. g) AVPdb = Antiviral Peptide 
database. h) SPdb = Signal Peptide database. i) NeuroPedia = Neuropeptides database and spectral 
library. j) DADP = Database of Anuran Defense Peptides. k) Quorumpeps = Quorumpeps database. l) 
AntiAngioPred = Server for Prediction of Anti-Angiogenic Peptides. 
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Figure 25. TMAP of the MAP4 encoded peptides databases space colored according to (a) sequence 
length, (b) Source database (DB, entries present in multiple databases were assigned to the smallest 
one), (c) occurrences across databases, (d) antimicrobial and anticancer activity. Further colors based 
on different activity criteria are available, and they can be found in the TMAP at 
https://tm.gdb.tools/map4/peptide_databases_tmap/. 
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6.7 Conclusive Remarks and Future Perspectives 
In this review, we presented computational approaches to explore the peptide chemical space. 
Structure-based designs are well-suited when detailed information exists on the targeted site of 
action. GAs on the other hand have broader applicability since they can be used to design 
peptide sequences even if the targeted activity is not defined by a structure but more generally 
by a set of properties. ML is similarly broad in its applicability but requires a large number of 
known peptides with documented activity to enable model training. Finally, molecular 
fingerprints can be used to guide the sampling of large virtual peptide libraries as well as the 
optimization of known actives, as well as to compute graphical representations in the form of 
a map that facilitate a global understanding of the peptide chemical space. Most interestingly, 
GAs, ML, and molecular fingerprint-based approaches are possible without detailed 
knowledge of the peptide 3D-structure and allow to explore diverse peptide chain topologies, 
also incorporating non-natural amino acids. Such computational methods can play an enabling 
role in expanding the reach of peptides for therapeutic applications.  
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Chapter Seven – Populating 
chemical space with peptides 
using a genetic algorithm 
This work is based on the peer-reviewed publication. 
Reprinted with permission from American Chemical Society. Capecchi, A.; Zhang, A.; 
Reymond, J.-L. Populating Chemical Space with Peptides Using a Genetic Algorithm. J. Chem. 
Inf. Model. 2020, 60 (1), 121–132. https://doi.org/10.1021/acs.jcim.9b01014. Copyright 2021 
American Chemical Society.  
Abstract 
In drug discovery one uses chemical space as a concept to organize molecules according to 
their structures and properties. One often would like to generate new possible molecules at a 
specific location in chemical space marked by a molecule of interest. Herein we report the 
peptide design genetic algorithm (PDGA, code available at https://github.com/reymond-
group/PeptideDesignGA), a computational tool capable of producing peptide sequences of 
various topologies (linear, cyclic/polycyclic or dendritic) in proximity of any molecule of 
interest in a chemical space defined by MXFP, an atom-pair fingerprint describing molecular 
shape and pharmacophores. We show that PDGA generates high similarity analog of bioactive 
peptides with diverse peptide chain topologies, as well as of non-peptide target molecules. We 
illustrate the chemical space accessible by PDGA with an interactive 3D-map of the MXFP 
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property space available at http://faerun.gdb.tools/. PDGA should be generally useful to 
generate peptides at any location in chemical space.   
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7.1 Introduction 
In drug discovery chemical space represents the ensemble of all molecules of possible interest 
as drugs.285,286 The structural diversity of drugs and therefore their chemical space is extremely 
large and potentially overwhelming.45,287 One possibility to gain an overview of chemical space 
is to artificially reduce its complexity by focusing on a subset of molecular properties which 
one can use to construct a mathematical “property space” which is also called “chemical 
space”. Such spaces are most often high dimensional because one uses multiple properties to 
describe molecules. Nevertheless, dimensionality reduction methods enable to represent these 
spaces as 2D or 3D-maps and lead to a  geographical understanding of molecular diversity 
because molecules that are found close to one another have similar 
properties.288,103,289,46,118,290,24,12,105 The pertinence of this approach is supported by the fact that 
simple nearest neighbor searches in chemical spaces defined by high dimensional molecular 
fingerprints often perform as well or even better in virtual screening and target prediction 
benchmarks than more complex machine learning algorithms.7,16,90,291,8,120  
 Given a compound of interest, one would often like to generate new molecules at the 
same location in chemical space. In the area of small molecules one can identify such close 
analogs by virtual screening of possible molecules listed in computational combinatorial 
libraries287,292 or generated on demand using deep neural networks.293–295,149 The same 
approaches can be in principle applied to larger molecules beyond Lipinski’s rule of 5 limit13 
considered in the present report, which are of interest as new modalities to address targets that 
are not druggable with small molecules.71,296,297 However, the number of possible molecules 
and their structural diversity increases exponentially as function of molecule size.298 Therefore, 
for large molecules one must first focus on well-defined subsets defined by a family of building 
blocks and the corresponding coupling chemistry before considering a computational strategy. 
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Such focus limits structural diversity but at the same time ensures that the proposed molecules 
should be synthetically accessible.  
 The most common subset of large molecules is that of peptides consisting of chains of 
amino acids linked by amide bonds. Machine learning, genetic algorithms and artificial 
intelligence have been used previously to design new peptides sequences with targeted 
structural and functional properties, mostly antimicrobial and anticancer activities. However, 
the reported examples were entirely focused on short linear peptides and often required large 
training sets of active compounds to produce new sequences.264,252,299,300,256,301–304,236 Herein, 
we report a genetic algorithm capable of generating high similarity peptide analogs of diverse 
large molecules, including not only linear peptides but also cyclic/polycyclic peptides and 
peptide dendrimers and even non-peptides. Our peptide design genetic algorithm (PDGA) 
requires only a single target molecule as input.  
 PDGA generates peptides with diverse topologies of the peptide chain (linear, cyclic, 
polycyclic or dendritic) with high similarity to this target by using as fitness function a 
similarity calculated using MXFP (macromolecule extended atom-pair fingerprint). MXFP is 
a molecular fingerprint which uses the principle of atom pairs and is suitable for mapping the 
chemical space of large molecules beyond Lipinski’s rule of five limit in ChEMBL and 
PubChem. 14 Atom pair fingerprints consider pairs of atoms in a molecule and the topological 
distance separating them counted in bonds. Despite of the fact that only topological 2D-
information is considered, atom-pair fingerprints have the ability to represent 3D-molecular 
shape and pharmacophores, which often correlate with biological activities.10,121,305,306,9,97,98,307 
Most importantly, we recently used atom-pair fingerprint similarity searching to discover and 
optimize antimicrobial bicyclic peptides and peptide dendrimers against multidrug resistant 
Gram-negative bacteria despite the fact that these peptides do not have a well-defined folded 
conformation and that their activity in fact depends on conformational flexibility.4–6 These 
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experiments provided an important validation of atom-pair fingerprint guided searches for 
practical peptide discovery even in the absence of well-defined 3D-conformations. In the 
present report we show that PDGA, guided by MXFP similarity as fitness function, provides 
the means to populate the non-Lipinski chemical space with peptides of diverse topologies in 
a targeted manner.  
7.2 Results and Discussion 
7.2.1 Peptide design genetic algorithm (PDGA) 
Our Peptide Design Genetic Algorithm (PDGA, available at https://github.com/reymond-
group/PeptideDesignGA) starts with a target molecule and a population of random peptide 
sequences with user-defined topology of the peptide chain (linear, cyclic, or dendritic), and 
performs rounds of modification and MXFP-similarity selection until the target or a preset time 
limit has been reached. The algorithm performs amino acids point mutations, insertions, 
deletions, cross-over, and cyclization/linearization or insertion of a branching unit depending 
on the selected topology, on character strings representing peptides. In these strings each 
character represents a building block. PDGA can use any natural or non-natural amino acid 
(e.g. β-, -, -amino acids, any non-natural side-chain, see Table 24 for the selection of building 
blocks used in this study), and includes variations in topology of the peptide chain by 
considering C to N cyclization and bridging cysteines for cyclic and polycyclic peptides and 
branching diamino acids (such as lysine) for dendrimers. Note that chirality is not encoded by 
MXFP and therefore not included in the PDGA output. 
 In its main implementation PDGA uses MXFP similarity to the target molecule as 
fitness function. To calculate MXFP similarity PDGA performs the following operations: 1) 
convert the character string to a SMILES taking topology of the peptide chain into account; 2) 
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assign atomic properties (H-bond donor, H-bond acceptor, positive and negative charges, 
aromaticity, and hydrophobicity) to each atom by assigning substructures to precomputed 
residues using SMARTS and compute MXFP values considering the properties assigned to 
each atom; 3) calculate the Manhattan distance (city-block distance, CBD) to the target 
molecule.  
 In all case studies described herein, we found that PDGA operates best with a 
population of 50 sequences with the same topology as the target molecule, retaining the 10 
fittest sequences for the next round, inserting 5 new random sequences per generation, and 
generating the rest of the new population through mutation and crossover. PDGA stops after 
24 hours if the target has not been reached. Sequences generated with a distance value 
CBDMXFP ≤ 300 to the target generally correspond to interesting analogs, which are stored to 
constitute the analog database. All studies presented below use this set of value for these PDGA 
parameters (Figure 26).    
 
Figure 26. PDGA flowchart and analogs generation. 24 hours, 50, 10, 40, and 300, are variables 
depending on input parameters and settings. The input/output of the algorithm is exemplified for the 
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We exemplify PDGA with four peptides of different topologies as targets, namely linear 
peptide indolicidin,308 cyclic peptide tyrocidine A,309 polycyclic peptide ω-conotoxin-
MVIIA,310 and peptide dendrimer G3KL, running the algorithm with the corresponding PDGA 
topology subclass (Table 14).270 In all cases the minimum CBDMXFP per generation decreases 
with increasing generation number, reflecting the progress of the genetic algorithm driven 
optimization (Figure 27a). Remarkably, PDGA mostly generates peptides within the CBDMXFP 
≤ 300 limit, which represents significant target similarity. Indeed, by comparison randomly 
generated peptides have an average distance of CBDMXFP ~ 1000 to the targets and almost no 
occurrence within the CBDMXFP ≤ 300 limit (Figure 27b-d). Note that most runs do not reach 
their target before the 24 h limit, nevertheless these runs are useful because they produce large 
numbers of high similarity analogs.  
 The number of new peptides with CBDMXFP ≤ 300 to the target keeps growing regularly 
as the number of PDGA runs increase, suggesting that a very large and possibly unlimited 
number of analogs can be produced in each case (Figure 27f). In fact, different PDGA runs 
rarely generate the same compounds. This is not surprising if one considers the extremely large 
size of the peptide chemical space, which has a size of MN for M building blocks assembled in 
an N-mer sequence, corresponding from 1016 to 1032 for 39 building block forming sequences 
of 10 to 20 residues.  
Table 14. Compounds used targets for PDGA 
Topology Name Sequence a) Analogs b) Unique c) Target d) 
linear  indolicidin ILPWKWPWWPWRR 2,617,229 88 % 15/50 





8,189,307 100% 0/50 
dendritic G3KL (KL)8(KKL)4(KKL)2KKL 462,523 85 % 16/50 
a) Free carboxy termini are carboxamide -CONH2. b) Number of unique peptides generated within 
CBDMXFP ≤ 300 from the target compound after 50 runs of PDGA. c) Percentage of analogs generated 
which occurred in only one of the 50 PDGA runs. d) Number of runs where the target was reached.  
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Figure 27. (a) Minimum CBDMXFP from the target as function of generation number for an example 
PDGA run. (b) Histogram of CBDMXFP distance to indolicidin for 10,000 randomly sampled linear 
peptides (dashed gray line) and sequences generated by PDGA (magenta). (c) Histogram of CBDMXFP 
distance to tyrocidine A for 10,000 randomly sampled cyclic peptides (dashed gray line) and sequences 
generated by PDGA (red). (d) Histogram of CBDMXFP distance to ω-conotoxin-MVIIA for 10,000 
randomly sampled polycyclic peptides (dashed gray line) and sequences generated by PDGA (cyan). 
(e) Histogram of CBDMXFP distance to peptide dendrimer G3KL for 10,000 randomly sampled peptide 
dendrimers (dashed gray line) and sequences generated by PDGA (green). (f) Cumulative plot of the 
unique analogs created per run. 
 
7.2.2 Indolicidin analogs and sequence similarity comparison 
In 50 runs towards indolicidin as target, each of them with a time limit of 24 h, PDGA produced 
2.6 million unique peptide sequences within CBDMXFP ≤ 300 from the target, while the target 
sequence was found in 15 runs (Table 14). A closer analysis of the analogs showed that the 
structures generated by PDGA were similar in terms of size and hydrophobicity to the target 
indolicidin (Figure 28a, b, and c). The analogs were also similar to indolicidin when analyzing 
the properties of residues at specific positions without compromising the variety of the amino 
acid composition, reflecting the perception of pharmacophore features by MXFP (Figure 28e).  
 In principle, PDGA can be run using similarity measures other than CBDMXFP as fitness 
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comparison, namely the Levenshtein distance (lev), to evaluate the sequence similarity to the 
target.311,312 The modified algorithm (here named PDGA-lev) found its target much more 
efficiently than PDGA, with 49 out of 50 runs converging to the target in only 6 hours overall 
computing time. In this short time PDGA-lev nevertheless produced a large number (4.4 
million) unique sequences with high similarity to indolicidin in terms of lev distance (lev ≤ 5), 
but with a larger spread in terms of MXFP similarity (Figure 28d). When compared with 
analogs generated using MXFP as fitness function, the PDGA-lev analogs however show a 
lower sequence diversity while retaining less of the indolicidin size and hydrophobicity both 
globally (Figure 28a, b and c) and for each amino acid position (Figure 28f). 
 
Figure 28. Physiochemical properties and amino acids composition of indolicidin analogs. Heavy atom 
count (a), hydrophobic atom count (b), and HBA atom count (c) of two 10,000 analog random subsets 
generated by PDGA (blue) and PDGA-lev (orange); the target values are reported as black lines. (d) 
Levenshtein distance and CBDMXFP from indolicidin for 10,000 randomly picked analogs generated by 
PDGA (blue) and by PDGA-lev (orange); similarity threshold values are reported as red dashed lines. 
WebLogo313 Amino acids (AA) frequency per position of 10,000 13-residues sequences randomly 
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7.2.3 Cyclic and polycyclic peptides 
Macrocyclic peptides are largely present in the natural realm and they are numerous among 
candidate and approved drugs.314,315 Tyrocidine A (Table 14) is an antimicrobial cyclic 
decapeptide produced by the gram-positive Brevibacillus brevis, and shares structural 
similarities with other natural AMPs produced by the same bacteria: tyrocidine B and C, 
laterocidin, Gramicidin S, and loloatins A, B, C, and D.316 When challenging our algorithm to 
reach tyrocidine A in 24 hours, PDGA converged to the target in 9 out of 50 runs and produced 
4.1 million unique sequences with CBDMXFP ≤ 300 from tyrocidine A. In the course of these 
runs towards tyrocidine A, PDGA generated the well-known analog tyrocidine B. Interestingly, 
also the retro-sequences317,318 of loloatin A and of tyrocidine C were retrieved as analogs by 
our algorithm (Table 15).  
Table 15. Known analogs of tyrocidine A generated by PDGA 
Analog Sequence a) CBDMXFP 
tyrocidine B cyclo[fPWfNQYVOL] 67 
retro-loloatin A cyclo[VYDNfFPyLO] 157 
retro-tyrocidine C cyclo[VYQNwWPfLO] 188 
a) PDGA analogs do not contain any stereochemistry information, the right stereochemistry was added; 
O is ornithine. 
 
For the case of ω-conotoxin-MVIIA, an analgesic 25-residue tricyclic natural peptide 
containing three disulfide bonds,319 PDGA was unable to identify the target even after 72 hour 
runs, probably due to the polycyclic nature of the molecule. Nevertheless, the algorithm 
produced 8.1 million analogs with CBDMXFP ≤ 300 from the target. These analogs comprised 
peptides featuring a similar pattern of three cystine bridges, as well as C-to-N cyclized peptides 
with two or three cystine bridges and a similar overall topology. As can be appreciated by the 
relative positions of residues of different types in the sequences, many these analogs share the 
same ring topologies and distribution of cationic and anionic residues as the target conotoxin 
(Table 16, Figure 29).  
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Table 16. ω-conotoxin-MVIIA and 10 examples of its PDGA analogs. 
Sequence a) CBDMXFP 
ω-conotoxin-MVIIA 
           C(1)KGKGAKC(2)SRLMYDC(3)C(1)TGSC(2)RSGKC(3)-NH2* 
- 
Cyclo[C(1)KC(2)GC(3)C(2)SGKAEC(1)TGFKGTC(3) KGRGKRS]** 26 





          C(1)KC(2)NSAC(3)STRTKC(2)SGKASFC(3)LRGKC(1) 33 
          C(1)KC(2)NSTC(3)SSRGKC(2)SGKLCFC(3)VRGKC(1) 34 
          C(1)KC(2)NSTC(3)ATRAKC(2)SGKLSFC(3)GRGKC(1) 35 
          C(1)KC(2)NSTC(3)SSRAKC(2)SGKVCFC(3)LRGKC(1) 36 
a) Disulfide bridges are indicated with matching numbers. Red = Anionic residues, blue = cationic 
residues. The structures of the target* and its closest analog** are shown in Figure 29.  
 
 
Figure 29. ω-conotoxin-MVIIA and the closest analog generated by PDGA.  
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7.2.4 Peptide dendrimers 
Antimicrobial peptide dendrimer G3KL used as target to challenge PDGA with branched 
topologies belongs to a class of regularly branched peptide dendrimers, which can be prepared 
by solid-phase peptide synthesis and display a broad range of properties depending on the 
amino acid sequence and degree of branching.270,320,321 Starting from randomly generated 
branched peptides with an extended time limit of 48 h, PDGA converged to G3KL in 16 out 
of 50 runs, generating 462,523 high similarity (CBDMXFP ≤ 300) analogs of the target. Among 
the analogs generated, 95 sequences belonged to a family of 200 high similarity analogs of 
G3KL selected from an exhaustive enumeration library consisting only of leucine and lysine 
among which active analogs were previously identified by synthesis and testing.4 PDGA also 
generated many high similarity analogs with other residues than just leucine and lysine, thereby 
expanding sequence diversity while retaining high similarity to the target G3KL (Figure 30).  
 
Figure 30. (a) WebLogo frequency plot for 10,000 randomly selected sequences among the 319,884 
PDGA analogs of G3KL that have three generations and a maximum 4 amino acids per generation (69 
% of the G3KL analogs database); B is a branching unit and X is a deletion. (b) Percentage presence in 
the 319,884 sequences of the diamino acids branching units: lysine, ornithine, Dab, and Dap. (c) 
Reference sequence. 
 
B POS 6 POS 12 POS 18
Lys 62 % 38 % 30 %
Orn 30 % 37 % 15 %
Dab 5 % 18 % 10 %
Dap 3 % 7 % 45 %
c) G3KL:
XXXKLBXXXKLBXXXKLBXXXKL
B = Lys; X = deletion
b)
a)
B = Lys, Orn, Dab, Dap; X = deletion
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7.2.5 Non-peptide targets 
PDGA can optimize peptides towards any molecule for which an MXFP similarity can be 
calculated. We therefore challenged PDGA to generate analogs of five non-peptide targets of 
different topologies and sizes, namely acetyl-CoA, epothilone A,322 cholic acid, α-cyclodextrin, 
and a lipidated PAMAM dendrimer for siRNA transfection.323 For each target, we ran 50 
instances of PDGA for 24 hours using the same parameters as for peptides, and we set the 
PDGA topology to linear for acetyl CoA, to cyclic for epothilone A, cholic acid, and α-
cyclodextrin, and to dendritic for the PAMAM dendrimer.   
 Although none of these targets could be reached and the majority of the generated 
sequences fell outside the similarity threshold, PDGA generated a remarkably large number of 
close analogs (CBDMXFP ≤ 300) in each case (Table 17, Figure 31). Note that for the smallest 
target molecules a relatively high number of analogs were generated more than once due to the 
limited possibilities found by PDGA to mimic these targets (Figure 31 h-i). Unusual amino 
acids such as β-alanine, -aminobutyric acid and hydroxyproline played a decisive role in 
forming high-similarity peptide analogs of the non-peptide targets (Figure 32 and Figure 52).  
Note that for cholic acid PDGA was run with cyclic topology, however one of the best analogs 
is a linear peptide which was generated because PDGA also performs linearizing mutations. 
 These non-peptide examples illustrate the ability of PDGA to compose a peptide 
structure matching the overall shape and pharmacophore of a non-peptide target molecule using 
amino acid building blocks only. For acetyl CoA PDGA used carboxylate side chains to mimic 
anionic phosphate groups, while the purine base was approximated by the indole side chain of 
tryptophan. In the case of epothilone A, PDGA identified macrocyclic peptides of similar size 
and displaying a 5-membered ring heterocycle at the correct position by selecting -
aminobutyric acid, proline, and histidine as the most appropriate building blocks. Proline and 
-aminobutyric acid were also selected together with hydroxyproline as suitable building 
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blocks to mimic cholic acid with a tripeptide. α-cyclodextrin was approximated by a cyclic 
nonapeptide featuring hydroxyprolines, serine, threonine, glutamine and asparagine as residues 
with side chains featuring H-bond donors and acceptor atoms mimicking a carbohydrate.  
 For the case of the PAMAM dendrimer, PDGA composed a similar peptide dendrimer 
using amino-heptanoic acid, -aminobutyric acid and diaminobutyric acid branching units to 
mimic the extended branched structure of PAMAM. The extended hydrophobic core of the 
PAMAM dendrimer is approximated using aminoheptanoic acid, glycine, and a histidine 
featuring a 5-membered ring heterocycle matching the 1,2,3-triazole present in the target due 
to the click chemistry linkage used to attach the hydrophobic core to the dendrimer. Note that 
PDGA identified a G2 dendrimer with four end groups to mimic the PAMAM target bearing 
eight end-groups.  Indeed, PDGA mimics the positive charges present at the branching tertiary 
amines and primary amine end group of PAMAM by using lysine side chains and the amino 
termini, which achieves a similar number of cationic groups despite of the lower generation 
number.   
 In all of these non-peptide example PDGA selects the most suitable building blocks 
available in the set to approximate features of the non-peptide targets. The algorithm would 
probably identify more similar analogs if given to choose from building blocks with better 
matching features such as phosphates, aromatic heterocycles, carbohydrates, and more 
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Table 17. Compounds used targets for PDGA 
Compound PDGA topology a) No. of analogs b) Unique c) 
acetyl-CoA linear  13,087 24 % 
epothilone A cyclic  56,568 30 % 
cholic acid cyclic  2,694 5 % 
α-cyclodextrin cyclic 735,206 83 % 
PAMAM dendritic 114,346 97 % 
a) Value of the input parameter topology. b) Number of unique peptides generated within CBDMXFP ≤ 
300 from the target compound after 50 runs of PDGA. c) Percentage of analogs generated which 
occurred in only one of the 50 PDGA runs. 
 
 
Figure 31. (a) Minimum CBDMXFP from the target across generations for an example PDGA run. 
CBDMXFP between the target (b: acetyl CoA; c: epothilone A; d: cholic acid; e: α-cyclodextrin; f: 
PAMAM dendrimer) and a 10,000 randomly chosen subset of the unique sequences generated by 
PDGA in comparison with the CBDMXFP between the target and 10,000 randomly sampled sequences 
with the same PDGA topology (plotted as a gray dashed line). (g-i) Cumulative plot of the unique 
analogs created per run for the non-peptide targets (g: PAMAM dendrimer and epothilone A; h: acetyl-
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Figure 32. Structures of the non-peptidic targets acetyl CoA, cholic acid, α-cyclodextrin, and their best 
analogs. For dendrimer, italics indicate branching points, C2HN3 = 1,2,3-triazole, a7a = 7-
aminoheptanoic acid, Orn = ornithine, Gaba = g-aminobutyric acid, Dab = branching diaminobutyric 
acid. See supporting information for the extended version of dendritic structures.  
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7.2.6 Visualizing PDGA output in chemical space 
To appreciate the extent of chemical space that can be covered by PDGA, we generated a 
random sample of the different peptide topologies considered by the algorithm. For this study 
we limited our sampling to the 20 proteinogenic amino acids selected with equal probability 
and assembled them as linear peptides, head-to-tail cyclic and disulfide-bridged cyclic and 
polycyclic peptides, and regularly branched peptide dendrimers (Table 18). We then converted 
all peptide sequences to SMILES, computed 217D MXFP fingerprint, and projected the 
resulting dataset into 3D by principal component analysis (PCA). The resulting 3D-map, which 
covered 73% of data variance (PC1: 60%, PC2: 8%, PC3: 5%), was  represented using Faerun, 
24 a web-based application to visualize very large datasets in 3D connected to SmilesDrawer99 
to interactively draw the structural formula of the molecules corresponding to each datapoint. 
 The interactive Faerun map is available at http://faerun.gdb.tools including a broad 
range of color-coded representations. In this map molecules form a cloud resembling a helical 
wave with linear, cyclic and polycyclic peptides on separate sides of the first (from the left) 
turn of the wave and peptide dendrimers in the second turn (Figure 33a). This arrangement 
corresponds mostly to increasing molecule size as measured by the heavy atom count (HAC, 
Figure 33b). Furthermore, compounds are also distributed within the helical wave according to 
the fraction of aromatic atoms (Figure 33c) and to their structural intrinsic linearity (Figure 
33d). Mapping the four peptides and five non-peptide target molecules and their analogs on 
this map illustrates how PDGA densely populates the chemical space vicinity of each target 
and readily stretches out of the standard peptide chemical space when challenged with non-
peptide targets by using unusual amino acids (Figure 33e).    
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linear c) 4 – 26 420.5-3328.9 Da 300,000 Linear sequences. 
cyclic C-N c) e) 4 – 28 384.4-3424.8 Da 50,000 One cycle achieved through 
head-to-tail cyclization. 
cyclic S-S c) e) 7 – 28 791.9-3371.8 Da 50,000 One cycle achieved through 
one disulfide. 
polycyclic c) e) 6 – 36 629.7-3846.6 Da 250,000 Up to 4 cycles achieved 
through a maximum of three 
disulfide bonds and/or head-
to-tail cyclizations. 
dendritic d) 3 – 22  462.5-11232.6 Da 350,000 39,116 G1, 140,822 G2, and 
170, 062 G3 dendrimers. 
a) All N-termini are NH2, all C-termini are COOH, 20 proteinogenic amino acids sampled with equal 
probability at variable positions. b) (XXXXXB)nXXXXX, where X is a proteogenic amino acid position 
with 50% chance of being empty and B is the position of a branching lysine which marks a doubling of 
the peptide chain. c) B probability of being empty = 100%, n = 5. d) B probability of being empty = 20%, 
n = 3. e) the sequence was cyclized head-to-tail and/or from 1 to 3 pairs of cyclized cysteines were 
inserted. 
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Figure 33. Peptide chemical space as visualized interactively at http://faerun.gdb.tools. PCA of MXFP 
values for 1 million randomly generated peptide sequences visualized in Faerun and color-coded with 
sequence topology (a, N-C and SS cyclic are grouped), HAC (b), AR/HAC (c), and linearity. (d) 
Projection of 10,000 analogs of indolicidin (magenta), tyrocidine A (red), ω-conotoxin-MVIIA (cyan), 
G3KL (light green), acetyl-CoA (yellow), epothilone A (orange), cholic acid (purple), α-cyclodextrin 
(dark green), and of the PAMAM dendrimer (blue) on a random subset of the MXFP peptide chemical 
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7.2.7 Properties of PDGA analogs 
The map of chemical space above illustrates the fact that PDGA analogs are very close to their 
targets in terms of MXFP similarity, which is somewhat trivial since MXFP was the fitness 
function. The abundance of high similarity analogs nevertheless illustrates the important 
finding that the genetic algorithm succeeds not only with linear sequences but also with cyclic, 
polycyclic and dendritic peptides, which is not trivial since the algorithm operates on a linear 
representation while the fitness function is computed on the SMILES of the actual molecules 
featuring the complete topology of the peptide chain. The MXFP similarity calculation is much 
more complex than the linear sequence comparison exemplified with indolicidin but allows 
more substantial sequence variations while retaining the overall molecular properties of the 
target and is necessary to identify peptide analogs of non-peptide targets.   
 The central question is whether matching the target in terms of overall molecular shape 
and pharmacophores by featuring a comparable size and distribution of functional groups, 
which are the features selected by MXFP similarity, is sufficient for a peptide to share the 
biological properties of the target. For indolicidin, tyrocidine A and peptide dendrimer G3KL 
which are membrane disruptive antimicrobial compounds, these features are indeed important 
for activity. For such membrane disruptive compounds computational designs related to our 
PDGA have been shown to perform well in multiple cases.4–6,236,252,256,264,299–304 Here we found 
a known active analog of tyrocidine A among the high similarity analogs generated by PDGA, 
providing proof-of-principle of our approach (Table 15). On the other hand, the situation is 
expected to be more difficult when considering analogs of bioactive molecules that act by very 
specific interactions, such as the polycyclic conotoxins, where computational designs have not 
been demonstrated to date. The generated conotoxin analogs would furthermore be 
synthetically challenging due to the presence of multiple disulfide bridges.  
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For the case of the non-peptide targets, whether any of the peptide analogs generated by PDGA 
can display a biological activity similar to their target is probably case dependent. One would 
not expect any peptide mimic of acetyl CoA or epothilone A to match their activity which 
depend on specific reactivities and binding interactions with enzymes (AcCoA) respectively 
tubulin (epothilone A). On the other hand, the tripeptide analog of cholic acid identified by 
PDGA might display detergent properties related to bile acids. Similarly, the macrocyclic 
nonapeptide analog proposed as analog of α-cyclodextrin might feature comparable 
supramolecular complexation properties. In the case of the PAMAM dendrimer reported as an 
siRNA transfection reagent, we recently showed that peptide dendrimers related to those 
proposed by PDGA indeed display remarkable transfection reactivities.324    
7.3 Conclusion 
In contrast to previous computational approaches for peptide design which were limited to the 
specific case of linear peptides, we showed here that one can generate peptide analogs of any 
large molecule of interest, including both peptides and non-peptides, using a genetic algorithm. 
Our algorithm PDGA operates with peptides of diverse topologies of the peptide chain and 
diverse amino acid building blocks and selects molecules based on molecular shape and 
pharmacophore similarity to the target as fitness function. PDGA uses the Manhattan distance 
of the 217D atom-pair fingerprint MXFP for selection, however the algorithm can also operate 
using any other type of similarity measure as long as it is based on descriptors encoding 
information on the relative position of functional groups in a molecule, as exemplified here 
with the Levenshtein distance in the linear peptide example indolicidin. The pertinence of the 
analogs generated by PDGA is supported by the presence of known actives among these high 
similarity molecules in the case of macrocyclic peptide tyrocidine A and peptide dendrimer 
G3KL.  
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The PDGA application is versatile. On the one end through additional building blocks and 
cyclization types it is possible to further expand the size of the explored chemical space. On 
the other end selecting building blocks allows the exploration of specific chemical subspaces. 
The extent of peptide chemical space accessible by PDGA was illustrated by an interactive 
map of one million peptide structures. PDGA should be generally useful to generate peptides 
at any location in chemical space.  
7.4 Methods 
7.4.1 Converting peptide sequences to SMILES 
The conversion of the peptide sequences to SMILES is performed by the Peptide Design 
Genetic Algorithm (PDGA). PDGA recognizes as inputs sequences of amino acids represented 
with their three-letter codes and separated by hyphens, with the N-terminus on the left and C-
terminus on the right, considering sequences that can in principle be prepared by solid-phase 
peptide synthesis. For cyclic peptides, cyclization between C- and N-terminus is specified by 
adding “cy-” at the beginning of the sequence. Cyclization by disulfide bond is introduced by 
double insertion of a pair of bridged cysteines indexed with matching numbers. For peptide 
dendrimers, the appearance of a branching diamino acid in the sequence, marked by specific 
building blocks, implies that the peptide chain extending at left of the branching residue is 
doubled, and the total chain multiplicity depends on the number of branching residues present 
in the sequence. In the current implementation, the available building blocks are natural amino 
acids, defined with their standard three-letter code, and a selection of non-natural amino acids 
with assigned three-letter codes (Table 24).  
The three-letter codes are translated to single characters that correspond to the one letter 
code symbol for the natural amino acids and are arbitrary for the other building blocks (Table 
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24). Starting at the sequence C-terminus (right end of the line notation), the SMILES 
corresponding to the first building block is transformed into an RDKit123  molecule object and 
treated as structure seed. Then, each symbol is transformed into an RDKit molecule object and 
sequentially attached to the growing structure until the N-terminal is reached. C-terminus and 
N-terminus of each building block, sulfur of cyclized cysteines, and di-amines of branching 
units are flagged in the respective SMILES so that it could be tracked where amide and 
disulfide bonds must take place. Once the entire sequence is processed, the resulting RDKit 
molecule object is converted back into its SMILES string. 
7.4.2 MXFP calculation – SMARTS 
MXFP first assigns each atom to one or more of the following seven categories: non-hydrogen 
atom, hydrophobic, aromatic, hydrogen bond acceptor, hydrogen bond donor, positively 
charged, and negatively charged. For each atom pair within each category, the topological 
distance, which is the shortest path between the two atoms counted in bonds, is converted to 
gaussian of width 18% centered on the distance itself. The sum of atom pair gaussians in each 
category are sampled at the following 31 distances 0, 1, 2, 3, 4, 5, 6, 7.1, 8.4, 9.9, 11.6, 13.7, 
16.2, 19.1, 22.6, 26.6, 31.4, 37.1, 43.7, 51.6, 60.9, 71.8, 84.8, 100.0, 118.0, 139.3, 164.4, 193.9, 
228.9, 270.0, and 318.7 bonds, which results in 217 distance values forming the fingerprints 
after normalization. Details of the calculation and formula have been reported previously.14 In 
this work, MXFP was adapted to work faster on peptides by assigning hydrogen bond acceptor 
(HBA)/donor (HBD) properties and formal charges using SMARTS (Table 25). The rest of the 
properties were assigned as previously described, with 0.5 as scale factor for the categories 
HAC and Aromatic.  
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7.4.3 Genetic algorithm workflow 
PDGA takes six input parameters: population size ( ), mutation rate (𝛼), generation gap (𝛽), 
target sequence (accepted building blocks and their meaning, Table 24), similarity threshold 
(ST), and topology (TP: linear, cyclic, or dendritic). The algorithm produces   random 
sequences and assigns them a survival probability according to the reciprocal Manhattan 
distance between their MXFP to that of the target sequence.  
 Then, the new generation of peptides sequences is formed in the 4 steps reported below. 
1) The best    − 𝛽  sequences (survivors) are kept unchanged. 2)  𝛽 new sequences are 
produced. If TP is linear or dendritic, 90% of the new sequences are created through crossover. 
Meaning that two sequences of the previous generation are randomly picked according to a 
distribution based on their survival probability and the first half of the first one is merged with 
the second half of the second to give a “child” sequence. The remaining 10% is randomly 
generated (see section 7.4.5). When TP is cyclic, only 40% of the new sequences come from 
crossover, 50% are picked from the previous generation sequences according to their survival 
probability, and the remaining 10% are generated randomly. 3) the new sequences (    ) 
undergo the mutation process: one of the available mutations is randomly chosen, and 
𝛼     sequences are picked and mutated for each allowed mutation. For all topologies, 
PDGA performs single point mutations and insertions of amino acids, and each position can 
undergo single point deletion. If TP is dendritic, PDGA also performs insertion and mutation 
of branching units; mutation can affect both the building block type and its position (±1). If TP 
is cyclic, PDGA performs additional “cyclization/linearization” type mutations: amide bond 
head-to-tail cyclization/linearization, insertion/deletion of cyclized cysteines, and 
transformation of amide bond head-to-tail cyclization to a couple of cyclized cysteines at the 
beginning and at the end of the sequence. 4) The survivors are merged with the new sequences 
into the new generation.  
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Once formed, the new generation of peptide sequences is then evaluated again, and the cycle 
continues until CBDMXFP 0 is found for ten times or the time limit is reached. PDGA writes out 
all generated sequences in a “generations” file, which is updated each generation, and every 
sequence with CBDMXFP from the target MXFP lower than the ST in a “results” file. The PDGA 
code is open source and freely accessible at https://github.com/reymond-
group/PeptideDesignGA.  
7.4.4 PDGA runs and reproducibility 
Each PDGA use reported in this work has been repeated 50 times with different random seeds 
(integers from 1 to 50). In the ω-conotoxin and the G3KL examples, PDGA time limit was set 
to 72 and 48 hours, respectively; while in the other case studies PDGA was run for 24 hours. 
PDGA-lev was run for 6 hours, but most instances found the target in few minutes. Settings, 
input parameters, and the excluded building blocks are reported in Table 26. Regarding panel 
a of Figure 30, the reported PDGA instances have been ran with seed 7, 6, 11, 1, 1, and 37 for 
indolicidin, tyrocidine A, ω-conotoxin-MVIIA, G3KL, epothilone A, and the PAMAM 
dendrimer respectively.  
7.4.5 Random generation of sequences 
The random generation of peptide sequences is performed by the PDGA. To construct the 
peptide chemical space map, 350,000 peptide dendrimer sequences were generated with 
“XXXXXBXXXXXBXXXXXBXXXXX” composition, where X is a natural amino acid, B is 
a branching lysine, and the latter marks a doubling of the peptide chain at its left. All amino 
acids and branching residue have an equal probability of being picked in their respective 
positions. To allow sequences of different lengths, both X and B positions can be empty with 
a probability of 50% and 20%, respectively. If one branching unit position is empty, the 
neighbor generations are merged; therefore, the maximum generation length increases when 
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the number of generations decreases. At its maximum extent, this can lead to no branching unit 
and linear sequences of 20 amino acids maximum length that were filtered out. 
650,000 more peptide sequences were generated with no branching units and a 
maximum length of 30 amino acids. Then 350,000 of these linear sequences were cyclized 
using amide bond head-to-tail cyclization and cysteine disulfide bonds. The sequences were 
divided in seven groups of 50,000 peptides and each group was cyclized with 1 S-S bond, 2 S-
S bonds, 3 S-S bonds, amide bond head-to-tail, amide bond head-to-tail and 1 S-S bond, amide 
bond head-to-tail and 2 S-S bonds, or amide bond head-to-tail and 3 S-S bonds, respectively. 
To add a disulfide bond, two cyclized cysteines were randomly inserted into the sequence. The 
cyclization through disulfide bond is not always possible: if two cyclized cysteines are inserted 
next to each other, they were removed, and the cyclization did not take place; to avoid linear 
sequences the cysteines insertion was repeated until the desired number of cycles was present 
in the sequence.  
According to their topology, PDGA first generation sequences and the random 
component of each new generation were created as described above. In this case, linearity was 
kept and a selection of non-natural building blocks was allowed (see Table 26 for the building 
blocks used in each case study and Table 24 for their meaning). To compare the PDGA results 
with random peptides (Figure 27 panels b-e and Figure 31 b-f), 10,000 sequences for each 
topology were randomly picked among the one generated for the map.  
7.4.6 Property calculation 
The peptide chemical space can be navigated using 16 different properties: heavy atom count 
(HAC), hydrophobic atom count and fraction, aromatic atom count and fraction, H-bond donor 
and acceptor atom count and fraction, positive atom count and fraction, negative atom count 
and fraction, linearity, number of branching units and sequence topology.  
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Linearity is a measure of the MXFP values difference between the considered sequence and 
the linear alkane with the same HAC. 14 The number of branching units is the count of cyclized 
cysteines (Cys1, Cys2, Cy3) and branching lysine (BLys) in the sequence. Sequence topology 
describes the possible peptide structure and can be linear, cyclic, polycyclic, or a G1, G2, or 
G3 dendrimer peptide. All the other properties are calculated by MXFP using ChemAxon325 
plugins. 
7.4.7 PDGA analogs visualization in the peptide chemical space map 
The visualization of the PDGA analogs in the peptide chemical space was done by projecting 
the MXFP values of the generated sequences with CBDMXFP ≤ 300 on the PCA of a 10,000 
molecules random subset of the peptide chemical space. As in Faerun the PCA was performed 
using scikit-learn. 162 
  
150 | P a g e  
  
Chapter Eight – Machine Learning 
Designs Non-Hemolytic 
Antimicrobial Peptides 
This work is based on the peer-reviewed publication: 
Capecchi, A.*; Cai, X.*; Personne, H.; Köhler, T.; van Delden, C.; Reymond, J.-L. Machine 
Learning Designs Non-Hemolytic Antimicrobial Peptides. 2021. 
https://doi.org/10.1039/D1SC01713F.  
*These authors contributed equally to the publication.  
This article is licensed under a Creative Commons Attribution International License (CC BY 
3.0). 
Peptide synthesis and tests were performed by Xingguang Cai and Hippolyte Personne. 
Molecular dynamics simulations were performed by Hippolyte Personne.  
Abstract 
Machine learning (ML) consists of the recognition of patterns from training data and offers the 
opportunity to exploit large structure-activity databases for drug design. In the area of peptide 
drugs, ML is mostly being tested to design antimicrobial peptides (AMPs), a class of 
biomolecules potentially useful to fight multidrug-resistant bacteria. ML models have 
successfully identified membrane disruptive amphiphilic AMPs, however mostly without 
addressing the associated toxicity to human red blood cells. Here we trained recurrent neural 
networks (RNN) with data from DBAASP (Database of Antimicrobial Activity and Structure 
151 | P a g e  
  
of Peptides) to design short non-hemolytic AMPs. Synthesis and testing of 28 generated 
peptides, each at least 5 mutations away from training data, allowed us to identify eight new 
non-hemolytic AMPs against Pseudomonas aeruginosa, Acinetobacter baumannii, and 
methicillin-resistant Staphylococcus aureus (MRSA). These results show that machine 
learning (ML) can be used to design new non-hemolytic AMPs.  
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8.1 Introduction 
Machine learning (ML) is a part of artificial intelligence consisting of using algorithms to 
recognize patterns in training data. In the context of computer-aided drug discovery,31,326 ML 
allows one to exploit experimental structure-activity data on known drugs to generate new 
molecules and predict their properties and activities.294,295,327 Generating new molecules is 
commonly a two-step approach that requires first a more general training and then a fine-tuning 
towards a specific set of characteristics. The fine-tuning of a generative ML model can be 
achieved with transfer learning (TL), which is essentially a second learning of a prior 
generative model with a smaller set of compounds.328  
 In the area of computational peptide design,23,329 ML models for generation and activity 
classification can readily be trained with structure-activity data using the linear sequence of 
amino acids as input for the peptide structure. Efforts to develop and test ML for peptide design 
mostly focus on antimicrobial peptides (AMPs)330,236  because relatively large structure-activity 
databases are available in the public domain.331–335,278,336 Antimicrobial peptides (AMPs) are 
synthesized by microorganisms, plants, and animals as a defense against bacterial predators 
innate immunity. They often show good activity against multidrug-resistant bacteria, thereby 
offering an opportunity to address this global public health threat.337–340  
Most AMPs are polycationic and act by disrupting bacterial membranes, usually by 
folding into an amphiphilic α-helix at the membrane surface,269,341 a mechanism against which 
resistance is not easily obtained and which has been used broadly to guide the design of new 
AMPs. Unfortunately, designing amphiphilicity often results in compounds lacking selectivity 
against eukaryotic membranes and showing hemolytic properties, which strongly limits their 
use.342 In principle, ML should be optimally suited to address this challenge by training models 
with data on AMPs with annotated hemolysis data.  
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Several ML models for AMP de novo design have been reported so far, and they range from 
classifiers for AMPs prediction applied to select sequences from randomly generated, existing, 
or genome derived libraries,264,343–349,261 to standalone generative models,267 to a combination 
of both generative models and classifiers.268,350,351 Furthermore, ML has also been used in 
combination with evolutionary algorithms for the optimization of AMPs.256,352 However, only 
two of the discussed studies considered both activity and hemolysis in the design of novel 
AMPs,348,351 reflecting the challenge of avoiding hemolysis in designing AMPs and 
highlighting the importance of its further investigation. 
Here we considered the use of ML for AMP design considering activity and hemolysis 
by training our models on sets of active, inactive, hemolytic, and non-hemolytic sequences 
derived from reported activity data. We also aimed to validate if ML can be used to identify 
new AMPs by testing only sequences substantially different from known AMPs. Starting with 
sequence information and antimicrobial and hemolysis data from DBAASP (Database of 
Antimicrobial Activity and Structure of Peptides),332 which contains manually curated 
information on activity values and hemolysis behavior, we trained a combination of generative 
and predictive recurrent neural networks (RNN). To generate peptide sequences, we trained a 
generative model and we fine-tuned it using TL to target three problematic and often drug-
resistant pathogens: the Gram-negative Pseudomonas aeruginosa and Acinetobacter 
baumannii, and the Gram-positive Staphylococcus aureus. Furthermore, to select non-
hemolytic AMPs among the generated sequences, we implemented two RNN classifiers to 
predict antimicrobial activity and hemolysis. Our combination of supervised and unsupervised 
learning to design non-hemolytic AMPs is unprecedented, and it allowed us to maximize the 
use of highly curated data on antimicrobial activity and hemolysis. Synthesis and testing of 
twenty-eight of the generated and selected sequences resulted in twelve new active AMPs, 
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eight of which were also non-hemolytic. Detailed characterization of the best two peptides 
showed that they are typical α-helical membrane disruptive AMPs.   
8.2 Results and Discussion 
8.2.1 Machine learning  
8.2.1.1 DBAASP 
DBAASP contains peptides annotated with activity values, and when known, with their 
hemolytic behavior. This allowed us to obtain reliable AMP activity and hemolysis data. With 
a threshold of 32 µg/mL and 10 µM, we identified 4,774 active and 1,867 inactive linear 
peptides. Additionally, we considered the DBAASP peptides reported to cause less than 20% 
hemolysis at a concentration of at least 50 µM as non-hemolytic and the peptides reported to 
cause more than 20% hemolysis at any concentration as hemolytic, which resulted in 1,319 
hemolytic and 943 non-hemolytic linear peptide sequences. Finally, we extracted 339 non-
hemolytic peptides active against the Gram-negative bacteria P. aeruginosa and/or A. 
baumannii and 458 non-hemolytic peptides active against the Gram-positive bacterium S. 
aureus.  
8.2.1.2 Generative models 
Alone, the 339 and 458 non-hemolytic AMPs active, respectively, against P. aeruginosa and/or 
A. baumannii and S. aureus are not enough to directly train a generative model able to design 
a diverse set of novel AMPs. To overcome the challenge posed by the scarcity of data points 
on specific strains in the DBAASP, we first trained a general generative model on the entire 
DBAASP, and then we fine-tuned it with the smaller subset of AMPs with reported hemolysis 
data and specific activity (Figure 34a). The 4,774 active peptides in the DBAASP were divided 
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into a training and a test set, and the training set was used to train an RNN generative model to 
produce AMPs (prior model).  
 
Figure 34. (a) Strategy schematic. An AMP RNN generative model, an AMP activity classifier, and a 
hemolysis RNN classifier were trained using activity (orange) and hemolysis (blue) data from 
DBAASP. (1) Two copies of the AMP RNN generative model (prior model) were transferred learned 
using active and non-hemolytic peptides against specific strains: P. aeruginosa/A. baumannii and S. 
aureus, respectively. (2) The fine-tuned models were sampled, and the generated sequences were first 
classified using the RNN AMP activity classifier and then the RNN hemolysis classifier. (3) The 
selected sequences were further filtered to obtain short peptides of maximum 15 residues with at least 
five mutations from the sequences in DBAASP and no D amino acids. Then two different selection 
strategies were used. In the first selection strategy (1st strategy) we used the calculated amphiphilicity 
of the sequences to further filter them, and we clustered the selected ones. In the second selection 
strategy (2nd strategy) we select at random 10 sequences. (4) Finally, the 28 chosen sequences were 
synthesized and tested. (b) ROC curves of the test set for the NB, RF, SVM, RNN, and RNN with 
scrambled labels (RNN scr.) models for the AMP activity (b) and hemolysis (c) classification tasks. 
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Subsequently, two generative models were derived by fine-tuning the prior model with TL 
using two smaller sets of sequences with a specific activity and known non-hemolytic behavior: 
(i) the 242 non-hemolytic peptide sequences present in the training set of the prior model and 
active against the Gram-negative P. aeruginosa and/or A. baumannii and (ii) the 321 non-
hemolytic sequences present in the training set of the prior model and active against the Gram-
positive S. aureus. Interestingly, 170 peptides were common to both sets (see methods section 
8.4.1 and 8.4.5 for details). 
To avoid overfitting, the prior and the two fine-tuned generative models were trained 
with the respective training sets until the probability of generating the related test sets reached 
their maximum value. For the fined-tuned models, the 97 and 137 sequences active, 
respectively, against P. aeruginosa /A. baumannii and S. aureus, which were present in the test 
set of the prior model, were used as test set. We then sampled 50,000 peptide sequences from 
each of the two fine-tuned models. The percentage of unique sampled sequences was 82.8% 
for the P. aeruginosa /A. baumannii model and 82.3% for the S. aureus model. Furthermore, 
in both cases over 99% of the sampled sequences were not present in the corresponding training 
set used for transfer learning due to our attention in avoiding overfitting. The high percentage 
of uniqueness and the novelty of the generated sequences within the 50,000 samples showed 
that our fine-tuned models were capable of generating new and diverse sequences. This allowed 
us to proceed in our analysis with a relatively small and manageable number of candidate 
peptide sequences.  
8.2.1.3 Classifiers 
To assess the capabilities of the prior model and to predict the AMP activity of the generated 
peptide sequences, we implemented a NB (Naive Bayes), an SVM (Support Vector Model), a 
RF (Random Forest), and an RNN AMP activity classifiers. The DBAASP active compounds 
in the same training/test split used for the prior model were used as positive class. As negative 
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class, we used an equally sized set of inactive sequences dived in training and test sets. The 
inactive sequences consisted of all inactive sequences in DBAASP and additional sequences 
generated by scrambling active peptides and by fragmenting SwissProt entries. As a baseline 
and to make sure that the performance of the RNN model was due to a trend in the data and 
not to an artifact, an RNN activity classifier with the same architecture but trained with 
scrambled labels was implemented. The models were trained using the training set, and their 
performances were evaluated using the test set (Figure 34b, Table 27). The RNN activity 
classifier performed best across all computed metrics (ROC AUC = 0.84, accuracy = 0.76, 
precision = 0.74, recall = 0.80, F1 score = 0.77, MCC = and 0.53) and was selected for further 
investigation. 
To account for non-hemolytic behavior, a second classifier to distinguish between 
hemolytic and non-hemolytic sequences was trained. In this case, the DBAASP entries with 
hemolysis annotation were used to train the models. Non-hemolytic sequences were considered 
as the positive class and hemolytic sequences as the negative class. Being the sequences with 
hemolysis data a subset of the ones having activity data, we used the same training/test split 
used for the activity classifier (for details refer to method section 8.4.1). Similar to the AMP 
activity classification discussed above, an RNN classifier with scrambled labels (baseline), NB, 
SVM, RF, and RNN classifiers were trained with the training set and evaluated for the 
hemolysis task with the test set. As for the activity classifier discussed above, the RNN 
classifier had the best overall performance for hemolysis prediction (ROC AUC = 0.87, 
accuracy = 0.76, precision = 0.70, recall = 0.76, F1 score = 0.73, MCC = 0.52) and was selected 
for further study (Figure 34c, Table 27).  
To increase the precision of the RNN AMP activity and RNN hemolysis classifiers, we 
raised the threshold used to transform their probabilistic output to a binary classification from 
0.5 to over 0.95 for both classifiers (refer to methods 8.4.6 for details). This resulted in an 
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adjusted precision of 0.91 and 0.84 for the RNN AMP activity classifier and the RNN 
hemolysis classifier, respectively. Therefore, when considering the antimicrobial activity and 
the hemolysis behavior of a peptide sequence as two independent characteristics, we obtained 
a combined precision of 0.76, which means that 76% of predicted positives are expected to 
have antimicrobial activity and non-hemolytic properties. However, because hemolysis is a 
known drawback of antimicrobial peptides, non-hemolytic behavior and antimicrobial activity 
are likely to be inversely proportional. This is also evident when looking at the 1,786 active 
peptides reported in the DBAASP with a hemolysis annotation, as only 721 are reported as 
non-hemolytic. For this reason, a lower overall performance of the two classifiers was 
expected.   
8.2.1.4 Sequences selection 
The RNN AMP activity and hemolysis classifiers were used to filter the 50,000 sequences 
sampled from each of the two fine-tuned generative models, resulting in 3,046 sequences from 
the model fine-tuned for P. aeruginosa and A. baumannii and 2,717 from the model fine-tuned 
for S. aureus (Figure 34a). To facilitate the synthesis process, sequences longer than 15 amino 
acids were excluded (Figure 53a). The sequences were further filtered to ensure novelty, 
considering a minimum of four mutations from the test set peptides and, to further challenge 
our model, of five mutations from the training set peptides (Figure 53b to e). This selection 
criterion has not been used in previous AMP discovery approaches using ML, however, we 
believe it to be fundamental to avoid trivial analogs of known peptides and analogs which have 
already been studied within SAR analysis. Finally, since the percentage of D amino acids in 
the training sets of the generative model and of the classifiers was low, we decided to exclude 
the sequences containing D amino acids since the data would be insufficient for the model to 
learn features for such peptides (Figure 53f). The selection yielded 148 and 160 peptides from 
the P. aeruginosa/A. baumannii model and S. aureus model, respectively.  
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Then, two different strategies to further select the sequences were followed. In the first case, 
we used the calculated hydrophobic moment353 and the predicted α-helix fraction as estimations 
of amphiphilic helix to further filter the sequences (Figure 53g) and performed clustering to 
diversify our selection (first selection strategy). In the second case, we randomly sampled 10 
sequences out of each pool of peptides to follow the model sampling distribution (second 
selection strategy, see methods section 8.4.7 for details). This selection resulted in 20 peptide 
sequences from the P. aeruginosa/A. baumannii model and 26 peptide sequences from the S. 
aureus model. From each set, 14 peptides were chosen manually for experimental evaluation. 
Thanks to the applied filters and selection processes, all selected sequences were distinct from 
the training and test sets of both AMP activity and hemolysis classifiers in at least five 
positions, and to the best of our knowledge, they were not present in any peptide databases. 
The sequences coming from the P. aeruginosa/A. baumannii model were labeled as Gram-
negative targeting compounds (GN), and the sequences selected from the S. aureus model were 
labeled as Gram-positive targeting compounds (GP).  
8.2.2 Synthesis and testing 
8.2.2.1 Antibacterial activity and hemolysis 
We synthesized the selected 14 GN and 14 GP peptides by solid phase peptide synthesis and 
evaluated the activity of their HPLC-purified trifluoroacetate salts by determining minimum 
inhibitory concentrations (MIC) against bacteria by broth microdilution assay in Muller-Hinton 
medium and minimum hemolysis concentrations (MHC) on human red blood cells by serial 
dilution in phosphate buffer saline (Table 19. Synthesis and activity of generated peptides.Table 
19).   
 Considering an activity threshold of MIC ≤ 16 µg/mL for activity and MHC ≥ 500 
µg/mL for hemolysis, 9 of 14 GN peptides (64 %) turned out as actives, but only 6 of 14 GN 
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(43 %) were both active against P. aeruginosa or A. baumannii and non-hemolytic. By the 
same measure, only 3 of 14 GP peptides (21 %) were active against MRSA, and only 2 of 14 
GP peptides (14 %) were also non-hemolytic. Furthermore, three of the active GN peptides 
were also active against MRSA, while all three active GP peptides and one GP inactive peptide 
were also active against P. aeruginosa or A. baumannii, and 11 out of 14 GN and 6 out of 14 
GP peptides showed activity against Escherichia coli tested as an additional Gram-negative 
bacterium. Therefore, in terms of overall activity, 18 out of the 28 synthesized peptides (64 %) 
were active below the threshold, and 14 out of 28 (50 %) were active and non-hemolytic, which 
is not very much below the precision of 76 % for the combined activity/hemolysis classifier 
(see above).  
The lack of selectivity of the generated AMPs for the bacteria they were trained on, 
either Gram-negative (P. aeruginosa and A. baumannii) or Gram-positive (S. aureus) bacteria 
suggested to test our AMPs in a broader context. We therefore tested the best GN (GN1) and 
the best GP (GP1) AMP against additional pathogenic bacteria available in our laboratory 
(Table 20). Both peptides were also active against ZEM-1A, which is a multidrug-resistant 
clinical strain of P. aeruginosa, but not against the related ZEM9A which is more resistant to 
polymyxin B, a pattern which we have observed previously with other AMPs.5,122 GN2 also 
showed good activity against P. aeruginosa PA14 and several mutant strains generated to be 
resistant to polymyxin and antimicrobial dendrimers,272 and against S. maltophilia, E. cloacae, 
both Gram-negative, and to a lesser extent against S. epidermidis (Gram-positive), but was 
inactive against two different strains of Klebsiella pneumoniae (Gram-negative). GP1 also 
showed significant activity against several of these strains, and even against the two K. 
pneumoniae strains. This extended profiling confirmed the robust activity of both AMPs but 
also underscored the fact that our generative models did not produce AMPs with selectivity 
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between Gram-negative and Gram-positive strains, reflecting the fact that many AMPs 
appeared as actives in both TL training sets.  
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Table 19. Synthesis and activity of generated peptides. 


































































Gram-neg. active, non-hemolytic: 
GN1 AKRIRKLIKKIFKKI 4 4 16 >2000 8 
GN2 RRWKWRRKIKKWL 8 8 4 1000 16 
GN3 IDKWKAAFKKIKNLF 8-16 2 8 500 16-8 
GN4 LNALKKVFQKIRQGL 32 16 >64 >2000 4 
GN5 KFFRKLKKLVKK 16 >64 64 >2000 64 
GN6 RLRKKWRKLKKLL 32 32-16 64 2000 32-16 
Gram-neg. active, hemolytic:  
GN7 KRIRKWVRRILKKL 4 4 4 250 16 
GN8 LRKFWKKIRKFLKKI 8 4 4 62.5 16 
GN9 KRLWKRIYRLLKK 8 8 8 250 8-4 
Gram-neg. inactive: 
GN10 IRRIRKKIKKIFKKI 32 32 64 >2000 16 
GN11 LRKARRLLKKLRARL >64 32 32 >2000 32 
GN12 GNWRKIVHKIKKAG 32 >64 >64 >2000 16 
GN13 AGRLQKVFKVIAK 64 >64 >64 >2000 32 
GN14 IHKLAKLAKNVL >64 >64 >64 >2000 32 
Gram-pos. active, non-hemolytic : 
GP1 FLKAVKKLIPSLF 16 8-16 16 2000 8 
GP2 RWRWPILGRILR 8 16 16 500 16 
Gram-pos. active, hemolytic: 
GP3 FLHSIGKAIGRLLR 16 16 8 250 8 
Gram-pos. inactive: 
GP4 GIGAVLNVAKKLL 64 32 32 >2000 16 
GP5 KVARFLKKFFR 64 64-32 32 >2000 4 
GP6 LKKLWKRIIKVGR 32 32-16 64 >2000 8 
GP7 ARKWRKFLKKI >64 64 64 >2000 64-32 
GP8 GRIKRIRKIIHKY 8 32 >64 >2000 32 
GP9 ARKKWRKRLKKLKI 64-32 >64 >64 >2000 64-32 
GP10 AKKVVKKIYKRFQK >64 64 >64 >2000 64 
GP11 ARKFRRLVKKLR >64 >64 >64 >2000 64 
GP12 LRKARRLVKKLA >64 >64 >64 >2000 >64 
GP13 KRLWKIRQRIAK >64 >64 >64 >2000 32 
GP14 LNALKKVFQKIH >64 >64 >64 >2000 >64 
a) Compounds labeled as GN were obtained from the P. aeruginosa/A. baumannii model, compounds 
labeled as GP were obtained from the S. aureus model; in both sets, compounds were ordered according 
to their activity and hemolysis profile; GN2, 6, 9, 10 and GP2, 6, 9, 11 were obtained using the second 
selection strategy. b) One-letter code for amino acids. All peptides are carboxamides (-CONH2) at the 
C terminus. c) MIC was determined after incubation for 16-20 h at 37°C. d) MHC was measured on 
human red blood cells in 10 mM phosphate buffer saline, pH 7.4, 25°C. 0.1% Triton X-100 was used 
as a positive control. Highlight in green denotes MIC < 32 µg/mL towards the bacterial strains used for 
the design (P. aeruginosa/A. baumannii for GN and S. aureus for GP) or MHC ≥ 500 µg/mL. 
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Table 20. MIC a) of GN1 and GP1 towards further MDR and non-MDR bacterial strains. 
 
GN1 GP1 Polymyxin B 
P. aeruginosa ZEM-1A b, c,) 4 4 0.5 
P. aeruginosa ZEM9A b, c,) 64 64 4 
P. aeruginosa PA14 c) 2 8-16 <0.5 
P. aeruginosa PA14 4.13 (phoQ) c, d) 2 8-16 1 
P. aeruginosa PA14 4.18 (pmrB)c, d) 4 32-64 2 
P. aeruginosa PA14 2P4  (pmrB)c, d) 8 64 2 
S. maltophilia b, c) 4 16 0.5 
E. cloacae b, c) 8 16-32 1 
K. pneumoniae (OXA-48) b, c) >64 16-32 1 
K. pneumoniae NCTC148 b, c) >64 32 1 
B. cenocepacia b, c) >64 >64 >64 
S. epidermidis b, e) 16 16 32-64 
a) The MIC was determined in Müller-Hinton medium after 16-20 h of incubation at 37 °C. Each result 
represents two independent experiments performed in duplicate. b) MDR strains. c) Gram-negative 
strains. d) Strains carrying spontaneous mutations in the indicated genes, all leading to polymyxin B 
resistance. e) Gram-positive strain. 
 
8.2.2.2 α-helical folding and membrane disruption 
The amino acid sequences of peptides GN1 (15 residues, 8 cationic, 7 hydrophobic) and GP1 
(13 residues, 3 cationic, 9 hydrophobic) both had an amphiphilic composition. Circular 
dichroism (CD) spectra showed that both peptides were unordered in pure water but adopted 
an α-helical conformation in the presence of n-dodecyl phosphocholine (DPC) micelles 
mimicking the membrane environment. The effect was very strong with GN1 (89 % α-helix 
with 5 mM DPC) and still quite strong with GP1 (56 % α-helix with 5 mM DPC) despite the 
presence of a helix-breaking proline residue in its sequence and in line with the fact that this 
sequence passed the α-helical filter used for sequence selection. By comparison, the second 
most active, non-hemolytic AMP GN1 (13 residues, 8 cationic, 5 hydrophobic) which had been 
selected from the RNN generator and classifiers without the α-helix filter, only showed 36 % 
α-helix with 5 mM DPC. Nevertheless, all three AMPs were predicted to adopt an amphiphilic 
arrangement of their cationic and hydrophobic side chains upon α-helical folding (Figure 35c).  
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Figure 35. (a) CD spectra of GN1, GN2, and GP1 recorded at 0.100 mg/mL in 10 mM phosphate 
buffer pH 7.4 with or without 5 mM DPC. (b) Extraction of percentages of secondary structure from 
primary CD data using DichroWeb. The Contin-LL method and reference set 4 were used. (c) Helix 
properties predicted by HeliQuest. Circle size proportional to side-chain size, blue indicates cationic 
residues, yellow indicates hydrophobic residues, grey indicates alanine, green indicates proline, purple 
indicates serine. The arrows inside each helix wheel indicates the magnitude and direction of the 
hydrophobic moment. 
 
To confirm the secondary structure determined by CD, we performed MD (Molecular 
Dynamics) simulations for our most active peptides GN1, GP1, and GN2 using GROMACS.354 
In each case, 250 ns simulations were performed both in water and in presence of DPC micelle.  
As expected, simulation in water led to the unfolding of GN1 (Figure 36a). Interestingly, GN1 
kept a complete amphiphilic α-helix after 250 ns in presence of DPC micelle (Figure 36b, c 
and d), which is consistent with the 89% α-helix obtained with 5 mM DPC during the CD 
measurements. Similarly, GP1 and GN2 unfolded in water and partially folded in presence of 
DPC micelle (Figure 56, Figure 57). Partial α-helical conformation was observed in the case 
of GP1 while interacting with the micelle, confirming the CD data and the conservation of the 
secondary structure despite the presence of a proline residue. Surprisingly, GN2 unfolded and 
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refolded into a stable partial π-helix in contact with DPC, suggesting a stable transition state 
between α-helix and random coil. As both types of helices cannot be distinguished using CD, 
this is coherent with the helicity signal observed with 5 mM DPC. Overall, MD simulations 
confirmed a helical secondary structure behavior in a membrane-like environment. 
 
Figure 36. MD simulations of GN1 in water and in presence of a DPC micelle over 250 ns using 
GROMACS. (a) Average structure (stick model) in water over 100 structures sampled over the last 100 
ns (thin lines). Hydrophobic side chains are colored in red and cationic side chains in blue. (b) Average 
structure (cartoon model for backbone and stick model for side chains) with DPC micelle over 100 
structures sampled over the last 100 ns (thin lines). (c) RMSD (root mean square deviation) of the 
peptide backbone atoms relative to the starting α-helical conformation. (d) Number of intramolecular 
hydrogen bonds. The DPC micelle was omitted for clarity. 
 
The CD, MD, and sequence analysis above clearly pointed to membrane disruption as the 
probable mechanism of action for our AMPs. This hypothesis was further supported by 
transmission electron microscopy (TEM) imaging of bacterial cells exposed to the AMP in the 
case of GN1, which showed bacterial membrane ruptures for P. aeruginosa, while in the case 
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of A. baumannii the cell shape was preserved but cell contents were altered, an effect also 
observed with other membrane disruptive AMPs on this bacterium (Figure 37). 
 
 
Figure 37. TEM images of P. aeruginosa and A. baumannii, after 2 hours treatment of GN1 in MH 




In this work, we have demonstrated ML capable of designing non-hemolytic AMPs. We 
extracted a highly reliable dataset of AMPs and non-AMPs, as well as hemolytic and non-
hemolytic peptides from the DBAASP, a manually curated antimicrobial peptide database. We 
used the data to train a generative peptide model (prior model), an AMP activity classifier, and 
a hemolysis classifier. Two copies of the prior model were fine-tuned using active and non-
hemolytic peptides against specific strains: P. aeruginosa/A. baumannii and S. aureus, 
respectively. The fine-tuned models were sampled, and the generated sequences were filtered 
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obtain short peptides of maximum 15 residues with at least five mutations from the sequences 
in DBAASP.  
Out of the 28 synthesized peptides, 12 were measured active towards the pathogens 
used in the design (P. aeruginosa/A. baumannii or S. aureus) with a MIC < 32µg/ml, which 
was the activity threshold selected to train our ML models, and eight of them showed low 
hemolysis against human blood cells with an MHC ≥ 500 µg/ml. Additionally, our best 
compounds GN1 and GP1 displayed remarkable activity also against a broader panel of 
pathogenic bacteria including MDR strains.  
In the context of the AMPs previously discovered through a ML-guided 
approach,264,268,345,348–350 GN1 and GP1 have a broader and overall higher activity combined 
with better hemolytic behavior. Two notable exceptions are the AMPs reported by Nagarajan 
et. al.350 which have activity and hemolysis comparable to our results, and the two AMPs 
reported by Cherkasov et. al.264 which show higher activity but a worse hemolytic behavior 
than our compounds. However, in both cases, hemolysis was not a design feature and the low 
hemolysis of the reported compounds was serendipitous. Our results indicate that ML can 
acquire sufficient information from known AMPs to guide the discovery of new AMPs 
substantially different from the training set and that ML can overcome the challenging task of 
designing both antimicrobial activity and non-hemolytic behavior. It should be noted that the 
ML approach exploiting experimental data helped us discover non-hemolytic AMPs even in 
the absence of a simple design rule for this property, highlighting the usefulness of ML in 
peptide design.  
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8.4 Methods 
8.4.1 Datasets Preparation 
All peptide sequences without intrachain bonds were downloaded from the DBAASP peptide 
database website (https://dbaasp.org/), resulting in a dataset of 11,805 linear peptides. Only the 
9,946 sequences with free or amidated C-terminus, free or acetylated N-terminus, and 
containing only natural amino acids and their D-enantiomers were kept. 
The targets and the activity measurements of the 9,946 sequences were extracted using 
the DBAASP Python API. Sequences with a registered activity measure below 10 µM, or 
10,000 nM, or 32 µg/ml towards at least one reported target were labeled as active; the 
sequences active against P. aeruginosa, A. baumannii, or S. aureus were flagged. Sequences 
with registered activity measures above 10 µM, or 10,000 nM, or 32 µg/ml towards all reported 
targets were labeled as inactive; when P. aeruginosa, A. baumannii, or S. aureus was one of 
the reported targets the sequences were flagged. When present, activity against human 
erythrocytes was used to label the sequences as hemolytic or non-hemolytic. The concentration 
was normalized to µM and sequences causing less than 20% of hemolysis with a concentration 
equal or above 50 µM were flagged as non-hemolytic. Sequences causing more than 20% of 
hemolysis were flagged as hemolytic regardless of the concentration. The remaining sequences, 
together with the ones not having reported data against human erythrocytes, were labeled as of 
unknown hemolytic properties. The procedure resulted in 4,774 peptides labeled as active, 
1,867 labeled as inactive, 1,319 labeled as hemolytic, and 943 labeled as non-hemolytic.   
To achieve a balanced dataset for the activity classifiers, 2,907 additional inactive 
sequences were generated. (1) 1,453 unique sequences with the same length distribution of a 
randomly selected subset of the active sequences were obtained fragmenting an equally sized 
set of sequences randomly selected from Swissprot. (2) 1,454 unique sequences were obtained 
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scrambling a randomly selected subset of the active sequences. The 9,548 obtained active and 
inactive unique peptide sequences were divided in training and test with a 75-25 random split. 
In the evaluation process, the active sequences were considered as the positive class and the 
inactive sequences as the negative class. For the hemolysis classifier, we used the same training 
test split but selecting only the sequences with hemolysis data. In the evaluation, we considered 
the non-hemolytic sequences as the positive class and the hemolytic sequences as the negative 
class. 
8.4.2 NB, SVM, and RF Classifiers  
The NB, non-linear SVM, and RF classifiers were implemented using scikit-learn. 162 The 
sequences were padded to the maximum sequence length (190 residues) and tokenized as 
singular amino acids (or empty position), then each token was mapped to a unique number. 
The SVM and the RF models were optimized with a grid search to increase the ROC AUC of 
the test set (Table 19).  
8.4.3 RNN Classifiers  
The AMP activity RNN classifier and the hemolysis RNN were implemented in PyTorch.355 
The input of the implemented RNN classifiers are the tokenized and “one-hot” encoded 
sequences. The sequences were tokenized as singular amino acids and a start and an end tokens 
were added; then each token was mapped to a unique number. The resulting vector was 
transformed into a matrix where the number of columns is the length of the vocabulary and the 
number of rows was the length of the vector itself. The presence of a specific residue at each 
position was represented with a 1 while the rest of the matrix is filled with zeros.  
The models were composed of an embedding layer, gated recurrent unit (GRU)356 cells, and a 
linear transformation layer followed by a softmax function.357 The output of the model was 
considered only when the last token was reached  (Figure 54). The hyperparameters of the RNN 
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classifiers were optimized to maximize the ROC AUC of the test set (Table 27). A threshold 
was picked to keep the prediction of false positives below 6%. The parameters were learned 
using a negative log-likelihood loss357 and a stochastic gradient descent358 with a momentum 
of 0.9 and a learning rate of 0.01.  
To create a baseline prediction for both RNN classifiers, a second RNN AMP activity 
and hemolysis classifiers (RNN AMP activity classifier scrambled labels and RNN hemolysis 
classifier scrambled labels) were implemented (Table 28) and trained using a different dataset, 
where the sequences were the same, but the activity and the hemolytic labels were randomly 
scrambled.  
8.4.4 RNN Generative Models 
A generative model was implemented in PyTorch with the same architecture of the previously 
described RNN activity classifier, with the exception of the dimensionality of the last linear 
layer which is the same size of the vocabulary (41 tokens, 41 dimensions, Figure 55). 
Furthermore, in this case, the output of the model was considered at every token, allowing the 
sequence generation. The input sequences were processed as for the RNN classifiers. The 
parameters of the RNN generative model were learned using negative log-likelihood loss 
(NLLL) and Stochastic gradient descent with a momentum of 0.9 and a learning rate of 0.001. 
During the training of the generator, only the active sequences of the training set were used, 
but the NLLL on the test set was also monitored. The training was stopped when the NLLL of 
the test reached its minimum. 
8.4.5 Transfer Learning 
The 242 active sequences of the training set flagged against P. aeruginosa or A. baumannii and 
annotated as non-hemolytic were used to train again the generative model and fine-tune it 
against gram-negative bacteria. The 312 active sequences of the training set flagged against S. 
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aureus and annotated as non-hemolytic were used to train again the generative model and fine-
tune it against gram-positive bacteria. The parameters were learned using negative log-
likelihood loss (NLLL) and Stochastic gradient descent with a momentum of 0.9 and a learning 
rate of 0.00001. As for the training of the prior model, the NLLL on the flagged subset of the 
test set, consisting of 97 for the P. aeruginosa or A. baumannii and of 137 sequences for the S. 
aureus model, was monitored and when it reached its minimum the training was stopped.  
8.4.6 Sampling and Properties Calculation 
50,000 sequences were sampled from each of the two transfer learned models. The Levenshtein 
distance (LD) from the nearest neighbor (NN) in the training and the test of both RNN 
classifiers was calculated using the Levenshtein Python package.311,359 The helicity prediction 
was performed using SPIDER3,360 and the helicity fraction was calculated as the number of 
residues predicted helical in a peptide sequence divided by the length of the sequence itself. 
The hydrophobic moment was calculated as described by Eisenberg et al.353  Hemolysis and 
activity were predicted by the respective classifiers converting the probabilistic prediction 
values into binary classification using the threshold that kept the prediction of false positive 
below 6% (0.99205756 for the activity classifier and 0.99981695 for the hemolysis classifier).  
8.4.7 Sequences Selection 
The generated sequences were filtered based on multiple criteria. First, to ensure novelty, we 
have chosen sequences with LD > 5 from the hemolysis classifier training set sequences and 
LD > 4 from the hemolysis classifier test set sequences. Second, we remove all sequences that 
were outside the applicability domain of the hemolysis classifier. To do so, we calculated the 
minimum LD of every test set compound to the training set. Giving this minimum LD values 
we defined to applicability domain of the classifier to be the 90% quantile. This led to the 
exclusion of all generated sequences with a LD distance of 8 or more to the training set of the 
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hemolysis classifier. Only sequences up to 15 residues were selected to facilitate the synthesis 
process and due to the low percentage of D amino acids in the training set, sequences containing 
D-residues were excluded. The sequences were further selected following two different 
strategies. 
8.4.7.1 First selection strategy 
Since helicity and amphiphilicity often correlate with antimicrobial activity, we selected 
sequences with a predicted helicity fraction above 0.8 and an Eisenberg hydrophobic moment 
above 0.3. The thresholds for the predicted helicity fraction and hydrophobic moment were 
chosen based on the median values of the active sequences in the training and test, respectively 
0.83 and 0.31. The filtered sequences were clustered using the RDKit123 Butina module with a 
threshold of 10 and the Levenshtein distance as distance function. Sequences containing 
methionine and sequences with an LD > 5 from the training and test sets of the activity classifier 
were excluded from all clusters. The center of each cluster was picked, and in addition, one 
additional compound was selected at random from the clusters containing more than 6 
compounds. The workflow resulted in 10 sequences predicted active against gram-negative 
bacteria and 16 sequences predicted active against gram-positive bacteria 10 sequences for 
each class were selected for synthesis.  
8.4.7.2. Second selection strategy 
To avoid the bias that secondary structure evaluation and the clustering might create and to 
gain a better insight on the activity of the sequences generated by the two transfer learned 
models, we randomly sampled 20 sequences (10 for each class). four sequences predicted 
active against gram-positive and five against gram-negative were manually selected. Non-
containing methionine sequences with higher distances from the training and test sets of the 
activity classifier were preferred.  
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8.4.8. Evaluation metrics 
ROC AUC is the area under the ROC curve, and the ROC curve is obtained by plotting the true 
positive rate (TPR) against the false positive rate (FPR): 
𝑇   
𝑇 
𝑇    
 
    
  
𝑇    
 
where TP stands for true positives, TN for true negatives, FP for false positives, and FN for 
false negatives predicted by the classifier.  
The F1 score is defined as the harmonic mean of precision and recall: 
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The balanced accuracy is defined as: 
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The Matthews correlation coefficient (MCC) is a correlation between the observed and the 
predicted class and it is defined as: 
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√ 𝑇      𝑇      𝑇      𝑇     
 
8.4.9 Peptide synthesis 
Peptides were synthesized using standard 9-fluorenylmethoxycarbonyl (Fmoc) Solid Phase 
Peptide Synthesis. All syntheses were performed at 60°C under nitrogen bubbling. 400 mg 
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Rink Amide AM resin LL (0.26 mmol/g) were used for each peptide. The resin was firstly 
deprotected twice one minute and four minutes using a deprotection cocktail containing 5% 
w/v piperazine, 2% v/v 1,8-Diazabicyclo(5.4.0)undéc-7-ene (DBU) and 10% v/v 2-Butanol in 
N,N-dimethylformamide (DMF). For each amino acid, a doubling coupling was performed 
(twice eight minutes) using for each coupling 3 mL of 0.2 M of the corresponding Fmoc 
protected amino acid in DMF, 1.5 mL of 0.5M Oxyma in DMF, and 2 mL of 0.5 M N,N’-
diisopropylcarbodiimide (DIC) in DMF. Deprotection steps (double deprotection, one minute, 
and four minutes) were achieved using the same cocktail described above, except for sequences 
containing aspartic acid for which a solution of 20% v/v piperidine + 0.7% v/v formic acid in 
DMF was used to avoid aspartimide and side products formation. 
After the last deprotection, peptides were cleaved from the resin using 7 mL of a 
mixture trifluoroacetic acid/triisopropylsilane/mQ water (TFA/TIS/H2O) with the 
corresponding ratios 94/5/1 during three hours. Peptides were then precipitated using 
approximatively 25 mL of cold terbutylmethyl ether and centrifuged 10 minutes at 4400 rpm. 
Supernatant was removed and peptides were washed twice with 15 mL of cold terbutylmethyl 
ether before lyophilization.  
8.4.10 Minimal inhibitory concentration  
Antimicrobial activity was assayed against P. aeruginosa PAO1 (WT), Acinetobacter 
baumannii (ATCC 19606), K. pneumoniae (NCTC 418), Methicillin-resistant Staphylococcus 
aureus (COL). To determine the minimal inhibitory concentration (MIC), the broth 
microdilution method was used. A colony of bacteria was grown in LB (Lysogeny broth) 
medium overnight at 37 °C. The samples were prepared as stock solutions of 8 mg/mL in H2O, 
diluted to the initial concentration of 64 or 128 µg/mL in 300 µL Mueller-Hinton (MH) 
medium, added to the first well of 96-well microtiter plate (TPP, untreated), and diluted serially 
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by ½. The concentration of the bacteria was quantified by measuring absorbance at 600 nm and 
diluted to OD600 = 0.022 in MH medium. The sample solutions (150 µL) were mixed with 4 
µL diluted bacterial suspension with a final inoculation of about of 5 x 105 CFU. The plates 
were incubated at 37 °C until satisfactory growth (~18 h). For each test, two columns of the 
plate were kept for sterility control (broth only) and growth control (broth with bacterial 
inoculums, no antibiotics). The MIC was defined as the lowest concentration of the peptide 
dendrimer that inhibited visible growth of the tested bacteria, as detected after treatment with 
MTT. 
8.4.11 Hemolysis Assay  
Compounds were subjected to a hemolysis assay to assess the hemolytic effect on human red 
blood cells (hRBCs). The blood was obtained from Interregionale Blutspende SRK AG, Bern, 
Switzerland. 1.5 mL of whole blood was centrifuged at 3000 rpm for 15 minutes at 4 ℃. The 
plasma was discarded, and the hRBC pellet was re-suspended in 5 mL of PBS (pH 7.4) then 
centrifuged at 3000 rpm for 5 minutes at 4 ℃. The washing of hRBC was repeated three times 
and the remaining pellet was re-suspended in 10 mL of PBS.  
 The samples were prepared as the initial concentration of 4000 µg/mL in PBS, added 
to the first well of 96-well microtiter plate (TPP, untreated) and diluted serially by ½. After 
diluted, 100 μL of sample was in each well and the final sample concentration was 4000 μg/mL, 
2000 μg/mL, 1000 μg/mL, 500 μg/mL, 250 μg/mL, 125 μg/mL, 62.5 μg/mL and 31.3 μg/mL. 
Controls on each plate included a blank medium control (PBS 100 μL) and a hemolytic activity 
control (0.1% Triton X-100). 100 μL of hRBC suspension was incubated with 100 μL of each 
sample in PBS in 96-well plate (Nunc 96-Well Polystyrene Conical Bottom MicroWell Plates). 
After the plates were incubated for 4 h at room temperature, minimal hemolytic concentration 
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(MHC) was determined by visual inspection of the wells. 100 μL supernatants was carefully 
pipetted to a flat bottom, clear wells plate (TPP® tissue culture plates, polystyrene). 
8.4.12 Circular dichroism spectroscopy 
CD spectra were recorded using a Jasco J-715 spectrometer equipped with a PFD-350S 
temperature controller and a PS-150J power supply. All experiments were measured using a 
Hellma Suprasil R 100QS 0.1 cm cuvette. Stock solution (1.00 mg/mL) of dendrimers were 
freshly prepared in 10 mM phosphate buffer (pH 7.4). For the measurement, the peptides were 
diluted to 100 µg/mL with buffer and 5 mM Dodecylphosphocholine (DPC, Avanti Polar 
Lipids, Inc., USA) was added when specified. The range of measurement was 185-260 nm, 
scan rate was 20 nm/min, pitch 0.5 nm, response 16 sec. and band 1.0 nm. The nitrogen flow 
was kept above 10 L/min. The blank was recorded under the same conditions and subtracted 
manually. Each sample was subjected to two accumulations. The cuvettes were washed with 
1M HCl, mQ-H2O and buffer before each measurement. Percentage of different secondary 
structure was calculated by DichroWeb.  
8.4.13 Transmission electron microscopy 
Exponential phase of Pseudomonas aeruginosa PAO1 and A. baumannii were washed with 
MH medium and treated with GN1 at the concentration of 10 x MIC. After 2h incubation, 1 
ml of the bacteria (OD600 = 1) were centrifuged at 12 000 rpm for 3 min and fixed overnight 
with 2.5% glutaraldehyde (Agar Scientific, Stansted, Essex, UK) in 0.15M HEPES (Fluka, 
Buchs, Switzerland) with an osmolarity of 670 mOsm and adjusted to a pH of 7.35. The next 
day, PAO1 were washed with 0.15 M HEPES three times for 5 min, postfixed with 1% OsO4 
(SPI Supplies, West Chester, USA) in 0.1 M Na-cacodylate-buffer (Merck, Darmstadt, 
Germany) at 4°C for 1 h. Thereafter, bacteria cells were washed in 0.1 M Na-cacodylate-buffer 
three times for 5 min and dehydrated in 70, 80, and 96% ethanol (Alcosuisse, Switzerland) for 
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15 min each at room temperature. Subsequently, they were immersed in 100% ethanol (Merck, 
Darmstadt, Germany) three times for 10 min, in acetone (Merck, Darmstadt, Germany) two 
times for 10 min, and finally in acetone-Epon (1:1) overnight at room temperature. The next 
day, bacteria cells were embedded in Epon (Fluka, Buchs, Switzerland) and hardened at 60°C 
for 5 days. 
Sections were produced with an ultramicrotome UC6 (Leica Microsystems, Vienna, 
Austria), first semithin sections (1um) for light microscopy which were stained with a solution 
of 0.5% toluidine blue O (Merck, Darmstadt, Germany) and then ultrathin sections (70-80 nm) 
for electron microscopy. The sections, mounted on single-slot copper grids, were stained with 
1% uranyl acetate at 40°C for 30 min and 3% lead citrate at RT for 20 min or UranyLess 
(Electron Microscopy Sciences, Hatfield, UK) at 40°C for 10 min and 3% lead citrate at 25°C 
for 10 min with an ultrostainer (Leica Microsystems, Vienna, Austria). Sections were then 
examined with a Tecnai Spirit transmission electron microscope equipped with two digital 
cameras (Olympus-SIS Veleta CCD Camera, FEI Eagle CCD Camera). 
8.4.14 Molecular Dynamics 
Molecular dynamics (MD) simulations were performed for the peptides GN1, GP1 and GN2 
using GROMACS software version 2018.1 and the gromos53a6 force field354,361. The starting 
topologies were built from the existing X-ray structures. A dodecahedral box was created 
around the peptide 1.0 nm from the edge of the peptide and filled with extended simple point 
charge water molecules. Sodium and chloride ions were added to produce an electroneutral 
solution at a final concentration of 0.15 M NaCl. The energy was minimized using a steepest 
gradient method to remove any close contacts before the system was subjected to a two-phase 
position-restrained MD equilibration procedure. The system was first allowed to evolve for 
100 ps in a canonical NVT (N is the number of particles, V the system volume, and T the 
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temperature) ensemble at 300 K before pressure coupling was switched on and the system was 
equilibrated for an additional 100 ps in the NPT (P is the system pressure) ensemble at 1.0 bar. 
8.4.14.1 MD in presence of DPC micelle 
MD simulations in the presence of a DPC (n-dodecylphosphocholine) micelle were performed 
as follows. Parameters and references for the DPC molecule362 for the GROMOS53a6 
forcefield are given in the SI (Note 4). Peptides were manually placed at a distance from the 
pre-equilibrated micelle (of 65 DPC molecules) equal to the diameter of said peptide. Box, 
solvation and NVT equilibration procedures were performed as explained previously. For each 
peptide/micelle system, 10 runs of 50 ns were generated to show the possibility for the peptide 
to either interact or diffuse away from the micelle. Then, runs of interest were extended up to 
250 ns. 
8.4.14.3 Clustering of stable structures 
To obtain a representative conformer for each SA-MD run, the last 100 ns (10001 frames) of 
each run were clustered using an RMSD cut-off adapted to get a good balance between the 
number of clusters and the size of the main cluster. A large number of clusters combined with 
a very large percentage of structures in the top cluster is an indication of the stability of the one 
main conformer in each case. The PyMol Molecular Graphics System, version 1.8 
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Chapter nine – General 
Conclusions and Outlook 
In this thesis, cheminformatics tools for larger molecules and peptides were developed and 
applied. Two new molecular fingerprints were introduced: MXFP and MAP4. These allowed 
for a previously unexplored examination of larger molecules databases. The chemical space of 
molecules that do not obey Lipinski rules within known databases, the natural products space, 
the human metabolome space, and the virtual and the known chemical space of peptides were 
encoded and visualized. The visualization was carried out using scatter plots of the first 
principal components of a PCA of the MXFP feature space, MXFP similarity maps, and MAP4 
TMAPs. The resulting maps are all interactive and available to be navigated using different 
properties. 
Furthermore, classical machine learning and the MAP4 fingerprint were used to 
characterize natural products by their origin, and a genetic algorithm (PDGA) and deep 
learning were used to generate novel peptide sequences. In addition to the reported studies, 
PDGA and the deep learning workflow described in chapters seven and eight have been used 
in additional and yet unpublished projects. For instance, PDGA was used to search analogs of 
dendritic peptides, and a version of PDGA that uses the RDKit AP in combination with the 
hemolysis classifier was used to generate anticancer peptides. These projects are carried out in 
collaboration with two brilliant peptide chemists in the Reymond group: Xingguang Cai and 
Elena Zakharova. Further development of this generative approach could see a SMILES-based 
adaptation to explore the chemical space of non-peptidic large molecules.  
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An important topic that has been only partially addressed in this thesis is the role of 
stereochemistry and conformation in peptide activity. In fact, MXFP and MAP4 are 2D 
fingerprints, and they do not explicitly encode stereochemistry.14,18 On the one hand, the 
correlation between the conformation of a peptide and its properties is well accepted.333,363 For 
instance, most active peptides in DBAASP332 were predicted to be amphiphilic helixes, an 
observation that led us to use the same estimation to guide the selection of peptide sequences 
in output of the RNN generative workflow.364 Furthermore, in a recent study,37 Gao et al. 
compared 2D-fingerprint-based machine learning models with the state-of-the-art 3D 
structure-based models in different drug discovery-related applications. They showed that 2D 
fingerprint-based models had the same capabilities as the state-of-the-art 3D approach in 
different drug discovery-related tasks, except estimating protein-ligand binding affinity based 
on ligand and protein information. These findings highlight the possible limits of 2D models 
in handling complex systems that can assume multiple conformations.  
On the other hand, in a recent publication, Siriwardena et al. showed that some peptides 
that were widely believed to require folding for activity also work when stereorandomized.365 
Furthermore, Senior et al. demonstrated that sequence information alone could be used to 
predict a protein structure with machine learning even when only a few homologs are 
available.366 Taken together, these factors highlight the validity of a fast 2D fingerprints-guided 
approach to lead early findings and its orthogonality to a three-dimensional analysis that 
considers stereochemistry and conformation for further optimization processes.  
A possible future direction of the work presented in this thesis could be investigating 
the space of another important class of macromolecules: glycans. Glycans are generally 
reported with specific nomenclatures. The first example of glycan-specific nomenclatures is 
the Kornfeld model, where monosaccharides are represented by geometric symbols and 
glycosidic linkages by a simple line.367 Since then, the model has been expanded, and the 
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current version, called Symbol Nomenclature for Glycans (SNFG), includes colors and new 
monosaccharides.368 SNFG is a symbolic graphic, and its application within fingerprint 
calculation, visualization, and structure generations is not trivial. However, SNFG can be 
converted into Web3 Unique Representation of Carbohydrate Structure (WURST),369 a unique 
string representation of glycan structures partially based on SMILES. WURST itself could be 
used as input for a machine learning workflow or converted into SMILES and encoded with 
molecular fingerprints. This latter approach would have the advantage of also allowing for the 
encoding of glycosylated molecules such as glycosylated peptides and lipids.   
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Note A.1: Table 21 
Table 21. Examples of SMILES strings that give error or not meaningful analogs using PubChem 
and/or ChEMBL search. 




















PuChem search ignores 
size ans shape, as the first 





































PubChem search ignores 
size ans shape, as the first 
results are all small 
oligonucleotides. 
 






























PubChem search fails. 
ChEMBL search ignores 
shape, as the frst results 
are linear peptides. 









PubChem search fails. 
























PubChem search doesn’t 
find similar compounds. 
 





























































Both PubChem and 
ChEMBL searches 
ignore dendrimer shape, 
as the first results are 
linear peptides. 





















































Both PubChem and 
ChEMBL searches fail. 
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Note B.1: Table 22 
Table 22. Linear random peptide sequences used to generate the mutated and scrambled peptide 
datasets (available at https://github.com/reymond-group/map4) for the extended fingerprint benchmark.  
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Note B.2: Figures 42-48 
 
Figure 38. Hydrogen bond acceptor (HBA, a) and donor (HBD, b) count, Molecular Weight (MW, c), 
and calculated logarithm octanol-water partition coefficient (cLogP, d) of the actives/decoys used in the 
original version of the Riniker fingerprint benchmark. The percentage of molecules that violate each 
rule is reported in the corresponded panel. 
  
2.1%< 1%
< 1% < 1%
a) b)
c) d)
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Figure 39.  RIE100 (a), RIE20 (b), BEDROC20 (c), and EF1 (d) of MAP4 (magenta), ECFP4 (orange), 
MHFP6 (blue), MXFP (solid green line), TT (dashed green line), AP (dotted green line), MACCS (solid 
gray line), and ECFP0 (dashed gray line) across all small molecules and peptide targets.  
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Figure 40.  a) Relative ranking and p-values of and MAP4-1024 compared to MXFP-217, AP, ECFP0-
1024, ECFP4-1024, ECFP4-2048, MAP4-2048, MHFP6-1024, MACCS-166, TT, and MHFP6 in the 
Riniker fingerprint benchmark when using only the DUD, MUV, and ChEMBL datasets. b) Relative 
ranking and p-values of and MAP4-1024 compared to MAP2-2048, MAP6-2048, MAP8-2048, MAP2-
1024, foldedAP2-2048, foldedAP4-2048, MAP6-1024, foldedAP6-2048, MAP8-1024, and foldedAP6-
2048 in the Riniker fingerprint benchmark when using only the DUD, MUV, and ChEMBL datasets. 
Orange color corresponds to MHFP6 being ranked higher than the other fingerprint, while green color 
indicates a lower ranking. P-values below 0.05 (dashed horizontal line) indicate significance. 
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Figure 41. a) Relative ranking and p-values of MAP4-1024 compared to MXFP-217, AP, ECFP0-1024, 
ECFP4-1024, ECFP4-2048, MAP4-2048, MHFP6-1024, MACCS-166, TT, and MHFP6 in the Riniker 
fingerprint benchmark when using only the peptide datasets. b) Relative ranking and p-values of and 
MAP4-1024 compared to MAP2-2048, MAP6-2048, MAP8-2048, MAP2-1024, foldedAP2-2048, 
foldedAP4-2048, MAP6-1024, foldedAP6-2048, MAP8-1024, and foldedAP6-2048 in the Riniker 
fingerprint benchmark when using only the peptide datasets. Orange color corresponds to MHFP6 being 
ranked higher than the other fingerprint, while green color indicates a lower ranking. P-values below 
0.05 (dashed horizontal line) indicate significance. 
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Figure 42.  AUC (a), BEDROC100 (b) and 20 (c), EF1 (d) and 5 (e), RIE100 (f) and 20 (g) of AP2 
(orange), AP4 (magenta), AP6 (blue), AP8 (green), in their 2014-dimensions (solid) and 2048-
dimensions (dashed) minhashed implementation (MAPs), and in their 2048-dimensions folded (dotted) 
implementation (foldedAPs). MHFP6 (solid) and AP (dashed) are reported in gray. 




Figure 43. Examples of structures found in the most (a), second-most (b) and third most (c) populated 
fingerprint value bins in the Metabolome ECFP4-1024 chemical space. The total amount of molecule 
present in the three fingerprint value bins is reported.  
 




Figure 44. Examples of structures found in the most (a), second-most (b) and third most (c) populated 
fingerprint value bins in the Metabolome MHFP6-1024 chemical space. The total amount of molecule 
present in the three fingerprint value bins is reported.  
 




Figure 45. Examples of structures found in the most (a), second-most (b) and third most (c) populated 
fingerprint value bins in the Metabolome TT chemical space. The total amount of molecule present in 
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Note C.1: Table 23 
 
Table 23. MAP4 SVMN classification of known non-microbial natural products. 
Natural Product Origina) MAP4 SVM 
pred.b)  
fungal, bacterial  
Training set NN JD from 
NNc) 
Salidroside Plant  0.75, 0.25 NPA016219 0.75 
Prostacyclin Animal  0.94, 0.06 Shorghumoic acid (NPA005601) 0.78 
Serricorole Animal  0.16, 0.84 6-deoxyerythronolide B 
(NPA004018) 
0.81 
Cholesterol Animal  0.93, 0.07 Micaceol (NPA018196) 0.37 
Farnesol Plant, 
animal 
0.92, 0.08 Trans-beta-Farnesene 
(NPA013150) 
0.64 





Animal 0.13, 0.87 Siamycin II (NPA020589) 0.75 
a) Natural product origin. b) Predicted origin: fungal or bacterial. c) Approximated Jaccard Distance 
(JD, see methods for details) from the training set NN. 
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Note C.2: Figures 49-54 
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Figure 46. Physico-chemical properties distribution across the NPAtlas entries are shown in blue. The 




Figure 47. Approximated Jaccard distance from the top 20 NNs of all NPAtlas entries. 
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Figure 48. MAP4 TMAP of NPAtlas colored with the available continuous properties (a) HBA, (b) 
HBD, (c) AlogP, (d) TPSA, and (e) calculated boiling point. 
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Figure 49. MAP4 TMAP of NPAtlas colored with the ranked continuous properties (a) MW, (b) fsp3C, 
(c) HBA, (d) HBD, (e) AlogP, (f) TPSA, (g) and calculated boiling point. 
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Figure 50. MAP4 TMAP of NPAtlas colored with categorical properties. (a) Lipinski classification. 









Figure 51. Salidroside, prostacyclin, serricorole, cholesterol, farnesol, menthol, conotoxin MVIIA, and 
their training set NN. For a better visualization, all query structures are shown in blue. 
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Note D.1: Tables 24-26 
 
Table 24. PDGA recognized symbols and their correspondent internal character. 
Symbola) idb) Description Example 
Orn O Ornithine 
 
Hyp Z Hydroxyproline 
 




























acid as branching 
unit 
Ala-Dab-Leu 
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cy X Amide bond 
head-to-tail 
cyclization. 
It is always 
placed at the 
beginning (left, N 




Cys1 Ä First pair of 
cyclizes 
cysteines, 
Always in pair, 




Cys2 Ö Second pair of 
cyclizes 
cysteines. 
They are always 
present in pair, 
never next to 
Cys1-Cys2-Gly-Leu-Gly-Lys-Val-Cys1-Gly-Arg-Cys2-
Ala 
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each other, 
present only if 
Cys1 is already 
part of the 
sequence. 
 
Cys3 Ü Third pair of 
cyclizes 
cysteines. 
They are always 
present in pair, 
never next to 
each other, 
present only if 
Cys1 and Cys2 
are already part 




Ac & N-terminus 
acetylation. 
It is always 
placed at the 
beginning (N-




NH2 + C-terminus 
amide. 
It is always 
placed at the end 
(C-terminus, 




a) PDGA input. b) Internally used characters. c) Lower case. 
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Table 25. SMARTS HBA/HBD and charge assignment. 
Description SMARTS HBA/HBD a) b) Charge b) 
Aliphatic 
carbon 
[C] 0 0 
Nitrogen [#7] 1 0 
Tertiary 
nitrogen 
[NX3;H0] 0 0 
Aliphatic 
oxygen 
[O] 2 0 





























[$([NH2X3]-[CX4]),$([N]=[CX3])] 1,0 1,0 
Carbonyl [$([O]=[C])] 2,0 0,0 
Carboxyl [OH,O-]-[C](=O) 2,0,2 -1,0,0 
Ether [OX2]([CX4])[CX4] 2,0,0 0,0,0 
Phenol [OH1X2]-[c] 3,0 0,0 
a) 0 = no hydrogen donor or acceptor site; 1 = donor site; 2 = acceptor site; 3= donor and 
acceptor site. b) When more values are present, they refer to the SMARTS atom in the 
correspondent position. 
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Table 26. Input parameters and excluded building blocks (bb).  















































Acetyl-CoA 50 1 0.8 300 linear Ac 24 h 
Epothilone 
A 
50 1 0.8 300 cyclic Ac 24 h 
Cholic Acid 50 1 0.8 300 cyclic Ac 24 h 
α-
cyclodextrin 
50 1 0.8 300 cyclic Ac 24 h 
PAMAM 
dendrimer 
50 1 0.8 300 dendrimer Ac 24 h 
a) For a definition of the mentioned building blocks refer to Table 24.  
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Note D.2: Figure 55 
 
Figure 52. Structures of the non-peptidic PAMAM target and its best analog. 
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Appendix E – Supplementary 
Tables and Figures Chapter Eight 
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Note E.1: Tables 27,28 
 
Table 27. Performance on the test of the NB, RF, SVM, RNN, and RNN with scrambled labels (RNN 
scr.) models for the AMP activity (act.) and hemolysis (hem.) classification tasks.  
Classifier ROC AUC  Accuracy a) Precision a) Recall a) F1 score a) MCC a) 
NB act. 0.55 0.55 0.59 0.32 0.42 0.11 
SVM act. 0.75 0.68 0.68 0.68 0.68 0.36 
RF act. 0.81 0.71 0.70 0.75 0.73 0.44 
RNN act. 0.84 0.76 0.74 0.80 0.77 0.53 
RNN scr. act. 0.51 0.49 0.35 0.03 0.05 -0.06 
NB hem. 0.58 0.56 0.48 0.76 0.59 0.19 
SVM hem. 0.69 0.73 0.72 0.58 0.65 0.44 
RF hem. 0.80 0.77 0.81 0.60 0.69 0.53 
RNN hem. 0.87 0.76 0.70 0.76 0.73 0.52 
RNN scr. hem. 0.45 0.61 0.41 0.05 0.10 0.01 
a) The probabilistic prediction values were converted into binary classification values using a 
threshold of 0.5. The best values and the selected classifiers are reported in bold. 
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Table 28. Classifiers optimization 
Classifier Hyperparameters optimization a) 
SMV AMP activity C = 0.1, 1, 10, 100 
γ = 0.1, 0.01, 0.001 
RF AMP activity maximum depth = 10, 30, 50, 70, 90, None 
no. estimators = 10, 100, 250, 500, 750, 1000, 1500, 2000 
RNN AMP activity embedding dimensions = 2, 21, 42, 100 
GRU dimensions = 50, 100, 200, 300, 400 
no. layers = 1, 2, 3 
epoch = [1, 2, 3, ..., 150]; best epoch = 38 
RNN AMP activity 
scrambled labels 
embedding dimensions 2, 21, 42, 100 
GRU dimensions = 50, 100, 200, 300, 400 
no. layers = 1, 2, 3 
epoch = [1, 2, 3, ..., 150]; best epoch = 1 
SMV Hemolysis   C = 0.1, 1, 10, 100 
γ = 0.1, 0.01, 0.001 
RF Hemolysis   maximum depth = 10, 30, 50, 70, 90, None 
no. estimators = 10, 100, 250, 500, 750, 1000, 1500, 2000 
RNN Hemolysis   embedding dimensions = 2, 21, 42, 100 
GRU dimensions = 50, 100, 200, 300, 400 
no. layers = 1, 2, 3 
epoch = [1, 2, 3, ..., 150]; best epoch = 95 
RNN Hemolysis   
scrambled labels 
embedding dimensions 2, 21, 42, 100 
GRU dimensions = 50, 100, 200, 300, 400 
no. layers = 1, 2, 3 
epoch = [1, 2, 3, ..., 150]; best epoch = 150 
a) The selected hyperparameters are highlighted in bold. All hyperparameters that have not been 
discussed have been used in their default values. 
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Note E.2: Figures 56-60 
 
Figure 53. Properties distribution and filters. (a) length, (b-e) minimum Levenshtein distance (minLD) 
from training and test sets, (f) presence of D-amino acids (D-AA), (g, h) Amphiphilic helix estimation, 
of the 3,046 predicted active and non-hemolytic sequences derived from the model fined tuned for A. 
baumannii and P. aeruginosa (Generated GN) and the 2,717 predicted active and non-hemolytic 
sequences derived from the model finetuned for S. aureus. (a-d) Solid vertical lines indicate that the 






































Figure 54. RNN AMP activity classifier architecture. The tokenized and “one-hot” encoded sequences 
enter an 100 dimensions (dim) embedding layer (a), then they are processed through two layers of 400 
dimensions GRU cells (b), and finally, a linear transformation layer shapes the last GRU output into 
two dimensions (c), followed by a softmax function that normalizes it into a probability (d). The 
architecture of the hemolytic classifier differs only by having one layer of GRU cells.    
 
 
Figure 55. RNN generative models architecture. The tokenized and “one-hot” encoded sequences enter 
an 100 dimensions (dim) embedding layer (a), then they are processed through two layers of 400 
dimensions GRU cells (b), and finally, a linear transformation layer shapes the last GRU output into 41 
dimensions (c), followed by a softmax function that normalizes it into a probability (d). The architecture 
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Figure 56. MD simulations of GP1 in water and in presence of a DPC micelle over 250 ns using 
GROMACS. (a) Average structure (stick model) in water over 100 structures sampled over the last 100 
ns (thin lines). Hydrophobic side chains are colored in red and cationic side chains in blue. (b) Average 
structure (cartoon model for backbone and stick model for side chains) with DPC micelle over 100 
structures sampled over the last 100 ns (thin lines). (c) RMSD (root mean square deviation) of the 
peptide backbone atoms relative to the starting α-helical conformation. (d) Number of intramolecular 
hydrogen bonds. The DPC micelle was omitted for clarity. 
 




Figure 57. MD simulations of GN2 in water and in presence of a DPC micelle over 250 ns using 
GROMACS. (a) Average structure (stick model) in water over 100 structures sampled over the last 100 
ns (thin lines). Hydrophobic side chains are colored in red and cationic side chains in blue. (b) Average 
structure (cartoon model for backbone and stick model for side chains) with DPC micelle over 100 
structures sampled over the last 100 ns (thin lines). (c) RMSD (root mean square deviation) of the 
peptide backbone atoms relative to the starting α-helical conformation. (d) Number of intramolecular 
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